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Abstract 
Deletions of the short arm of chromosome 12 (12p) are found in around 6% of acute myeloid 
leukaemia (AML).  Particularly in paediatric AML they often occur as the sole cytogenetic 
change and are associated with a poor prognosis. Amplifications of the long arm of 
chromosome 11 (11q) are rarer, found in around 1% of AML, but are particularly prevalent in 
the poor prognosis complex karyotype group. 
Despite multiple deletion mapping studies, single genes have not been identified from these 
regions that are responsible for driving leukaemic progression, thus it is clear that a functional 
approach is required. This study aimed to functionally implicate significant genes through the 
use of competitive selection assays. 
Publicly available array data from eight studies were used to determine copy number from 
AML patient samples to define minimal regions of copy number alteration. Data were obtained 
from 866 samples which had been analysed on Affymetrix SNP array platforms. In total 58 
samples (6.7%) were found to have deletions of 12p and were used to determine a minimally 
deleted region (MDR), whilst five samples (0.6%) were identified with amplifications of 11q 
and used to define a minimally amplified region (MAR). 
AML cell lines with deletions of 12p (NKM-1 and GDM-1) and amplification of 11q (UoC-M1) 
were selected to investigate the functional relevance of the genes within the regions of 
interest. Cell lines were used in vitro and in immunocompromised mouse models, where 
leukaemia was established by intrafemoral injection and monitored by luminescent imaging of 
luciferase expression constructs. Taking a pooled approach, 11 genes within the 12p MDR 
were overexpressed and 30 genes from the 11q MAR were knocked down using integrated 
lentiviral vectors. To evaluate effects of expression on leukaemia growth or survival, changes in 
construct copy number after cell line expansion in vitro and in vivo were determined by 
targeted high throughput sequencing on the Illumina MiSeq platform.  
Demonstrating a strong anti leukaemic effect for expression of this gene, a construct for cyclin 
dependent kinase inhibitor 1B (CDKN1B) was rapidly selected against in the 12p assay, whilst 
knockdown of MPZL3 and UBE4A from 11q were selected against in the 11q assay. Functional 
follow up work mainly focussed on CDKN1B, where its expression was measured in a range of a 
cell lines and patient samples, its effects on the cell cycle assessed and correlation of CDKN1B 
expression and treatment with a cyclin dependent kinase inhibitor (Flavopiridol) was 
established.  
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Chapter 1 Introduction 
1.1 Haematopoiesis 
Haematopoiesis is the process that drives the formation of the cellular components of blood. It 
allows the production of a wide range of cell types from a single type of progenitor cell – the 
multipotent haematopoietic stem cell (HSC). These stem cells reside within the bone marrow 
(BM) and give rise to approximately one trillion (1012) new cells per day in an adult human 
(Doulatov et al., 2012). HSCs demonstrate two main capabilities common to all stem cells. The 
first is that they are able to self-renew and produce additional HSCs with the same ability, and 
the second is that they are able to differentiate into all blood cell types (Seita and Weissman, 
2010).  
HSCs are defined operationally by their ability to reconstitute the entire blood system of a 
recipient who is haematopoietically deficient. This was first demonstrated in mice and guinea 
pigs who had been subjected to lethal doses of radiation, but were subsequently rescued 
following the injection of spleen or BM cells from unaffected donors (Lorenz et al., 1951).  
The development of fluorescence-activated cell sorting (FACS) techniques has been 
instrumental in tracking the range of cell populations present in the blood. This is achieved 
through the tracking of cell surface antigens, which are cell specific markers presented on cell 
membranes that can be detected using fluorescently labelled antibodies. Using FACS, HSCs can 
be purified by separating them from their more mature counterparts. Studies on these highly 
pure populations have demonstrated that a single HSC is able to provide haematopoietic 
reconstitution for a recipient for up to 4 months (Purton and Scadden, 2007).  
The products of HSC differentiation can be most loosely grouped into two fundamental 
branches – lymphoid and myeloid. Lymphoid lineage cells consist of T, B and Natural Killer (NK) 
cells, and their roles lie mainly in immune response. Myeloid lineage cells consist of a number 
of distinct and short-lived cell types, including granulocytes, monocytes, erythrocytes and 
megakaryocytes (Seita and Weissman, 2010). Myeloid cells have a range of roles, from 
mounting immune responses to producing red blood cells and platelets. The differentiation 
process can be summarised in the form of a flow chart, with HSCs residing at the top of this 
hierarchy (Figure 1). As cells become more differentiated, they lose their ability to self-renew 
and the cell surface markers that they express change. 
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 Figure 1. The adult human haematopoietic hierarchy. Haematopoietic stem cells (HSCs) give rise to the entire 
complement of human blood cell types, through a number of intermediary cell types. HSCs are able to self-renew and 
differentiate into multipotent progenitors (MPPs), which have a reduced self-renewal capacity. These go on to 
differentiate into the precursors of the two main lineages – immature lymphoid progenitors (MLPs) and commited 
myeloid progenitors (CMPs). MLPs give rise to earliest thymic progenitors (ETPs) which in turn produce T cells. CMPs 
differentiate into granulocytic-monocytic progenitors (GMPs) and megakaryocytic-erythrocytic progenitors (MEPs). 
Lineage markers (Lin) refer to a cocktail of markers that can be used to identify terminally differentiated 
haematopoietic cells. 
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1.2 Haematological Malignancies 
Normal cells involved in haematopoiesis can acquire mutations that lead to a block in 
differentiation or provide a growth advantage. If these cells go on to replicate, this can lead to 
the development of a haematological malignancy. These diseases are primarily classified by 
the cell lineage involved, and this is typically determined through the staining and light 
microscopy of either peripheral blood or a lymph node biopsy. The numbers of patients 
diagnosed each year in the UK with a haematological malignancy is listed in Table 1 (Yorkshire 
Humberside Haematology Research Network, 2014). 
Disease Children 
aged 0-14 
years 
Young 
adults 
aged 15-
24 years 
Adults 25+ 
years 
All ages % of total 
Acute lymphoblastic 
leukaemia (ALL) 
370 90 290 750 2.65 
Acute myeloid leukaemia 
(AML) 
70 90 2090 2250 7.94 
Chronic myeloid 
leukaemia (CML) 
- 20 530 550 1.94 
Chronic lymphocytic 
leukaemia (CLL) 
- - 3300 3300 11.64 
Other leukaemias  20 10  670 700 2.47 
Leukaemia (total) 460 210 6880 7600 26.81 
Hodgkin lymphoma 70 250 1330 1650 5.82 
Non-Hodgkin lymphoma 100 80 8820 9000 31.75 
Other 
lymphoproliferative 
disorders 
 - - 1050 1050 3.70 
Lymphoma (total)  170 330 11200 11700 41.28 
Myeloma (total)     3750 3750 13.23 
Other haematological 
malignancies 
10 35 - 45 0.16 
Myelodysplastic 
syndromes 
- - 2000 2000 7.06 
Myeloproliferative 
neoplasms 
- - 3300 3300 11.64 
Other haematological 
malignancies (total)  
10 35 5300 5345 18.86 
All haematological 
malignancies (total) 
640 575 27130 28345 100.00 
Table 1. Number of people diagnosed each year with a haematological malignancy in the UK. 
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1.3 Acute Myeloid Leukaemia 
1.3.1 Introduction 
Acute myeloid leukaemia (AML) is the most common myeloid malignancy, and accounts for 
around 0.9% of all newly diagnosed cancers in the UK (CRUK 2014). AML carries the worst 
prognosis of the 4 main subtypes of leukaemia, with a median survival of around 9.5 months 
(Bhayat et al., 2009). It is likely that this extremely poor overall survival rate is at least in part 
due to the majority of AML patients being older, with almost three quarters of cases being 
diagnosed in patients over the age of 60. These older patients are less likely to be able to 
tolerate the high dose chemotherapy required to achieve complete remission of AML. Despite 
a better overall outlook in paediatric cases, survival rates are still low when compared to other 
childhood leukaemias, with a 10 year event-free survival of 49% (Harrison et al. 2010). 
1.3.2 Epidemiology 
The annual incidence rate for AML in the UK can be estimated to be around 5 new AML cases 
for every 100,000 males, and 4 new cases for every 100,000 females.  In 2011, this equated to 
2921 new cases of AML being diagnosed: 1608 (55%) in males and 1313 (45%) in females 
(CRUK, 2014). 
A number of factors that may increase an individual’s risk of developing AML have been 
identified. Exposure to nuclear radiation, for example following the atomic bombing of Japan 
in 1945 (Nakanishi et al., 1999) as well as working in the nuclear industry (Cardis et al., 1995) 
have both been associated with an increased risk of AML, specifically with an increased 
incidence of chromosome 5 and 7 abnormalities. Radiation exposure in the cockpit of 
commercial jet airliners has also been associated with AML risk, with one study finding a 5 
times increased incidence of AML in Danish male cockpit crew with over 5000 hours flying time 
(Gudestrup and Storm, 1999). 
Exposure to the organic chemical compound benzene has been linked to AML development. 
The largest group exposed to benzene are cigarette smokers, who have been shown to have 
between a 1.2 and 2.3 times increased incidence of AML (Kane et al., 1999). Occupational 
exposure to benzene has also been demonstrated to greatly increase AML risk, with a large 
study of almost 75,000 benzene exposed workers in China demonstrating an increased 
incidence of AML, and an increased incidence of chromosome 5 and 7 aberrations in these 
patients’ leukaemias (Travis et al., 1994). 
Between 10-15% of patients who develop AML do so after treatment with chemotherapy for 
another cancer (therapy-related acute myeloid leukaemia; t-AML) (Smith et al., 2003). These 
patients can be roughly divided into two classes. The first of these develop AML between 1 and 
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5 years post treatment with DNA topoisomerase II inhibitors such as doxorubicin and 
etoposide. These patients often have cytogenetic abnormalities involving the long arm of 
chromosome 11 (11q23 rearrangements involving MLL) and balanced translocations between 
chromosomes 15 and 17, t(15;17)(q24;q21) PML/RARα. The second group develop AML 
approximately 5-10 years after exposure to DNA damaging alkylating agents, and have 
abnormalities of chromosomes 5 and/or 7, usually either as the loss of part of the long arm (-
5q/-7q) or as monosomy of the entire chromosome (-5/-7) (Smith et al., 2003). 
Patients with myelodysplastic syndrome (MDS) are at a high risk of developing AML. 
Approximately one third of patients with MDS will go on to develop AML (Barzi and Sekeres, 
2010), and they have a particularly poor prognosis when compared to other AML patients. 
MDS patients most at risk of developing AML are typically younger, present with higher blast 
counts, a history of chemotherapy and have multiple karyotypic abnormalities (Shi et al., 
2004). 
1.3.3 Origins of Disease 
It is widely believed that AML leukaemogenesis requires a number of cooperating genetic 
changes. Mouse models of AML have found that a single genetic aberration, for example the 
expression of t(8;21)(q24;q22) RUNX/RUNX1T1 or inv(16)(p13;q22) CBFB-MYH11 fusion genes, 
impair myeloid differentiation but do not alone cause an overt leukaemic phenotype (Frohling 
et al., 2005). Additionally, germline mutations in genes such as RUNX1 and CEBPA provide a 
genetic predisposition to AML, but do not always result in complete disease development. If 
leukaemia does develop in these patients, it is likely to carry additional acquired somatic 
mutations. Further supporting this hypothesis is the observation that many molecular events 
in AML patients are observed in conjunction with another mutation, for example the frequent 
association between FLT3-Internal tandem duplications (FLT3-ITD) mutations and the 
expression of a fusion transcript such as RUNX1/RUNX1T1 or PML/RARA (Dash and Gilliland, 
2001). The high rate of transformation of MDS into AML supports this multi-step theory of 
leukaemogenesis, where initial mutations in normal haematopoietic cells are not able to 
induce leukaemia, but do confer a growth advantage or differentiation block. These cells often 
go on to acquire additional detectable abnormalities, which result in the transformation of 
MDS to AML (Ripperger et al., 2009). 
Approximately 55% of de novo AML cases have cytogenetically detectable abnormalities 
(Sanderson et al., 2006). The most common of these are balanced translocations, where no 
genetic material is gained or lost, but the genetic location of a gene or genes is altered. 
Balanced translocations typically have one of two effects. Firstly, they can lead to aberrant 
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gene expression, for example when a gene is translocated to be in close proximity to a highly 
active promoter region (e.g. t(12;18)(p13;q12) ETV6/SETBP1, Cristóbal et al., 2010). 
Alternatively, the translocation process can result in the formation of a novel fusion gene with 
oncogenic properties (e.g. inv(16)(p13;q22) CBFB/MYH11, Kundu and Liu, 2001). The remaining 
45% of cases appear to be cytogenetically normal, however more sensitive diagnostic 
techniques are able to identify smaller changes in these patients, such as focal deletions, point 
mutations or aberrant CpG methylation leading to altered gene expression. 
The majority of genetic mutations in AML have previously been broadly classed into one of 
two categories (Renneville et al., 2008). Class I mutations activate signal transduction 
pathways and enable either an increased rate of proliferation or enhanced survival capabilities 
of affected cells. These mutations often enhance the activation of either the FLT3 or RAS 
signalling pathways. Class II mutations commonly affect pathways involved in the regulation of 
transcription, either transcription factors or members of the transcriptional co-activation 
complex. These mutations are able to block differentiation and aberrantly maintain cells in a 
pre-leukaemic state. They may also activate self-renewal pathways that are generally only 
active in HSCs (Kelly and Gilliland, 2002).  
Recent studies have suggested a further two classes of mutation to be present in AML. Class III 
mutations affecting TP53 and WT1 have been suggested to stand apart from Class I and Class II 
mutations, as they act as classical tumour suppressor genes, involved in the regulation of cell 
cycle and/or apoptosis (Dombret et al., 2011). A fourth class (Class IV) comprising of epigenetic 
regulator genes has also been identified. Despite being rarer than Class I and Class II 
mutations, some evidence suggests that Class IV mutations are associated with a worse patient 
outcome and are more frequently observed in older AML patients (Fathi and Abdel-Wahab, 
2012). It is possible that this may explain the poorer effects of treatment seen in older 
patients, including those with an otherwise favourable prognosis. 
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 Class I II III IV 
Pathway Signal 
Transduction 
Differentiation Tumour 
Suppression 
Epigenetic 
Regulation 
Genes FLT3 RUNX1 TP53 TET2 
NRAS, KRAS CBFβ WT1 IDH1, IDH2 
KIT CEBPA  DNMT3A 
JAK2 NPM1  ASXL1 
PTPN11 PU1  EZH2 
 MLL   
 RARα   
 EVI1   
Table 2. Summary of common genetic mutations observed in AML. 
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Figure 2 shows some of the key signalling pathways that are dysregulated in AML, and the 
downstream effects that these have, as well as the large amount of cross-talk that exists 
between pathways. Some of these pathways are discussed in more detail in later sections. 
 
Figure 2. Key signalling pathways involved in AML development. 
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1.3.4 Disease Classification 
The first widespread system used for the classification of AML was the French-American-British 
(FAB) classification, established in 1976. This system classified different AMLs based upon 
cellular morphology and cytochemical responses (Bennett et al., 1976). Certain genetic 
changes are associated with particular morphological changes (Table 3), although with the 
exception of the M3 subtype, these are not absolute. The FAB subtype M3 is defined by 
t(15;17)(q24;q21) and the PML/RARα fusion (Rowley et al., 1977). 
Type Cell Type Common Cytogenetics 
M0 Myeloblastic  
M1 Myeloblastic, with minimal maturation  
M2 Myeloblastic, with maturation t(8;21)(q22;q22) 
RUNX1/RUNX1T1, 
t(6;9)(p22;q34) DEK/NUP214 
M3 Promyelocytic t(15;17)(q24;q21) PML/RARα 
M4 Myelomonocytic inv(16)(p13;q22) 
CBFB/MYH11, del(16q) 
M5 Monocytic del(11q), t(9;11)(q34;q23) 
FNBP1/MLL 
M6 Erythroleukaemic  
M7 Megakaryocytic t(1;22)(p13;q13) 
RBM15/MKL1 
M8 Basophilic  
Table 3. The French-American-British classification of AML. Commonly associated cytogenetics are listed alongside 
associated disease classifications (Bennett et al., 1976). 
Although there are some examples in the FAB system where cell morphology correlates with 
cytogenetics, there are many in which the cytogenetic change is seen over a range of FAB 
types. Thus, the FAB classification based on morphology alone does not fully reflect the genetic 
and clinical diversity of AML. The World Health Organization (WHO) system of classification 
was established to include strong associated genetic changes. The classification of AMLs under 
this system is outlined in Table 4 (Vardiman et al., 2002; Vardiman et al., 2009). 
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 Acute myeloid leukaemia with recurrent 
genetic abnormalities 
AML with t(8;21)(q22;q22) RUNX1/RUNX1T1 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22) CBFB/MYH11 
APL with t(15;17)(q22;q12) PML/RARα 
AML with t(9;11)(p22;q23) MLLT3/MLL 
AML with t(6;9)(p23;q34) DEK/NUP214 
AML with inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2) RPN1/EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13) 
RBM15/MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukaemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise 
specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down 
syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down 
syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Table 4. The World Health Organization classification of acute myeloid leukaemia (Vardiman et al., 2002; Vardiman 
et al., 2009). 
A number of studies have utilised cytogenetic data to classify AML patients into different 
prognostic groups (Grimwade et al., 1998; Slovak et al., 2000; Grimwade et al., 2001; Byrd et 
al., 2002; Grimwade et al., 2010). These studies mostly overlap with their findings, and a 
general consensus of prognostication is listed in Table 5. Whilst cytogenetic risk group is the 
10 
 
most important factor in risk stratification, more recent studies have devised stratification 
methods that take into account clinical features for those patients not placed into the good 
prognosis group by the presence of t(8;21)(q22;q22) RUNX1/RUNX1T1, inv(16)(p13.1q22) 
CBFB/MYH11 or t(15;17)(q22;q12) PML/RARα (Grimwade et al., 2010). 
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 Prognosis MRC SWOG CALGB 
Good t(8;21)(q22;q22) 
RUNX1/RUNX1T1 
t(8;21)(q22;q22) 
RUNX1/RUNX1T1 
lacking del(9q) or 
complex karyotype 
t(8;21)(q22;q22) 
RUNX1/RUNX1T1 
inv(16)(p13.1q22) 
/t(16;16)(p13;q22) 
CBFB/MYH11 /del(16q) 
inv(16)(p13.1q22) 
/t(16;16)(p13;q22) 
CBFB/MYH11 /del(16q)  
inv(16)(p13.1q22) 
/t(16;16)(p13;q22) 
CBFB/MYH11 /del(16q) 
t(15;17)(q22;q12) 
PML/RARα 
t(15;17)(q22;q12) 
PML/RARα  
 
 CEBPA double 
mutations 
  
 NPM mutations   
Intermediate No abnormality No abnormality No abnormality 
Sole +8 +8  
11q23 abnormality +6  
Other intermediate (not 
otherwise classified as 
favourable or adverse) 
-Y -Y 
 del(12p) 12p abnormality 
  del(7q) 
  t(9;11)(p22;q23) 
MLLT3/MLL 
  +11 
  del(11q) 
  +13 
  del(20q) 
  +21 
Poor -7 -7/del(7q) -7 
del(5q)/-5 del(5q)/-5  
3q abnormality 3q abnormality inv(3)(q23q26) 
RPN1/MECOM or t(3;3) 
FLT3-ITD 9q  
12 
 
 11q  
 20q  
 21q  
 17p  
 t(6;9) t(6;9) 
 t(9;22) t(6;11) 
  Sole +8/+8 with one 
other abnormality 
  t(11;19) 
Complex karyotype 
(without favourable) 
Complex karyotype Complex Karyotype 
Table 5. Prognostic implications of AML cytogenetic subgroups. MRC = Medical Research Council (Grimwade et al., 
1998; Grimwade et al., 2001; Grimwade et al., 2010), SWOG = Southwest Oncology Group (Slovak et al., 2000), 
CALGB = Cancer and Leukemia Group B (Byrd et al., 2002). 
As paediatric AML is rarer than adult AML, there are fewer studies looking at the effects on 
prognosis of cytogenetics specifically in children. Although the abnormalities seen are largely 
the same, the distribution of cytogenetic changes in paediatric AML is different from that of 
adult AML (Raimondi et al., 1999; Betts et al., 2007). Despite the lower number of cases, a 
large recent study of 729 paediatric AML patients in the UK established a similar scheme of 
disease classification for children, outlined in Table 6 (Harrison et al., 2010) which was verified 
by a Dutch group (Balgobind et al., 2011). 
Prognosis Cytogenetics 
Good t(8;21) 
 inv(16) 
Intermediate Not included in Good or Poor risk 
Poor Abnormal 12 
 t(6;9) 
 5q Abnormalities 
 -7 
 t(9;22) 
Table 6. Medical Research Council classification of prognostic risk in paediatric AML (Harrison et al., 2010). 
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1.3.5 Pathophysiology 
The most common cause of death in AML is bone marrow failure. As AML blasts carry a genetic 
block to differentiation, these cells are unable to develop into mature red cells, neutrophils, 
monocytes and platelets. Cytokine expression by AML blasts prevents healthy BM cells from 
differentiating into their mature progeny, further compounding this effect (Youn et al., 2000). 
This BM failure often leads to death due to infection (Anderlini et al., 1996; Stalfelt et al., 
2001). Particularly high white blood cell counts (>50,000 cells per μL) often lead to potentially 
fatal organ infiltration, with an especially poor prognosis if the lung or brain is affected 
(Seymour et al., 1994). 
1.3.6 Treatment Strategies 
The treatment of AML has remained essentially the same for almost 40 years. The first phase 
of therapy (induction) consists of 3 days of treatment with the anthracycline daunorubicin in 
combination with cytarabine for 7 days. This treatment produces complete remission rates of 
around 65-75% (Tallman et al., 2005). Other treatments tested include the anthracycline 
idarubicin, the anthracenedione mitoxantrone, cytotoxic agents such as etoposide and 
fludarabine, as well as growth factors such as granulocyte colony-stimulating factor. However, 
these treatments have not been proven to be more successful than standard therapy except in 
a small number of subgroups (Estey and Dohner, 2006).  
If remission is achieved with initial therapy, postremission therapy (consolidation) is 
administered. This treatment is directed according to the risk group that the patient has been 
classified into – either good, intermediate or poor risk, depending on the cytogenetic group, 
age and white blood cell count. Patients stratified into the good risk arm tend to be continue 
on therapy consisting of high dose cytarabine, which has been shown to be highly effective 
(Schaich et al., 2013). Intermediate and particularly poor risk patients are often recommended 
for either autologous or allogeneic stem cell transplantation as an alternative to chemotherapy 
(Burnett et al., 2009). Stem cell transplantation has improved outcome in terms of relapse-free 
survival, but carries a risk of treatment-related deaths of between 10 and 25%, as well as 
conferring an inferior long-term quality of life (Watson et al., 2004). Patients classified as poor 
risk have less than 10% relapse-free survival on all treatments. 
Patients who either fail to enter complete remission after induction therapy, or who relapse 
early are placed onto salvage treatment. The treatment given in these cases depends on the 
previous treatment received but will typically consist of either high-dose cytarabine or 
fludarabine plus cytarabine. In some cases allogeneic stem-cell transplantation will be 
recommended, which has proved to be successful in certain subgroups (Wong et al., 2005). 
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The current definition of complete remission in AML is the presence of less than 5% 
myeloblasts in the BM. A number of studies have suggested that this number is too high, and 
there is increasing evidence that more sensitive techniques such as polymerase chain reaction 
(PCR) and FACS should be used to detect minimal residual disease (MRD) (Chen et al., 2011; 
Kronke et al., 2011; Roboz, 2011). It is believed that the high rate of relapse observed in AML is 
due to a small population of leukaemic stem cells (LSCs) that normally make up between 0.1% 
and 1% of the entire leukaemic population. These cells are mostly quiescent but are capable of 
self-renewal, and are highly resistant to both intensive chemotherapy and allogeneic stem cell 
transplants (Roboz and Guzman, 2009). For this reason, a number of novel therapies are 
currently in development with the aim of specifically targeting MRD. Such therapies include 
drugs that target the PI3K pathway or the transcription factor complex NF-κB, both of which 
have been shown to be crucial for LSC function (Frelin et al., 2005, Thomas et al., 2013). Other 
possible treatments include antibody based therapies targeting cell surface antigens 
preferentially expressed by LSCs, such as CD33, CD44, CD47, CD123 and CLL-1 (Walter et al., 
2012). Finally, therapies that may disrupt regulatory pathways such as Wnt, Notch and HOX 
are being developed to disrupt the interaction of LSCs with the BM microenvironment (Roboz 
and Guzman, 2009; Schneider et al., 2014). 
There are currently a number of therapies in development to target commonly mutated genes 
in AML. For example, there are 5 drugs targeting FLT3 currently in trials (Lestaurtinib, 
Quizartinib, Sorafenib, Midostaurin and PLX3397, Hatzimichael et al., 2013). FLT3 is an 
important target in AML since mutations in the gene are frequent and FLT3-ITD imparts a 
particularly poor prognosis (Grimwade et al., 2010; Fathi and Chen, 2011). With therapies also 
in development for other genes involved in AML, including NPM1, PLK1, DOT1L and JAK2, 
there is hope that patient outcome can be improved in the future with new treatments. 
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1.4 Tumour Suppressor Genes 
Tumour suppressor genes and oncogenes are crucial factors that contribute to cancer 
development in a wide range of malignancies, and are the main focus of this project. Historical 
examples of each will be discussed and select examples involved in AML development will be 
explored in these sections. 
The classical “two-hit hypothesis” of cancer dates back to 1971, when it was first proposed by 
Alfred Knudson. In his hypothesis, he stated that loss of function mutations in tumour 
suppressor genes are recessive, so for a cell to become malignant, it would need to lose 
function of both alleles (Knudson, 1971). He reached this conclusion through the study of 
children who developed retinoblastoma, and found that 40% of cases were associated with a 
familial history of the disease. Additionally, these cases had a much higher rate of tumours 
that affected both eyes and occurred at a younger age, whilst nonhereditary cases were 
unilateral and typically occurred in older children. From this, Knudson concluded that 
retinoblastoma was caused by two separate mutation events, each affecting a single copy of a 
tumour suppressor gene (now known as the RB1 gene). For patients with hereditary disease, 
he hypothesised that they already carried one of these mutations, leading to frequent bilateral 
tumours and early onset of disease. From his work, he estimated that each mutation event 
would occur at a rate of 2 x 10-7 per year, and whilst many people in the general population 
would have acquired a single RB1 mutation in their lifetime, the cells carrying the mutations 
would have already differentiated and stopped dividing before they acquired a second 
mutation (Knudson, 2001). 
1.4.1 TP53 
The TP53 protein was originally identified as a component of the SV40 virus – a virus shown to 
transform cells and induce tumours in animals. It was known that the virus expressed 3 early 
antigens associated with cell transformation: a large antigen of 90kDa, a small antigen of 
17kDa, and a middle T antigen of around 55kDa. The identification of the middle antigen 
became an important topic. It was eventually found to be a 53kDa protein that was not an 
antigen, and was not coded by the virus, but by the host cell itself (Kress et al., 1979). This 
discovery sparked the field of TP53 research into life, with subsequent publications showing 
that TP53 accumulated in the nuclei of tumour cells (Linzer and Levine, 1979), and was also 
associated with the T antigen of SV40 (Lane and Crawford, 1979).  
In the early 1980s, the theory that cancer arose as the result of oncogene activation became a 
popular topic of research. At the same time, it was shown that transfected TP53 could 
cooperate with other known oncogenes to lead to cellular transformation (Parada et al., 1984), 
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leading to the classification of TP53 as an oncogene. However, further studies indicated that 
the gene did not quite fit into the oncogene classification. It was reported that TP53 alleles 
were inactivated in murine erythroleukaemias (Mowat et al., 1985), and that it was frequently 
deleted or rearranged in human and murine osteosarcoma (Masuda et al., 1987). It later 
became clear that early clones of mammalian TP53 genes contained base pair substitutions in 
regions coding functional domains (Finlay et al., 1989), which produced mutant TP53 protein 
with seemingly oncogenic properties, when it actually exhibited dominant negative features. 
The subsequent demonstration of the anti-proliferative characteristics of wild type TP53, in 
conjunction with its inactivation in human cancers, lead to its status finally being changed from 
oncogene to tumour suppressor. 
The TP53 gene is located on the short arm of chromosome 17. The encoded protein contains 
393 amino acids, divided into 7 functional domains. These functional domains are summarised 
in Figure 3. The first activation domain (TAD1) is required for transcription factor activation, 
whilst the second activation domain (TAD2) is important for apoptotic activity. The central 
DNA binding domain (DBD) is crucial to many of the roles of TP53 and is the hotspot for 
mutations in a wide range of cancers (Olivier et al., 2010). The homo-oligomerisation domain 
(OD) allows TP53 to form tetramers with itself, essential for its functional activity. 
 
Figure 3. A schematic representation of the p53 protein. TAD - Transactivation Domain; PRR - Proline Rich Domain; 
DBD - Central DNA-binding Core Domain; NLS - Nuclear Localisation Signalling Domain; OD - Homo-Oligomerisation 
Domain; CTD - C-Terminal Domain. 
TP53 primarily functions as a transcription factor, by enhancing the transcription of a number 
of genes that carry out the TP53-dependent functions in a cell. It has a number of additional 
roles, including the activation of DNA repair proteins, the arrest of the cell cycle at G1/S phase, 
and the induction of apoptosis. Two homologues of TP53 have been described: TP63 and TP73 
(Kaghad et al., 1997; Yang et al., 1998). Both are believed to have similar functions to TP53, 
while the 1p36.32 region (where TP73 is located) is frequently deleted in cancers. However 
deletions of TP63 and TP73 alone in murine models are insufficient to induce cancers, unlike 
deletions of TP53. 
A large study investigated the prognostic value of TP53 deletions in 2272 adult AMLs. Deletions 
were found in 105 patients (5%), and the majority of them occurred in conjunction with 
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multiple other aberrations (Seifert et al., 2009). They showed that TP53 deletions carried an 
inferior prognosis in both simple and complex karyotypes compared to patients without these 
deletions. Studies investigating the mutation rate in AML have found an occurrence of around 
13% across all AML subtypes (Schoch et al., 2006). 
TP53 aberrations frequently occur in conjunction with other high-risk abnormalities, such as 
del(5q), -5 and -7, as well as complex karyotypes (Christiansen et al., 2001; Rucker et al., 2012). 
In many of these patients, deletions often occur in conjunction with mutation of the remaining 
allele, leading to a complete loss of wild type function TP53. A study of 234 complex karyotype 
AML patients showed that whilst 40% of patients had deletion of TP53, 60% of patients had a 
mutated TP53, and two thirds of those with a mutant TP53 had deletion of the remaining 
allele, resulting in homozygous loss of wild type functional TP53 (Rucker et al., 2012). 
Some theories have implied that loss of TP53 in AML facilitates the development of further 
abnormalities due to the genomic instability associated with TP53 loss, leading not only to 
complex karyotypes but also to even rarer events such as gene amplification. It has also been 
related to the resistance to chemotherapy seen in patients with a complex karyotype, as the 
unstable genomic landscape is susceptible to changes that may be advantageous to their 
continued growth when faced with overcoming the effects of treatment (Schmitt et al., 2002; 
Haferlach et al., 2008). 
1.4.2 WT1 
The WT1 gene was one of the first tumour suppressor genes to be cloned, in 1990 (Call et al., 
1990; Gessler et al., 1990). When mutated, this gene led to predisposition to the development 
of a type of embryonal kidney malignancy, known as Wilms’ tumour or nephroblastoma. The 
gene contains multiple zinc finger motifs, as well as a DNA-binding domain. WT1 also contains 
multiple alternative splice sites, and 24 different isoforms of the gene have been identified 
(Hohenstein and Hastie, 2006). The exact mechanisms by which WT1 functions have not been 
fully elucidated, because the gene itself has different functions depending on which tissue it is 
expressed in as well as at what stage of development it is expressed. 
WT1 has been identified to have 3 main roles. The first is in transcriptional regulation. Through 
differential expression of Wt1 in mutant mouse models, in combination with chromatin 
immunoprecipitation techniques, a number of target genes have been identified, which appear 
to be activated by WT1, including Amphiregulin, Sprouty, TrkB, nephrin, nestin and Pou4f2. 
WT1 is also believed to have a role in RNA metabolism, as it has been shown to bind RNA in 
vivo (Ladomery et al., 2003). However it is not clear whether this leads to alternative splicing 
or processing of the RNA that it binds to. The second role of WT1 is believed to be in 
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differentiation, as WT1 has been shown to be required for proper kidney development by 
stimulating differentiation of immature kidney cells (Davies et al., 2004). In other organ types 
such as the heart, WT1 has the opposite role; to maintain an undifferentiated state in 
progenitor cells (Moore et al., 1998). 
Although first identified as a tumour suppressor, recent evidence has accumulated suggesting 
a possible oncogenic role for WT1 in tumours such as colorectal, breast, desmoid and brain. In 
these tumour types elevated WT1 expression has been identified, on a wild type WT1 
background. Additionally, RNAi targeted to WT1 in some cell lines has led to a reduction in 
proliferation rate, as well as the inhibition of apoptosis (Tuna et al., 2005). In tumours where 
elevated WT1 expression has been identified, the majority of the protein appeared to be 
located in the cytoplasm; an abnormal location for the majority of WT1 proteins which may 
reflect the upregulation of a specific WT1 isoform. The cell of origin of these tumour types is 
also likely to be highly important in unravelling the role of WT1, especially as it is clear that 
WT1 has a variety of roles in differentiation between tissue types, as well as in different stages 
of differentiation. 
In AML, WT1 mutations have been found to occur in 6-13% of all non-M3 AML patients, with a 
higher rate in younger patients with a normal karyotype (Gaidzik et al., 2009; Hou et al., 2010). 
Multivariate analysis of these data showed that WT1 mutations were an independent poor 
prognostic factor for both overall survival and relapse-free survival in these patients. High 
levels of WT1 expression have been associated with a worse outcome (Nomdedeu et al., 2013; 
Luo et al., 2014) and it has been suggested that levels of WT1 could be used as a target for 
MRD detection in AML with a high degree of accuracy (Nomdedeu et al., 2013). 
1.4.3 CUX1 
CUX1 was recently identified as a tumour suppressor gene in AML within the long-investigated 
long arm of chromosome 7 (7q). This region is frequently deleted in AML, but it was previously 
unknown how these deletions contributed to leukaemogenesis. CUX1 was identified to be 
within a minimal region of deletion of 7q, and to have a reduced expression in AML cases 
where it was deleted (McNerney et al., 2012). Additionally, one case with a CUX1 fusion gene 
was identified in this study, providing an alternative process by which its expression was 
reduced.  
CUX1 functions as a transcription factor involved in cell cycle progression and apoptosis, and 
has previously been implicated in the tumorigenesis of breast and pancreatic cancers (Hulea 
and Nepveu, 2012). However, these studies in solid tumours have found that its expression is 
increased in high grade tumours, and its high expression is associated with increased cell 
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proliferation as well as motility and invasiveness. Despite this seemingly conflicting evidence, 
McNerney et al. (2012) used RNAi to knock down the CUX1 ortholog, cut in D. melanogaster. 
They found that this resulted in the formation of melanotic tumours in Drosophila larvae and 
pupae as the result of haemocyte overgrowth. These findings were consistent with a human 
model, where CUX1 was knocked down in human haematopoietic progenitors and 
transplanted into immunocompromised mice. The proportions of cells expressing CUX1 shRNA 
were found to be significantly higher compared to cells expressing nonspecific shRNAs, but this 
change did not affect the ability of the cells to differentiate into various haematopoietic 
lineages (McNerney et al., 2012). These data suggest that CUX1 may act as a tumour 
suppressor gene in other haematopoietic cell types. 
Interestingly, unlike classical tumour suppressor genes such as RB1, CUX1 was found to act as a 
haploinsufficient tumour suppressor gene, as the transcript levels were found to be half of 
those found in samples with both CUX1 alleles intact. The large size of deletions within 
chromosome 7q in AML raise the possibility that there are other genes acting as tumour 
suppressors in this region, either through a heterozygotic or biallelic mutation. Indeed, this is 
likely to be the case as Chen et al. (2014) demonstrated that MLL3 is likely to have tumour 
suppressor properties in AML, as Mll3 suppression through shRNA knockdown and CRISPR 
gene editing in mice promoted the development of myeloid leukaemia (Chen et al., 2014). 
Mll3 suppression was found to impair haematopoietic stem cell differentiation both in vitro 
and in vivo, producing a MDS-like state and corresponding gene expression signature. 
Further compounding the complex nature of deletions in this region, two other genes have 
been put forward as possible tumour suppressors. EZH2 has been shown to act as a tumour 
suppressor in ALL (Simon et al., 2012) yet also acts as an oncogene in other cancer types (Lund 
et al., 2014). MLL5, another MLL family member has also been shown to be involved with 
differentiation and self-renewal in haematopoietic stem cells (Zhang et al., 2009) suggesting 
that the 7q region may harbour multiple tumour suppressor genes. 
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1.5 Oncogenes 
Whilst oncogenes play an equally large part in cancer development, their role is the opposite 
of a tumour suppressor gene. Rather than loss of function leading to tumourigenesis, a proto-
oncogene is normally affected by activating mutations that lead to their overactivity and 
subsequent classification as an oncogene. This may be a point mutation that leads to a gene 
product being constitutively activated, or mutations of genetic material resulting in 
overexpression of the gene. 
The first oncogene to be identified was src (Martin, 2001). It was identified after considerable 
research into the Rous sarcoma virus (RSV), which was first identified as a filterable agent that 
caused solid tumours in chickens. At the time, the research community was highly sceptical 
that cancers could be caused from an infectious origin, however further research 
demonstrated that the virus was released from infected tumour cells and led to the further 
propagation of both the tumour itself and viral particle release (Rubin, 1955). Subsequent 
work identified that different cellular morphology could be produced as a result of infection 
depending on which strain infected the cells, suggesting that the morphology of the 
transformed cell was controlled by a genetic property of the virus (Temin and Rubin, 1958; 
Temin, 1960). Although it was not known at the time, this was actually a property of the v-src 
gene. 
Additional strains of RSV were identified in 1970 that were unable to induce cellular 
transformation and were key to the physical identification of v-src (Golde 1970; Toyoshima et 
al., 1970). The strains that were unable to induce transformation were found to have a shorter 
viral genome, suggesting that these genes were lacking in a component that promoted 
transformation. This gene was first identified with oligonucleotide fingerprinting to allow it to 
be tracked through a series of genetic crosses, from which it was shown to be the gene 
responsible for transformation (Bernstein et al., 1976; Wang et al., 1976).  
The question still remained why RSV carried a gene that induced cellular transformation. 
Further research using sequence probes for v-src found that the gene had homologous 
sequences in normal avian genomes, and that regions of these genes were also conserved in 
vertebrates. The fact that the gene was present in vertebrates suggested that it was of cellular 
and not viral origin. This led to src being designated as the first proto-oncogene, due to its 
nature as a cellular precursor of a retroviral transforming gene (Stehelin et al., 1976). 
1.5.1 MYC 
Mutation, amplification or activation of MYC family genes is one of the most frequent events 
associated with cancer (Eilers and Eisenman, 2008). The discovery of the first MYC family genes 
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stemmed directly from the work researching RSV and the findings related to src. Another avian 
virus affecting chickens, MC29 was isolated and found to induce haematopoietic neoplasia, 
although it did not result in the development of overt leukaemia (Ivanov et al., 1964). Instead, 
the virus transformed myeloid cells which went on to form either diffuse growths known as 
myelocytomatosis, or solid tumours known as myelocytomas. These growths were to give the 
MYC family its name. 
In a similar story to src, finding the gene driving cellular transformation was difficult but the 
use of newly developed techniques (in this case, radiolabelled nucleic acid sequences) allowed 
researchers to identify and track the single functional gene it carried, the gag-myc fusion gene 
(Sheiness et al., 1978). The v-myc gene within this fusion gene was identified and found to be 
distinct from src. Additional work on other avian leucosis viruses that did not carry v-myc 
found that they acted by directly stimulating a v-myc homologue through retrovirial insertion 
(Hayward et al., 1981). This allowed the cellular homologue of v-myc to be identified, which 
was named c-myc and began the development of a huge amount of research into the Myc 
family of genes (Vennstrom et al., 1982). 
Mammalian cells express MYC proteins from 3 distinct genes, which are c-Myc, N-myc and L-
myc. They have similar functions but different patterns of expression as well as differing 
potencies (Tansey, 2014). They have a similar general structure, with a DNA-binding domain at 
their C-termini and a transactivation domain at their N-termini. This means that upon binding 
specific genomic sites, MYC proteins are able to recruit RNA polymerase II associated proteins 
to stimulate gene transcription (Tansey, 2014). 
The first human involvement of MYC driven cancer was found in Burkitt’s lymphoma. Large 
chromosomal translocations had been noted in a range of human malignancies, but their 
biological effects were unknown. After c-MYC was mapped to chromosome 8, it was noted 
that in Burkitt’s lymphoma, chromosomes 14, 2 or 22 were translocated with chromosome 8. 
The partners for c-MYC in these cases were found to be the loci for immunoglobulin heavy and 
light chains respectively, and the relocation of c-MYC to their highly active enhancer regions 
was found to result in overexpression of c-MYC (Adams et al., 1985). 
MYC family members typically drive cancer development through a number of mechanisms, 
however it is clear now that not all of these mechanisms are active in every cancer type where 
MYC is dysregulated. MYC has been shown to drive cellular growth through the activation of 
cyclin expression and through inhibiting cell cycle checkpoints, leading to cells being able to 
pass through G1 and G2 cell cycle phases faster (Oster et al., 2002). MYC also drives growth 
through promoting protein synthesis and RNA transcription (Iritani and Eisenman, 1999). It 
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achieves this by activating the expression of protein coding genes responsible for ribosome 
biogenesis and protein translation. MYC is also able to stimulate the activity of RNA 
polymerases I and III leading to enhanced rRNA and tRNA synthesis (Gomez-Roman et al., 
2003; Arabi et al., 2005). Finally, MYC is also able to converge with mTOR to increase the 
efficiency of mRNA-ribosome engagement (Pourdehnad et al., 2013). 
The increased levels of proliferation driven by MYC family members has been shown to lead to 
an increased level of cancer genome instability. This phenomenon is known as replication 
stress, and leads to the breakdown of DNA replication forks at fragile hotspots in the genome. 
As the cell cycle checkpoints in cancer cells are typically inhibited, these breaks are not 
resolved correctly and can lead to double-stranded DNA breaks, loss of heterozygosity, 
amplifications and rearrangements of select loci (Mai et al., 1996; Felsher and Bishop, 1999). 
MYC overexpression has also been linked to an increased production of reactive oxygen 
species (ROS), which themselves contribute to further DNA damage (Vafa et al., 2002). 
Somewhat counterintuitively for an oncogene, MYC is also able to drive apoptosis. In the 
absence of cellular survival factors, forcing high levels of MYC expression has been shown to 
promote apoptosis (Askew et al., 1991), and this is achieved mainly through stimulating 
expression of the ARF tumour suppressor gene, resulting in a rapid induction of TP53 (Li and 
Hann, 2009). It is clear that this mechanism needs to be overcome in MYC-driven cancer 
development, and one mechanism through which this is achieved is by the commonly 
observed loss of TP53 in cancer, as described previously. 
In AML, MYC  is upregulated by activating mutations of the FLT3 receptor tyrosine kinase 
(Gilliland and Griffin, 2002), as well as by a number of fusion genes commonly found in AML, 
including RUNX1-RUNX1T1, PML-RARα and PLZF-RARα (Müller-Tidow et al., 2004). Mutations 
in CEBPα have also been linked with elevated expression levels of MYC (Johansen et al., 2001). 
Amplification of the genomic region containing MYC is one of the most common amplifications 
detected in AML, and these additional copies are often found on double minute chromosomes 
(Slovak et al., 1994). Although microarray studies do not often report MYC overexpression, this 
may be due to stricter filtering protocols searching for fold changes greater than 2 times above 
control samples. However it is known that MYC can have relevant effects at a sub 2-fold 
expression level change, as demonstrated by the ability of c-Myc to cause transformation of 
rat fibroblasts and mouse embryonic stem cells with only modest overexpression (Murphy et 
al., 2008). 
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1.5.2 RAS 
The Ras family of genes contains 3 genes (HRAS, KRAS, and NRAS) that encode small GTPases 
critical to many signal transduction pathways within cells. Similar to Src and Myc¸ the first Ras 
genes were identified as homologues of the transforming components of Harvey and Kirsten 
murine sarcoma retroviruses, in 1981 (DeFeo et al., 1981). The Harvey sarcoma virus-
associated oncogene was named Ha-ras (H-RAS in mammals) and the Kirsten sarcoma virus 
transforming gene was named Ki-ras (K-RAS in mammals). After the identification of the 
human homologues of these genes, mutations in their sequences were discovered soon 
afterwards in a range of human cancer cell lines (Karnoub and Weinberg, 2008). The third 
member of the Ras family was identified in 1983 through cloning from neuroblastoma and 
leukaemia cell lines, and was named N-RAS (Shimizu et al., 1983). 
The GTPase activity of Ras family members was identified in 1980, when it was shown that Ras 
proteins bound to guanine nucleotides in a similar fashion to other previously identified 
GTPases (Shih et al., 1980). In mutated Ras, this function is disrupted and the commonly 
observed mutations in cancer lead to impaired GTP hydrolysis. This leads to Ras remaining in 
an active conformation for an increased period of time, during which it stimulates its 
downstream pathways. 
Downstream of Ras, the Ras/Raf/MEK/ERK pathway is central to the transduction of a variety 
of cell surface receptors to transcription factors in the nucleus, including mitogens and 
cytokines. The Raf protein family contains serine/threonine specific protein kinases related to 
retroviral oncogenes. There are 3 members, A-Raf, B-Raf and C-Raf (Raf-1), which are primarily 
activated by Ras family members. However they are also able to be regulated by AKT (Rommel 
et al., 1999), cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) (Dumaz et al., 
2002). The Raf family members contain a Ras-GTP binding domain and a catalytic protein 
kinase domain, linked by a serine rich hinge region.  
The primary target of Raf proteins are the MEK family of gene products (MEK1-5), which are 
tyrosine/threonine kinases. The MEK gene products (primarily MEK1 and MEK2) then 
phosphorylate and activate mitogen activated protein kinases (MAPK). These have many 
targets of phosphorylation, including a wide range of proliferation related transcription factors 
such as c-Myc and CREB (through MNK phosphorylation) (Avruch et al., 2001). Furthermore, 
translation of mRNA to protein is increased by phosphorylation of the 40S ribosomal protein 
S6 kinase, leading to phosphorylation of ribosomal protein S6 and enhanced translation. 
In AML, mutations in N-RAS or K-RAS are found in 12-27% of patients, with around two thirds 
of these occurring in N-RAS, and one third in K-RAS (Bowen et al., 2005; Neubauer et al., 2008). 
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There is much conflicting evidence about the prognostic effects of RAS mutations in AML, with 
some studies finding inferior, the same or a more favourable prognosis associated with RAS 
mutations. Despite these observations, there is evidence that patients with RAS mutations may 
benefit from increased doses of cytarabine during consolidation treatment (Neubauer et al., 
2008; Ahmad et al., 2011). 
1.5.3 BCL2 
BCL2 was one of the first oncogenes to be discovered that primarily drove oncogenesis 
through increased cellular survival rather than by promoting aberrant proliferation. It was first 
identified in cancer cells as being translocated in a t(14;18)(q32;q21) translocation to the 
immunoglobulin heavy chain locus in follicular lymphoma (Tsujimoto et al., 1984), leading to 
BCL2 overexpression. As BCL2 normally has an anti-apoptotic function, this overexpression 
prohibits cell death through inhibition of pro-apoptotic BCL-family members. There have been 
a large number of BCL2 family members identified, including inhibitors of apoptosis (for 
example BCL2 and BCLX), promoters of apoptosis (such as BAX and BAK), as well as regulators 
that act as either activators or inhibitors (for example BAD, BID and BIM) (Youle et al., 2008; 
Chipuk et al., 2010). 
BCL2 expression levels in AML have been associated with a number of AML disease 
characteristics. It is highly expressed in the immature FAB subtypes M0 and M1 (Venditti et al., 
2004), and its increased expression is associated with expression of the RUNX1-RUNX1T1 
fusion gene (Klampfer et al., 1996). High levels of BCL2 protein have been proposed to be 
markers of poor prognosis (Karakas et al., 1998) except in patients who have poor risk 
cytogenetics, for whom it is a marker of improved prognosis (Kornblau et al., 1999). 
Due to the widespread prevalence of altered BCL2 expression in AML, a number of studies are 
looking to use it as a target for therapy with the aim of improving treatment. ABT-199, a BCL2 
inhibitor currently under investigation for the treatment of lymphoid cancers has been shown 
to be effective in inducing cell death in AML cell lines in vitro (Pan et al., 2014). Similarly, 
another BCL2 inhibitor known as ABT-737 has been shown to be effective in treating 
chemoresistant primary AML blasts (Kohl et al., 2007), as well as in the treatment of AML in a 
transgenic mouse model (Beurlet et al., 2013). 
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1.6 12p Deletions in AML 
Both deletions and translocations of the short arm of chromosome 12 have been widely 
described in a variety of haematological malignancies, including AML, ALL, MDS and non-
Hodgkin lymphoma (Andreasson et al., 1997). Translocations in this region typically involve the 
Ets Variant 6 (ETV6) gene, and over 40 partner genes for ETV6 have been identified. In AML 
cases with translocated ETV6 however, it is rarely possible to detect the expression of a fusion 
protein and it is thought that the disruption of gene expression in this region leads to 
leukaemogenesis in these patients (Bohlander, 2005).  
Deletions of 12p are found in between 1% and 5% of AML patients from conventional 
cytogenetic studies (Grimwade et al., 2010; Harrison et al., 2010) and in adult AML they are 
frequently associated with other abnormalities such as -7/-7q and -5/-5q (Wall et al., 2012). It 
has been suggested that small deletions of 12p that are not detectable by cytogenetic analysis 
may occur in up to 10% of normal karyotype AML patients, as demonstrated by a sensitive 
FISH study performed by Andreasson et al. (1997). Deletions of 12p in paediatric AML have 
been found to have a poor prognosis, with a 35% event-free survival compared to 59% without 
deletions of 12p (Harrison et al., 2010). Although there is limited data for adult AML with 12p 
deletions, analysis of survival data from annotated copy number microarray data 
demonstrates that a poor prognosis is also observed in these patients (Parkin et al., 2010). 
 
Figure 4. Prognostic effects of 12p deletion in AML. A. 12p deletions in paediatric AML, from Harrison et al. (2010). B. 
12p deletions in adult AML, from Parkin et al. (2010) (GSE23452). 
A number of studies have attempted to define the boundaries of 12p deletions in AML. Whilst 
some studies have suggested boundaries defined by the ETV6 and CDKN1B genes, (Sato et al., 
1995; Wlodarska et al., 1996; Andreasson et al., 1997; Andreasson et al., 1998; Baens et al., 
1999) two studies based on findings in single patients have disputed this. Silva et al. (2008) 
excluded CDKN1B from the MDR whilst retaining ETV6, whilst Haferlach et al. (2009) excluded 
ETV6 whilst retaining CDKN1B in their MDR. Many of these studies used FISH probes to map 
the deletions relying on small numbers of patients, thus identifying the region of 12p deletions 
using a high resolution method and increased numbers of patients is warranted. 
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Few studies have measured the expression levels from within the deleted region of 12p and 
compared them to control samples; the studies that measured expression have generally 
focussed on single genes (Baens et al., 1999; Silva et al., 2008). In other haematological 
malignancies however, it has been demonstrated that loss of genes from this region results in 
reduced expression of affected genes, suggesting that the loss of material has functional 
consequences (Montpetit et al., 2004). 
  
27 
 
1.7 11q Amplifications in AML 
Gene amplification is an event rarely associated with AML and typically involves either the long 
arm of chromosome 8 (containing the MYC gene as described previously), or the long arm of 
chromosome 11 (11q). Amplifications of 11q are found in between 1 and 2% of AML patients 
overall. However, the gain of genetic material from 11q is the most commonly observed gain in 
complex karyotype AML, seen in between 15 and 40% of these patients (Schoch et al., 2002; 
Rücker et al., 2006). It is likely that if there is a gene or genes with an oncogenic dosage linked 
effect on 11q, it would reside within amplified regions that overlap with the commonly 
observed gains. 
Amplified chromosomal material of 11q has been found in a variety of cytogenetic 
manifestations, including homogenously staining regions, double minutes, ring chromosomes 
and marker chromosomes. The number of additional copies found in amplifications has ranged 
from 4 to 50 copies per cell (Avet-Loiseau et al., 1999). Typically, patients with amplifications 
of 11q have a complex karyotype, which are frequently associated with deletions of 
chromosome 5/5q, 7/7q and 17/17p (Zatkova et al., 2009). AML patients with 11q 
amplification tend to be older (median age = 71, Michaux et al., 2000) and respond poorly to 
treatment (Maitta et al., 2009). Both complex karyotype AML and 11q amplification are 
associated with therapy-related AML, with 11q amplification found in 12% of t-AML patients 
(Andersen et al., 2001; Mohamed, 2011). 
Whilst there are a number of historical studies that have looked at 11q amplifications using 
Fluorescence in situ Hybridisation (FISH) (Michaux et al., 2000; Streubel et al., 2000; Andersen 
et al., 2001; Dolan et al., 2002), there are few that have made use of array based techniques to 
define the extent of gains and amplifications of 11q in AML. A study by Rücker et al. (2006) 
used microarray techniques to identify a wide range of chromosomal aberrations in 60 
complex karyotype patients. Twenty-four of these patients (40%) had some form of 
chromosomal gain on 11q and three separate common regions of gain were identified. Fifteen 
cases had gains between 59.1 and 79.6 megabases (MB) on 11q12-q14. Twenty-one cases had 
gains between 116.3 and 119.6MB on 11q23.3 (containing the MLL locus), and of these, 5 
cases showed high level amplification greater than 2 additional copies. The third common 
region of gain was identified in 20 cases as being between 127.1 and 129.3MB on 11q23.3-
q24.1 (containing the ETS1 and FLI1 loci); 7 of these cases displayed high level DNA 
amplification. The authors also made use of expression microarray data to study a gene dosage 
effect in these patients, and found that patients with gains of 11q had a significantly increased 
average expression for gained genes compared to those patients without gains (1.17 vs. 1.00, 
p=0.005) (Rücker et al., 2006). 
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One of the largest studies seeking to map the extent of 11q amplifications in AML was 
performed using array comparative genomic hybridisation (CGH) in 12 patients with 11q 
amplification (Zatkova et al., 2009). This study found nine recurring amplified regions on 11q, 3 
of which were amplified in all cases studied. These included a similar region containing MLL to 
the Rücker et al. paper (117.4 to 117.9MB, 11q23.3.) as well as two amplicons spanning 126.4 
to 130.9MB containing ETS1 and FLI1 on 11q23.3-q24.1. Expression analysis of the same group 
of patients confirmed increased expression of probes from within the amplified regions, as 
well as a gene expression signature distinct from other complex karyotype patients and MLL 
translocated AML patients (Zatkova et al., 2009). 
A correlation between gene dosage and the presence of trisomy 11 has also been confirmed 
outside of complex karyotype samples, where 828 out of 1263 (65.6%) probe sets 
corresponding to chromosome 11 displayed an increased expression when compared to 
normal karyotype control AML samples (Schoch et al., 2005).  
1.7.1 TP53 Status and 11q Amplification 
Both AML and MDS patients with 11q amplifications have an unusually high frequency of TP53 
mutations and 17p deletions. TP53 mutations have been observed at a frequency of up to 94% 
in 11q amplification patients (Zatkova et al., 2009), compared to 78% in complex karyotype 
AML/MDS (Haferlach et al., 2008) and 13.4% in AML as a whole (Schoch et al., 2006). Similarly, 
17p deletions including the TP53 locus have been reported at 32% of 11q amplification 
patients (Zatkova et al., 2009), compared to 53% of complex karyotype AML/MDS patients 
(Haferlach et al., 2008). The loss of wild type TP53 function may result in genetic instability 
leading to the acquisition of a complex karyotype including 11q amplifications in these 
patients. TP53 mutations or losses may also provide a mechanism for the chemoresistance 
commonly seen in AML patients with a complex karyotype (Schmitt et al., 2002). 
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1.8 Oncogenic Drivers and Passengers 
Whilst it is clear that there are many recurrent genetic changes involved in the development of 
both AML and cancer as a whole, many of the affected genes are not likely to be directly 
involved in disease development. For this reason, the terms ‘driver’ and ‘passenger’ are used 
when referring to different classes of genetic changes (Stratton et al., 2009). 
Driver mutations are beneficial to cancer cells and are positively selected for by the 
microenvironment in which the cell is growing. These types of mutations confer a growth 
advantage through a range of mechanisms, for example, in addition to proliferative 
advantages, the ability to adapt their microenvironment (e.g. by promoting angiogenesis), by 
allowing the cancer to metastasise or through providing chemotherapeutic drug resistance to a 
cell. 
Passenger mutations are not selected for and do not provide a growth advantage. They exist 
because multiple genetic mutations are acquired throughout cancer development which may 
become fixed in a population if advantageous driver mutations are also acquired. Hence the 
passenger mutations are carried in the clonally expanded population by the driver mutations 
(Stratton et al., 2009). 
A difficulty arises in distinguishing driver mutations from passenger mutations. The advent of 
whole genome sequencing has further demonstrated that there are huge numbers of 
mutations present in cancer genomes, and it is likely that the majority of these are passenger 
mutations. Approaches to address this issue will be discussed in Chapter 4.1. 
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1.9 Hypothesis and Study Objectives 
As has been discussed above, deletions of chromosome 12p and amplifications of 11q have 
been identified as recurrent abnormalities in AML, with no clear single candidate gene within 
either chromosomal region known to contribute to leukaemogenesis. The presence of these 
abnormalities in patients often attributes towards a poor outcome, and patients may benefit 
from a therapy targeted to the leukaemogenic drivers behind their disease. Thus clear 
identification of the genes driving disease progression is required as well as an understanding 
of their functional effects. 
 
The hypothesis behind this study was that: 
Loss of material on chromosome 12p and gains of material on chromosome 11q result in the 
loss or gain of genes that contribute to the development of poor prognosis AML. 
 
The objectives of this study were: 
1. To clearly define the extent of deletions and amplifications in these regions and 
identify a set of candidate genes that may drive leukaemogenesis. 
2. To identify which genes contribute to disease development through the use of a 
negative selection assay performed in vitro and in vivo. 
3. To investigate the relevance of targets identified in the screening assay. 
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Chapter 2 General Materials and Methods 
2.1 Materials 
2.1.1 List of Manufacturers and Suppliers 
Supplier Location 
Abbott Molecular Chicago, IL, USA 
Affymetrix Santa Clara, CA, USA 
Agilent Technlogies Santa Clara, CA, USA 
Beckman Coulter Brea, CA, USA 
Becton Dickinson Franklin Lakes, NJ, USA 
BioRad Hercules, CA, USA 
BMG Labtech Ortenberg, Germany 
Caliper Life Sciences Hopkinton, MA, USA 
Clontech Mountain View, CA, USA 
Corning Inc. Corning, NY, USA 
Cytocell Cambridge, UK 
Enzo Life Sciences Farmingdale, NY, USA 
Eppendorf Hamburg, Germany 
Fisher Scientific Loughborough, UK 
GE Healthcare Little Chalfont, UK 
Genecopoiea Rockville, MD, USA 
Grant Instruments Cambridge, UK 
Integrated DNA Technologies Coralville, IA, USA 
Labnet International Edison, NJ, USA 
Labtech International Uckfield, UK 
Leica Biosystems Nussloch, Germany 
Life Technologies (includes Applied 
Biosystems, Invitrogen and Gibco) 
Carlsbad, CA, USA 
Macherey-Nagel Düren, Germany 
Marabu Tamm, Germany 
Merck Millipore Billerica, MA, USA 
MRC Holland Amsterdam, Netherlands 
Olympus Tokyo, Japan 
Promega Madison, WI, USA 
Qiagen Venlo, Netherlands 
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Santa Cruz Biotechnlogies Dallas, TX, USA 
SANYO Osaka, Japan 
Sigma-Aldrich St. Louis, MO, USA 
StarLab Milton Keynes, UK 
Syngene Cambridge, UK 
Thermo Scientific Waltham, MA, USA 
Vector Laboratories Peterborough, UK 
VELP Scientifica Brianza, Italy 
VWR International Radnor, PA, USA 
 
2.1.2 List of Equipment 
Equipment Manufacturer 
2100 Bioanalyser Agilent Technologies 
2720 PCR Machine Applied Biosystems 
5415R Microcentrifuge Eppendorf 
5418 Microcentrifuge Eppendorf 
800W Compact Microwave Sanyo 
Agarose Gel Electrophoresis Tank BioRad 
Amersham ECL Gel Box GE Life Sciences 
Bacterial Incubator Fisher Scientific 
BX61 Fluorescent Microscope Olympus 
CEQ 8800 Beckman Coulter 
CO2 Incubator Sanyo 
Evos FL Cell Imaging System Life Technologies 
FACS Calibur Becton Dickinson 
FACS Canto II Becton Dickinson 
Fluostar Omega plate reader BMG Labtech 
G-box Imaging System Syngene 
GD100 Waterbath Grant Instruments 
Gel Electrophoresis Tanks BioRad 
GeneAmp PCR System 2700 Applied Biosystems 
Heraeus Multifuge 3S+ Centrifuge Thermo Scientific 
Heraeus Multifuge 3SR Chilled Centrifuge Thermo Scientific 
HYBrite Probe Hybridisation Platform Abbott Molecular 
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IVIS Spectrum Bioluminescent Imaging System Caliper Life Sciences 
Nanodrop 1000 Spectrophotometer Labtech International 
Neubauer Improved Haemocytometer Sigma-Aldrich 
Optima L-100 XP Ultracentrifuge Beckman Coulter 
PCR Hood Labcaire 
REC Digital Heating Ceramic Plate VELP Scientifica 
Shaking Incubator Eppendorf 
Sub Aqua Waterbath Grant Instruments 
Technico Mini Microcentrifuge Fisher Scientific 
Veriti PCR Machine Applied Biosystems 
ViiA 7 Real Time PCR System Life Technologies 
Vortex Mixer Labnet 
 
2.1.3 List of Software 
Software Developer 
7-Zip Igor Pavlov 
CytoVision 7.1 Leica Biosystems 
GeneMarker SoftGenetics 
Genotyping Browser Affymetrix 
Genotyping Console Affymetrix 
Graphpad Prism 6 Graphpad Software 
ImageJ 1.48 National Institutes of Health 
Living Image 4.0 Caliper Life Sciences 
Primer 3 Whitehead Institute for Biomedical Research 
SeqNext JSI Medical Systems 
STATA 11 StataCorp 
ViiA 7 Software 1.1 Life Technologies 
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2.1.4 List of Online Resources 
Resource Developer 
ArrayExpress European Bioinformatics Institute 
Catalogue of Somatic Mutations in Cancer  Wellcome Trust Sanger Institute 
Gene Expression Omnibus National Center for Biotechnology 
Information 
MAPD: MLPA Probe Design Tool Stony Brook University 
R2: Genomics Analysis and Visualization Platform Academic Medical Center Amsterdam 
 
2.1.5 List of Chemicals, Reagents and Materials 
Reagent Supplier 
0.45µm PVDF Filter Merck Millipore 
100bp Ladder Promega 
10cm Tissue Culture Plates Corning Inc. 
125cm2 Tissue Culture Flask Corning Inc. 
13mm No. 1.5 Glass Coverslip VWR International 
1kb Ladder Promega 
24mm x 50mm No. 1 Glass Cover Slide VWR International 
25cm2 Tissue Culture Flask Corning Inc. 
75cm2 Tissue Culture Flask Corning Inc. 
Agar Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
AMPure XP Beads Agilent Technlogies 
Beckman Sample Loading Solution Beckman Coulter 
Bovine Serum Albumin Sigma-Aldrich 
Caffeine Sigma-Aldrich 
CellTiter 96 AQueous One Promega 
CEQ Size Standard 600 Beckman Coulter 
Chloramphenicol Sigma-Aldrich 
Chloroquine Sigma-Aldrich 
DAPI Vector Laboratories 
Dimethylsulphoxide Sigma-Aldrich 
DMSO Sigma-Aldrich 
EDTA Sigma-Aldrich 
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EndoFectin GeneCopoeia 
Ethanol Fisher Scientific 
Ficoll-Paque PREMIUM 1.077 GE Healthcare 
Fixogum Marabu 
Flavopiridol Santa Cruz Biotechnologies 
GelRed VWR International 
Glycerol Sigma-Aldrich 
Human Cot-1 DNA Invitrogen 
Human Reference cDNA, Random Primed Clontech 
Hybridisation Buffer Cytocell 
IGEPAL CA-630 Sigma-Aldrich 
Illustra ProbeQuant G-50 Micro Columns GE Healthcare 
Isopropanol Fisher Scientific 
Kanamycin Sigma-Aldrich 
Lenti-X Concentrator Clontech 
Loading Dye (6x) Promega 
LR Clonase II Invitrogen 
Methanol Fisher Scientific 
Mineral Oil Beckman Coulter 
Monosodium Phosphate Sigma-Aldrich 
Nitrocellulose Membrane Sigma-Aldrich 
One Shot Stbl3 Chemically Competent E. coli Life Technologies 
Parafilm StarLab 
PCR Markers Promega 
Phosphate Buffered Saline Tablets Sigma-Aldrich 
Polybrene Sigma-Aldrich 
Proteinase K Sigma-Aldrich 
PVDF Membrane Merck Millipore 
Saline-Sodium Citrate Buffer (20x) Fisher Scientific 
Skimmed Milk Powder Sigma-Aldrich 
SOC Medium Life Technologies 
Sodium Acetate Sigma-Aldrich 
Sodium Butyrate Sigma-Aldrich 
Sodium Chloride Sigma-Aldrich 
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Spectra Multicolour BR Protein Ladder Thermo Scientific 
Stbl3 Competent Cells Life Technologies 
Superfrost Glass Microscope Slides Thermo Scientific 
Synthetic MLPA Probes Integrated DNA Technologies 
Tris Base Sigma-Aldrich 
Trypan Blue Bio-Rad 
Trypsin Life Technologies 
Tryptone Sigma-Aldrich 
Urea Sigma-Aldrich 
Vybrant DyeCycle Ruby Stain Life Technologies 
XenoLight™ D-Luciferin Caliper Life Sciences 
Yeast Extract Sigma-Aldrich 
 
2.1.6 List of Kits 
Kit Supplier 
Amersham ECL Prime Western Blotting 
Detection Kit 
GE Healthcare 
BCA Protein Assay Kit Thermo Scientific 
DNeasy Blood and Tissue Kit Qiagen 
EndoFree Plasmid Maxi Kit Qiagen 
FIV Lentiviral Packaging Kit GeneCopoeia 
FXCycle PI/RNase Staining Kit Life Technologies 
High Capacity RNA-to-cDNA Kit Life Technologies 
Nick Translation DNA Labelling System Enzo Life Sciences 
Nucleobond Xtra Midi Macherey-Nagel 
P200-A1 Human DNA Reference-1 Probemix MRC Holland 
QIAPrep Spin Mini Kit Qiagen 
QIAshredder Qiagen 
RNeasy Mini Kit Qiagen 
SALSA MLPA Reagent Kit MRC Holland 
TransLenti Viral GIPZ Packaging System GE Dharmacon 
Xfect Lentiviral Packaging Kit Clontech 
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2.1.7 List of Solutions 
Name Composition 
10x TBS-T (1L) 12.11g Tris 
29.22g NaCl 
10ml Tween-20 
FIX 75% Methanol 
25% Acetic Acid 
LB Agar Plates LB Medium 
1.5% w/v agar 
LB Medium 1% w/v tryptone 
0.5% w/v yeast extract 
1% w/v NaCl 
pH 7 
TBE 5x (1L) 54g Tris 
27.5g Boric Acid 
20ml 0.5M EDTA 
TE 10mM Tris-HCl  
0.1mM EDTA 
pH 8.2 
Urea Buffer 7.92M Urea 
100mM NaH2PO4 
80mM Tris-HCl pH 8 
WASH 1 (1L) 20ml 20X SSC 
3ml NP40 
WASH 2 (1L) 100ml 20X SSC 
1ml igepal-CA-630 
Western Blotting 10x Running Buffer (1L) 30.3g Tris 
144g Glycine 
10g SDS 
Western Blotting 10x Transfer Buffer (1L) 144g Glycine 
30.3g Tris 
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2.1.8 List of Culture Media 
Use Cell Lines Identifier Manufacturer Supplements 
General UoC-M1, NKM-1, GDM-
1, KG-1, SKNO, U937, 
NB4, AML-3, Kasumi-1, 
MV4-11, AML-2, AML-
3, HL-60, THP-1 
RPMI-1640 Sigma-Aldrich 10% v/v foetal calf 
serum 
2mM GlutaMAX 
General 293T, 293FT, LX293T Dulbecco’s 
Modified 
Eagle’s 
Medium 
Sigma-Aldrich 10% v/v foetal calf 
serum 
4mM GlutaMAX 
1mM sodium 
pyruvate 
Lentiviral 
Production 
293T, 293FT, LX293T Dulbecco’s 
Modified 
Eagle’s 
Medium 
Sigma-Aldrich 5% v/v foetal calf 
serum 
4mM GlutaMAX 
1mM sodium 
pyruvate 
Lentiviral 
Packaging 
293T, 293FT, LX293T Opti-MEM I Gibco None 
 
2.1.9 List of Culture Supplements 
Supplement Manufacturer 
Foetal Calf Serum Sigma-Aldrich 
Foetal Calf Serum Gibco 
GlutaMAX Gibco 
Sodium Pyruvate Sigma-Aldrich 
 
2.1.10 List of Cell Lines Used 
Cell Line 
Identifier 
Cell of Origin Source Growth Density 
(cells/ml) 
293FT Human Embryonic Kidney Life Technologies, 
USA 
N/A (Adherant) 
293T Human Embryonic Kidney Kind gift from Prof. 
Olaf Heidenreich, 
Newcastle University 
N/A (Adherant) 
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AML-2 Acute Myeloid Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
AML-3 Acute Myeloid Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
GDM-1 Human Myelomonocytic Leukaemia DSMZ, Germany 0.5-1.5x106 
HL-60 Acute Promyelocytic Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
Kasumi-1 Acute Myeloblastic Leukaemia Kind gift from Prof. 
Olaf Heidenreich, 
Newcastle University 
0.5-1.5x106 
KG-1 Human Erythroblastic Leukaemia DSMZ, Germany 0.5-1.5x106 
LX-293T Human Embryonic Kidney Clontech, USA N/A (Adherant) 
MV4-11 Acute Monocytic Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
NB4 Human Promyelocytic Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
NKM-1 Human Myeloblastic Leukaemia HSRRB, Japan 0.5-1.5x106 
SKNO Human Myeloblastic Leukaemia Kind gift from Prof. 
Olaf Heidenreich, 
Newcastle University 
0.5-1.5x106 
THP-1 Acute Monocytic Leukaemia Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
U937 Myelomonocytic Development Kind gift from Dr. 
Sarah Fordham, 
Newcastle University 
0.5-1.5x106 
UoC-M1 Human Megakaryoblastic 
Leukaemia 
University of Chicago, 
USA 
0.5-1.5x106 
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2.2 General Laboratory Techniques 
2.2.1 DNA Extraction 
2.2.1.1 Cell Line 
The DNeasy Blood and Tissue kit (Qiagen) was used to extract DNA from cultured cell lines and 
patient material, either grown in vitro culture or from xenograft mouse samples. Key points of 
the process involve cell lysis, before adsorption of DNA to a silica membrane contained within 
a spin column. The membrane is washed before elution into a microcentrifuge tube.  
Up to 5x106 cells per spin column were taken from cell lines or primary patient material, either 
fresh or as cell pellets stored at -20°C. Cell pellets were allowed to reach room temperature, 
and resuspended in 200µl Phosphate Buffered Saline (PBS). To the cell suspension 20µl 
Proteinase K and 200µl Lysis Buffer AL were added, followed by pulse vortexing to mix and a 
subsequent incubation at 56°C for 10 minutes. 200µl ethanol was added and the suspension 
again mixed by vortexing. The cell lysate was applied to the top of a DNeasy Mini spin column 
placed inside a collection tube and centrifuged at 6000 x g for 1 minute. The flow through was 
discarded and the spin column was transferred to a new collection tube. 500µl Wash Buffer 
AW1 was applied to the spin column, and centrifuged again at 6000 x g for 1 minute. After 
transfer to a new collection tube, 500µl Wash Buffer AW2 was added and centrifuged at 20000 
x g for 3 minutes. The collection tube was then transferred to a 1.5ml microcentrifuge tube 
and 200µl elution buffer AE applied directly to the silica membrane of the spin column. After a 
1 minute wait at room temperature, the column was centrifuged at 6000 x g for 1 minute. The 
elution process was repeated a second time to give a separate second elution. DNA samples 
were then measured for concentration and purity using a Nanodrop 1000 Spectrophotometer, 
before storage at -20°C. 
2.2.1.2 Bacterial Plasmid Mini Prep 
To isolate DNA plasmids for use in cloning and sequencing, the QIAprep Spin Miniprep Kit 
(Qiagen) was used. This kit utilises a modified alkaline lysis protocol to release DNA from 
smaller quantities of bacterial cells (cultures in less than 5ml Lysogeny Broth). In this protocol, 
an alkaline mixture of sodium dodecyl sulphate and sodium hydroxide is added to bacterial 
cells. This mixture lyses bacterial cell walls and membranes, but also denatures genomic and 
plasmid DNA. Potassium acetate solution is then added to the solution to allow the plasmid to 
reanneal. As genomic DNA is too long to easily renature, it becomes tangled and remains 
attached to bacterial proteins which are removed when the lysate is centrifuged and the 
plasmid containing supernatant transferred to a spin column, where it is bound to a silica 
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membrane. Subsequent wash steps remove endonucleases and salts, and the DNA is then 
eluted into a microcentrifuge tube. 
Using a sterile pipette tip, a single colony was isolated from transformed bacteria spread onto 
Lysogeny Broth Agar (LBA) plates containing a suitable selection antibiotic. This pipette tip was 
then transferred to a 15ml conical centrifuge tube containing 5ml Lysogeny Broth (LB) culture 
media also containing selection antibiotics. The culture was incubated at 37°C overnight in a 
shaking incubator. Bacterial cells were harvested from the culture media by centrifugation at 
6800 x g for 3 minutes. The bacterial pellets were then resuspended in 250µl buffer P1. To 
achieve cell lysis, 250µl buffer P2 was added and the suspension mixed by inversion 6 times. 
After a 5 minute room temperature incubation, the cell lysis was terminated by the addition of 
350µl buffer N3 and mixing by inversion 6 times, causing precipitation of bacterial proteins. 
The lysate was then centrifuged at 18000 x g for 10 minutes to pellet the precipitate. The 
supernatant from this process was then applied to the QIAprep spin column containing the 
DNA binding silica membrane, before centrifugation at 18000 x g for 1 minute. The flow 
through was discarded, and 500µl buffer PB was applied to wash the membrane, with another 
centrifugation at 18000 x g for 1 minute. A second wash was then performed using 750µl 
buffer PE and centrifugation at 18000 x g for 1 minute. After discarding the flow through, an 
additional centrifugation at 18000 x g for 1 minute was performed to ensure that the silica 
membrane was free from ethanol. The QIAprep spin column was then placed into a clean 
1.5ml microcentrifuge tube and 50µl elution buffer EB applied directly to the membrane. The 
spin column was allowed to stand for 1 minute at room temperature, before centrifugation at 
18000 x g for 1 minute. The eluted sample was measured for DNA concentration and purity 
using a Nanodrop 1000 Spectrophotometer, before storage at -20°C. 
2.2.1.3 Bacterial Plasmid Maxi Prep 
For the isolation of DNA plasmids to use in the production of lentiviral particles, a larger scale 
extraction was required to obtain sufficient material in endotoxin free buffers amenable to 
tissue culture. In the EndoFree Plasmid Maxi Kit (Qiagen), bacteria are lysed using an alkaline 
lysis protocol, and the cell lysates containing genomic DNA are cleared by cartridge filtration. 
The plasmid DNA is bound to a silica membrane contained within a flow column and subjected 
to a number of wash steps to remove contaminants including endotoxins. Following these 
washes, the DNA is eluted and precipitated in isopropanol, before resuspension in TE buffer. 
Bacteria were seeded onto an antibiotic selection LBA plate by spreading from frozen glycerol 
stocks using a sterilised inoculation loop. After overnight incubation at 37°C, a single colony 
was picked using a sterile pipette tip and dropped into 200ml of LB media containing a 
selection antibiotic, which was subsequently incubated overnight at 37°C in a shaking 
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incubator. In the morning, the bacteria were harvested and pelleted by centrifugation at 6000 
x g and 4°C for 15 minutes. Pelleted bacteria were then resuspended in 8ml Buffer P1.To this, 
8ml Buffer P2 was added and mixed by inversion, followed by a 3 minute incubation at room 
temperature to allow bacterial lysis to occur. 8ml Buffer S3 was then added to the lysate and 
immediately inverted 6 times, then poured into a QIAfilter cartridge. The lysate was then 
incubated at room temperature for 10 minutes to allow a precipitate containing proteins, 
genomic DNA and detergents to float to the top of the QIAfilter cartridge. At this stage, the 
plunger was inserted into the QIAfilter cartridge and the cell lysate filtered into a new tube. 
The QIAfilter cartridge containing the remaining precipitate was discarded at this stage. 
To the filtered lysate, 2.5ml buffer ER was added, the solution mixed and incubated on ice for 
30 minutes to remove endotoxins. At this stage, the Qiagen-tip 500 was equilibrated by adding 
10ml buffer QBT. The filtered lysate was then added to the Qiagen-tip 500 after incubation on 
ice and allowed to flow through by gravity. Two 30ml volumes of wash buffer QC were added 
and allowed to flow through, before plasmid DNA was eluted using 15ml of buffer QN. The 
plasmid DNA was then precipitated with 10.5ml isopropanol and centrifuged for 30 minutes at 
15000 x g and 4°C. The supernatant was carefully decanted to ensure that the plasmid DNA 
pellet was not disturbed. The pellet was then washed with 5ml 70% ethanol in endotoxin free 
water and centrifuged for 10 minutes at 15000 x g and 4°C. The supernatant was again 
carefully decanted to ensure that the DNA pellet was not disturbed. The pellet was then air 
dried at room temperature for 10 minutes and resuspended in 300µl buffer TE. The DNA yield 
and purity was then determined using a Nanodrop 1000 Spectrophotometer and plasmid DNA 
stored at -20°C. 
2.2.2 Freezing Bacterial Stocks 
For the long term storage of bacterial stocks, 500µl of overnight bacterial culture was mixed 
with 500µl of 50% glycerol diluted with distilled H2O. The resulting suspension was mixed by 
pulse vortexing and transferred to a 1.5ml microcentrifuge tube, before storage at -80°C. 
2.2.3 RNA Extraction 
2.2.3.1 QIAshredder 
The QIAshredder kit (Qiagen) was used to homogenise cell lines or mouse tissues prior to RNA 
extraction, providing an increased yield of RNA. The QIAshredder columns homogenise lysate 
as they pass through the column under forces created by centrifugation. Up to 1 x 106 cells 
were resuspended in 700µl of buffer RLT and loaded into the column. The column was placed 
into a 2ml collection tube and centrifuged for 2 minutes at 20000 x g. 
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2.2.3.2 RNeasy Mini Kit 
The RNeasy Mini kit (Qiagen) was used to extract RNA from homogenised lysates produced by 
the QIAshredder kit. The RNeasy spin columns allow for on column DNase digestion, before 
binding RNA. The bound RNA is then washed with a series of buffers and finally eluted into 
RNase-free water for downstream applications. The homogenised lysate from the QIAshredder 
kit was applied to an RNeasy spin column and centrifuged for 15 seconds at 8000 x g. The flow 
through was discarded and 350µl of buffer RW1 was added to the column. Following 
centrifugation at 8000 x g for 15 seconds, the flow through was discarded and 10µl DNase I 
solution was mixed with 70µl of buffer RDD before being added directly to the RNeasy spin 
column membrane. After incubation at room temperature for 15 minutes, 350µl buffer RW1 
was added to the spin column and centrifuged for 15 seconds at 8000 x g, and the flow 
through discarded. Then 700µl buffer RW1 was added and the column was again centrifuged 
at 8000 x g for 15 seconds and the flow through discarded. This was followed by the addition 
of 500µl buffer RPE with the same centrifugation step and again the flow through was 
discarded, before repeating the addition of buffer RPE and subsequent steps again. The 
RNeasy spin column was then placed into a 1.5ml collection tube and 30µl RNase-free water 
was added directly to the column membrane. The column was centrifuged for 1 minute at 
8000 x g, and this process repeated with another 30µl RNase-free water to give a total elution 
volume of 60µl. RNA concentration was then calculated through the measurement of spectral 
absorbance using a Nanodrop 1000 spectrophotometer. 
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2.3 General Cell Culture Techniques 
2.3.1 Routine Cell Maintenance 
2.3.1.1 Suspension Cell Lines 
Leukaemic cell lines grown in suspension were cultured in upright flasks and cultured in an 
incubator providing a humid environment containing 5% CO2 heated to 37°C. Cells were 
counted every 2 to 3 days and diluted to a concentration of 0.5x106 cells/ml. Suspension cell 
lines were cultured in RPMI-1640 media supplemented with 10% Foetal Calf Serum (FCS) and 
2mM GlutaMAX. 
2.3.1.2 Adherent Cell Lines 
The cell line derivatives of HEK293 were cultured in flasks laid flat in an incubator providing a 
humid environment with 5% CO2 at 37°C, in high glucose Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FCS, 4mM GlutaMAX and 2mM sodium pyruvate. Cells were 
split 3 times a week in a suitable ratio between 1:6 and 1:10 of cell suspension to fresh media. 
To split cells, old media was aspirated from the cell layer and the cells were gently washed in 
10ml PBS. 2ml of a 0.25% Trypsin solution was applied to the cells for 2 minutes and the cells 
detached by gently tapping the side of the flask. 10ml fresh media was then added to the cell 
suspension to neutralise the Trypsin and cells were pelleted by centrifugation at 400 x g for 5 
minutes. The supernatant was aspirated and the cell pellet resuspended in a suitable volume 
of fresh media before transfer to a new tissue culture flask. Passage numbers were recorded 
and only cells between passage 5 and passage 20 were used for the production of lentivirus. 
2.3.2 Cell Counting 
Cell concentration was estimated using a Neubauer Improved Haemocytometer. Cells were 
mixed in a 1:1 ratio with trypan blue and 10µl of the mixture loaded into the counting 
chamber. The counting chamber consists of four counting quadrants, each of which has a 
volume of 0.1mm3. Viable cells (which do not take up the trypan blue dye) across all four 
quadrants were counted and an average count calculated by dividing the total number of cells 
by 4. This number was then multiplied by 20000 to give a cell concentration in cells per 
millilitre.  
2.3.3 Freezing Cell Stocks 
For the long term storage of cell lines, 5x106 cells were resuspended in 0.5ml of media 
containing 10% FCS. This was then mixed with 0.5ml of freezing media, consisting of 80% FCS 
and 20% DMSO, and the cell suspension transferred to a cryovial. Cryovials were inserted into 
a Mr. Frosty freezing container filled with isopropanol to ensure controlled cell cooling at a 
rate of -1°C per minute when placed into a -80°C freezer. After 24 hours at -80°C, cells were 
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transferred to storage racks contained within in the gaseous phase of liquid nitrogen for long 
term storage at -130°C. 
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Chapter 3 Determining Minimal Regions of Copy Number 
Alteration 
3.1 Introduction 
3.1.1 Early Genetic Mapping Techniques 
Chromosomal abnormalities were first observed in tissue samples from a range of tumours in 
the late nineteenth century and were believed to play a role in tumourigenesis (Von 
Hansemann, 1890). However, techniques for visualising chromosomes were of an extremely 
low resolution and as a result, for over 30 years it was commonly accepted that humans had 
48 chromosomes (Painter et al., 1921). Gradually, techniques were developed and chemicals, 
such as colchicine which arrests cells in a mitotic state, were introduced which greatly 
improved the quality of chromosomal preparations. These developments led to the correct 
human chromosomal number of 46 being recognised in 1956 (Tjio and Levan, 1956), which 
allowed conditions such as Down syndrome (trisomy 21) and Turner syndrome (-X) to be linked 
to the gain or loss of specific chromosomes. 
At this time, it was believed that most tumours had a normal complement of chromosomes 
(Bayreuther, 1960), thus there was little interest in studying the chromosomes of tumour 
samples. However, in 1960, Nowell and Hungerford discovered a recurrent chromosomal 
abnormality in the neoplastic cells of patients with CML. This small chromosome was named 
the Philadelphia chromosome after the city in which it was discovered (Nowell and 
Hungerford, 1960). Since this discovery, thousands of other chromosomal aberrations have 
been identified and associated with cancer development, and many techniques for their 
identification have been developed. 
Until early in the 1970s, cytogenetic studies were performed on chromosomes using stains 
that did not reveal a banding pattern, which made identifying individual chromosomes and 
detecting structural aberrations difficult. Torbjörn Caspersson and his colleagues showed that 
a banding pattern visible under the microscope could be unveiled using quinacrine fluorescent 
staining, known as Q-banding (Caspersson et al., 1968; Caspersson et al., 1970). This technique 
allowed the consistent recognition of each chromosome, but was flawed due to the short 
period of quinacrine fluorescence, making the technique unsuitable for routine patient studies. 
This led to the development of a number of novel banding techniques, the most successful and 
widespread of which has been G-banding. 
In the G-banding technique, preparations are stained by an application of trypsin followed by 
Giemsa (Seabright, 1971). This staining method led to approximately 500 bands per haploid 
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genome, allowing the identification of many novel structural aberrations such as 
translocations, inversions, deletions and duplications, in addition to the chromosomal number 
changes previously known. The resolution of the technique was increased through the 
synchronisation of cultures and preparation of slides from cells in pro-metaphase or prophase 
stages of the cell cycle rather than metaphase (Yunis, 1976). These chromosomes appear 
longer under the microscope and over 1000 bands can be observed in a normal haploid 
genome, allowing for the more precise identification of chromosomal aberrations. The use of 
G-banding has allowed for a standardised nomenclature of physical gene locations on a 
chromosome to be established. An example of this is the alpha tubulin gene, located at 
12q13.12. The first 12 refers to the chromosome number, whilst the q refers to the long 
chromosome arm (as opposed to p which signifies the short chromosome arm). The numbers 
following this letter represent the position on the chromosomal arm: in this case, region 1, 
band 3, sub-band 12 (Strachan and Read, 1999). 
3.1.2 FISH 
Fluorescence in situ hybridisation (FISH) techniques were developed in the early 1980s and 
involve the use of single stranded DNA probes which bind complementary genomic DNA 
sequences in both interphase and metaphase cells (Langer-Safer et al., 1982). These probes 
are labelled with various fluorophores, which fluoresce when excited at appropriate 
wavelengths and can be viewed using a fluorescence microscope. Due to the flexibility that 
FISH provides, both in the sequences that can be targeted and the range of available 
fluorophores, a number of different targets can be probed at the same time, and can be 
directed towards specific parts of a gene. This is highly useful in a diagnostic setting, where 
recurrent abnormalities can be quickly screened for in a large number of samples. FISH is 
however limited in that it will only detect the specific sequences that are being tested for, so 
finding novel abnormalities can be difficult without some prior understanding of their nature. 
Although some advanced probing techniques, such as whole chromosome painting and M-
FISH, are available (Ried et al., 1998), FISH remains limited in its ability to provide a whole 
genome screening process and other techniques are typically used for these applications. 
3.1.3 Comparative Genomic Hybridisation 
Comparative genomic hybridisation (CGH) was developed as a method for screening cancer 
genomes and comparing them to control DNA metaphase spreads, in order to ascertain 
genomic copy number at a range of chromosomal locations (Weiss et al., 1999). In this 
technique, tumour DNA and control DNA are labelled with fluorophores and mixed together. 
Cot-1 DNA is added to suppress repetitive sequences and the mixture is hybridised to normal 
human metaphases, where they can be scanned using a fluorescence microscope. The ratio of 
48 
 
tumour to control DNA hybridised to each point of the metaphase spread can then be 
measured, and regions of gain and loss identified. There are a number of limitations to CGH 
however, such as its low resolution; only able to detect abnormalities greater than 5MB in 
length (Weiss et al., 1999). 
This technique has since been further developed into what is known as array CGH (aCGH). 
Metaphases were replaced with bacterial artificial chromosome (BAC) clones, containing 
regions of the genome that were of particular interest, and spotted onto glass slides (Garnis et 
al., 2004). The normal and tumour DNA samples are prepared using a similar process to regular 
CGH and co-hybridised to the spotted BAC clones, where they are scanned and fluorescence 
levels assessed. As the technology has progressed, BAC clones have been replaced by cDNA 
clones, PCR products and more recently, synthetic oligonucleotides (Ylstra et al., 2006). The 
use of synthetic oligonucleotides carries a number of advantages. Their short sequences 
reduce cross hybridisation from off target sequences. Newer spotting technologies, such as 
inkjet spotting and photolithography, allow a large number of probes to be spotted in small 
spaces with high accuracy, further increasing the number of probes for greater depth of 
genome coverage. These improvements have achieved almost genome wide coverage in the 
current generation of copy number arrays. Oligonucleotide arrays have also opened up the 
possibility for genotyping to be carried out using single nucleotide polymorphism (SNP) probe 
arrays (Wang and Bucan, 2008). 
Similar to copy number arrays, SNP arrays contain many probes hybridised to a glass slide 
(LaFramboise, 2009). However, each probe is also designed to interrogate the identity of 
various SNPs located within the genome. They were developed from single locus SNP 
genotyping techniques, which interrogated the identity of a single SNP using a range of 
methods, from PCR and enzyme based strategies to methods relying on the hybridisation of 
specific oligonucleotides. Unlike copy number arrays, only sample DNA is hybridised to the 
oligonucleotides, which is instead compared to reference control DNA samples carried out in 
previous experiments. Each SNP is interrogated by a 25 base pair sequence which hybridises to 
both alleles of a SNP. If all 25 base pairs match (known as a perfect match), the signal 
produced from the probe is brighter than if only 24 base pairs match (known as a mismatch). 
Each SNP is interrogated by two probes, each of which is assigned as either allele A or allele B. 
From these, 3 possible genotype outcomes are computed for each SNP depending on which 
alleles are present – AA, AB or BB (LaFramboise, 2009). 
Both copy number and genotyping information can be extracted from SNP arrays. For the 
study of cancers, this is invaluable in providing information about loss of heterozygosity (LOH). 
LOH refers to the loss of a chromosomal region, which can result in a net change in copy 
49 
 
number, or be copy neutral (CN-LOH). CN-LOH can drive cancer development by acting as the 
‘second hit’ in the classical two-hit hypothesis of tumourigenesis as proposed by Alfred 
Knudson (Mao et al., 2007). If one copy of a tumour suppressor gene is mutated, loss of the 
wild type gene and duplication of the mutated copy leaves a cell without a functional wild type 
copy of the gene, and thus cancer may progress. 
This project has focussed on the use of 3 recent Affymetrix SNP arrays, the Human Mapping 
100K SNP Array Set (100K), the Human Mapping 500K Array Set (500K) and the Genome-Wide 
Human SNP Array 6.0 (SNP 6.0). These were chosen as the majority of publicly available SNP 
array data for AML makes use of one of these platforms. The main features of these arrays, 
along with the recently released CytoScan HD Array, are listed in Table 7. The newer SNP 6.0 
and CytoScan HD arrays are composed of a mixture of probe types, some of which are solely 
used in the detection of copy number variation and provide increased levels of coverage.  
 Total Probes Copy Number 
Probes 
SNP Probes Release Year 
100K 100,000 0 100,000 2006 
500K 500,000 0 500,000 2006 
SNP 6.0 1,800,000 946,000 906,600 2008 
CytoScan HD 2,600,000 1,850,000 750,000 2012 
Table 7. A comparison of the 3 most recently released Affymetrix SNP arrays for determining copy number and 
genotyping information (information obtained from Affymetrix: www.affymetrix.com). 
With the increasingly widespread use of aCGH on large numbers of samples, researchers are 
usually encouraged to share their data with other groups who may be able to extract further 
information from data sets generated. To facilitate this sharing, websites such as ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/), and the Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) have been established. Datasets can be searched for 
by their sample type and downloaded for further analysis by other researchers, allowing 
additional information that may not have been relevant to the original project to be extracted.  
3.1.4 Multiplex Ligation-dependent Probe Amplification 
To allow for the simultaneous screening of common copy number aberrations in large 
numbers of samples, the Multiplex Ligation-dependent Probe Amplification (MLPA) technique 
was devised (Schouten et al., 2002). The technique utilises probe pairs to detect changes in 
copy number. Each probe contains a universal primer recognition site in conjunction with 
target specific sequences for the region to be investigated. One of the probes also contains a 
‘stuffer sequence’ to increase the length of the product sequences for electrophoretic 
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resolution, with each probe pair in a probe mix assigned a different target size. The target 
sequences in each probe pair are each one half of a complete complementary sequence to the 
exon or gene of interest, and so are located adjacent to each other when hybridised to the 
same strand of genomic DNA. A ligation reaction is then able to seal the gap between the two 
probe sequences, PCR is used to amplify the ligated probe sequences, whilst unligated probe 
halves are unable to be amplified (Schouten et al., 2002). 
The PCR reaction amplifies probes in a manner proportional to their copy number status. The 
PCR products can be separated using capillary electrophoresis, where relative peak heights can 
be measured and compared to produce an estimate of copy number for the regions 
interrogated (Schouten et al., 2002). The technique is summarised in Figure 5. 
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 Figure 5. The MLPA technique. Genomic DNA is interrogated with complementary probe pairs that require an exact 
match to bind. The nick in between a complementary probe pair is ligated during the ligation reaction when bound 
to DNA. The samples are then denatured to remove bound probes from the DNA, before PCR amplification using 
universal primers to amplify successfully ligated probes. DNA fragments can then be separated by capillary 
electrophoresis to identify the relative copy number of each sequence.  
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3.2 Aims 
Despite a number of studies investigating deletions of 12p and 11q amplifications, no clear 
minimal regions of deletion or amplification have been established. The objectives of the 
studies described in this chapter were therefore: 
• To establish a minimally deleted region on the short arm of chromosome 12 using 
publicly available copy number array data. 
• To refine this minimally deleted region using MLPA on normal karyotype patient 
samples. 
• To establish a minimal region or regions of amplification on the long arm of 
chromosome 11 using publicly available copy number array data. 
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3.3 Methods 
3.3.1 Affymetrix Copy Number Array Analysis 
Publicly available AML datasets were selected from the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) website and raw data (.CEL) files were downloaded as 
compressed .TAR archives and extracted using 7zip. Raw data files were loaded into the 
Affymetrix Genotyping Console and underwent quality control checks before further analysis 
took place to ensure the integrity of the data. Genotyping data were compiled for each data 
file, before copy number and LOH data were calculated using the Birdseed v2 algorithm. The 
Affymetrix Genotyping Console Browser software was used to align the copy number and LOH 
calls to a suitable build of the human genome. For data generated from the Affymetrix 
GeneChip Human Mapping 500K Array this was the hg18 (NCBI36) assembly, whereas data 
from the Affymetrix Genome-Wide Human SNP Array 6.0 were aligned to the hg19 (GRCh37) 
assembly of the human genome. Copy Number Segmentation files were also generated using 
the Affymetrix Genotyping Console, with a minimum limit of 5 consecutive concurrent probe 
calls required for an altered copy number state to be identified by the software. 
Regions of interest containing copy number alterations were recorded by their location on the 
human genome. Coordinates obtained from 500K analysis were translated from the hg18 to 
the hg19 build using the LiftOver service provided by the University of California, Santa Cruz 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver) to allow direct comparison of results across 
different array platforms. Where matched remission or germline samples were available, these 
were compared to the samples taken at diagnosis to identify cases where somatic copy 
number alterations were present. 
3.3.2 Multiplex Ligation-dependent Probe Amplification 
3.3.2.1 Probe Design 
Synthetic MLPA probes were designed following the instructions provided in the “Designing 
synthetic MLPA probes” manual (MRC Holland) and the MAPD: MLPA Probe Design tool from 
Stony Brook University, New York (http://bioinform.arcan.stonybrook.edu/mlpa2/cgi-
bin/mlpa.cgi). Probes were synthesised by Integrated DNA Technologies and mixed with the 
MRC Holland SALSA MLPA P200-A1 Human DNA Reference-1 probemix (MRC Holland). 
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 Target 
Gene 
Product 
Size 
Left Probe Sequence Right Probe Sequence 
CREBL2 104 GGGTTCCCTAAGGGTTGGATCTGGCATCAGGG
AAGCGAACTGTTAGGCGA 
GAGGAGGAGGCAGCCAGAACCATATCCCCTTT
CTAGATTGGATCTTGCTGGCAC 
APOLD1 108 GGGTTCCCTAAGGGTTGGATCCTGAGTGGCTC
CCAATCCAGTCCTCCAAGTA 
CTCAGAGGGGAAGCCCGTGAAGCCGTCATCTA
ATCTAGATTGGATCTTGCTGGCAC 
LRP6 112 GGGTTCCCTAAGGGTTGGAGGCAGTCAGTTTG
TGGTCACTGCTCAAATTGCCCA 
TCCTGATGGTATTGCTGTGGACTGGGTTGCAC
GAATCTAGATTGGATCTTGCTGGCAC 
CDKN1B 118 GGGTTCCCTAAGGGTTGGAGGTTTTGTTTTTTT
GAGAGTGCGAGAGAGGCGGTCGTG 
CAGACCCGGGAGAAAGATGTCAAACGTGCGA
GTGTCTATCTAGATTGGATCTTGCTGGCAC 
CDKN1B 126 GGGTTCCCTAAGGGTTGGACAGAACAGAAGA
AAATGTTTCAGACGGTTCCCCAAATGCCGG 
TTCTGTGGAGCAGACGCCCAAGAAGCCTGGCC
TCAGAAGACGTCTAGATTGGATCTTGCTGGCA
C 
ETV6 130 GGGTTCCCTAAGGGTTGGATCTGGGTTGGGG
AGAGGAAAGGAAAGTGGAAAAAACCTGAGAA
C 
TTCCTGATCTCTCTCGCTGTGAGACATGTCTGA
GACTCCTGCTCTCTAGATTGGATCTTGCTGGCA
C 
ETV6 136 GGGTTCCCTAAGGGTTGGAGAAGCCCATCAAC
CTCTCTCATCGGGAAGACCTGGCTTACATGAA
CC 
ACATCATGGTCTCTGTCTCCCCGCCTGAAGAGC
ACGCCATGCCCATTTCTAGATTGGATCTTGCTG
GCAC 
ANO2 142 GGGTTCCCTAAGGGTTGGAGCTTTTGTCATTG
CGATCACCTCCGACTTTATCCCCCGCCTGGTGT
ACCA 
GTACTCCTACAGTCACAATGGGACTCTGCACG
GCTTTGTCAACCACACCCTCTAGATTGGATCTT
GCTGGCAC 
MANSC1 146 GGGTTCCCTAAGGGTTGGAGACCAAAACTAAA
CTGAAATTTAAAATGTTCTTCGGGGGAGAAGG
GAGCTTG 
ACTTACACTTTGGTAATAATTTGCTTCCTGACA
CTAAGGCTGTCTGCTAGTCTCTAGATTGGATCT
TGCTGGCAC 
Table 8. The MLPA probes designed to assess 12p copy number status. Probes were designed using the MAPD: MLPA 
Probe Design Tool and synthesised by Integrated DNA Technologies. 
3.3.2.2 Multiplex Ligation-dependent Probe Amplification Reaction 
50ng of sample DNA was diluted to 10ng/µl using 0.1M Tris-EDTA (TE) buffer (pH 8.2) and 
placed into individual tubes. TE buffer only was used as a negative control tube. These tubes 
were then placed into a thermocycler (Applied Biosystems) for the DNA denaturation process 
to take place, by heating the samples to 98°C for 5 minutes. After cooling to 25°C, the samples 
were removed from the thermocycler and 3µl of a hybridisation master mix were added. The 
hybridisation master mix consists of 1µl P200 reference probemix (MRC Holland), 0.5µl 
synthetic probemix (Integrated DNA Technologies) and 1.5µl MLPA buffer (MRC Holland) per 
reaction. The tubes were then returned to the thermocycler where they were incubated for 1 
minute at 95°C then held at 60°C for between 16 and 20 hours. 
After this incubation, samples were cooled to 54°C and 32µl of Ligase-65 master mix was 
added to each tube. The Ligase-65 master mix consisted of 25µl dH2O, 3µl Ligase Buffer A 
(MRC Holland), 3µl Ligase Buffer B (MRC Holland) and 1µl Ligase-65 enzyme (MRC Holland) per 
reaction.  Samples were then incubated at 54°C for 15 minutes to allow ligation to occur 
before heating to 98°C for 5 minutes in order to heat inactivate the Ligase-65 enzyme. The 
samples were then cooled to 20°C and 10µl of PCR master mix added to each sample. The PCR 
master mix consisted of 7.5µl dH2O, 2µl SALSA PCR primer mix (MRC Holland) and 0.5µl SALSA 
polymerase (MRC Holland) per reaction. The PCR thermocycler programme was then initiated, 
with 35 PCR cycles of 95°C for 30 seconds, followed by 60°C 30 seconds and then 72°C for 60 
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seconds. After the PCR cycles were complete, the samples were incubated at 72°C for 20 
minutes before being chilled to 15°C then removed from the thermocycler. This process is 
summarised in Table 9. 
Process Step Temperature Time (mm:ss) 
DNA Denaturation 1 98°C 05:00 
2 25°C Hold 
Hybridisation Reaction 3 95°C 01:00 
4 60°C Hold 
Ligation Reaction 5 54°C Hold 
6 54°C 15:00 
7 98°C 05:00 
8 20°C Hold 
PCR Reaction 9 – 35 Cycles: 95°C 
60°C 
72°C 
00:30 
00:30 
01:00 
10 72°C 20:00 
11 15°C Hold 
Table 9. Multiplex Ligation-dependent Probe Amplification One Tube Protocol PCR cycling conditions. 
3.3.2.3 Separation by Capillary Electrophoresis 
After the PCR reaction was completed, the MLPA products were separated by capillary 
electrophoresis to identify the relative concentrations of the various products. 0.7µl of the PCR 
reaction were mixed with 0.2µl of CEQ Size Standard 600 (Beckman Coulter) and 32µl of 
Beckman Sample Loading Solution (Beckman Coulter) in a 96 well plate. One drop of mineral 
oil (Beckman Coulter) was added to the top of each sample and the plate loaded into the CEQ-
8800 (Beckman Coulter) equipped with 33cm capillaries. The electrophoresis was then 
performed utilising the settings detailed in Table 10. 
Run Parameter Setting 
Run Method Frag 
Capillary Temperature 50°C 
Denaturation 90°C for 120 seconds 
Injection Voltage 1.6kV 
Injection Time 30 seconds 
Run Time 60 minutes 
Run Voltage 4.8kV 
Table 10. Beckman CEQ8800 Run Settings for Multiplex Ligation-dependent Probe Amplification. 
The data produced from the capillary electrophoresis run were analysed using the GeneMarker 
Software (SoftGenetics). For the analysis settings, MLPA Ratio was used as the analysis method 
and Peak Height used as the quantification method. Ratios of probe intensity between control 
and sample of less than 0.75 were classed as deletion and more than 1.3 were classed as gain. 
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3.3.3 Fluorescence In Situ Hybridisation 
3.3.3.1 Extraction of Bacterial Plasmid 
Plasmids were selected to target specific genes from a database of stocks currently held by the 
Leukaemia Research Cytogenetics Group (LRCG). These stocks consist of a bacterial suspension 
mixed with glycerol stored at -80°C. To extract plasmid DNA for use in FISH procedures, the 
Nucleobond Xtra Midi kit (Macherey-Nagel) was used. This kit is based on the NaOH/SDS lysis 
method of releasing plasmid produced by bacteria. The lysate is then filtered by gravity flow 
through a column filter and plasmid is bound to a silica resin. Whilst bound to the resin, the 
plasmid is washed before elution and precipitation, then is finally resuspended in water. 
A sterile pipette tip was used to take a pick from the required stock and the bacteria streaked 
out on an LB-agar plate containing an appropriate selection antibiotic for the bacteria. After 
incubation at 37°C for 16 hours, a single colony was picked and used to inoculate a starter 
culture of 5ml LB containing the appropriate selection antibiotic. After 8 hours of shaking 
incubation at 37°C, 200µl of the starter culture was transferred to 200ml LB containing 
selection antibiotics for a further 16 hours shaking incubation at 37°C. The bacteria were then 
harvested by centrifugation at 6000 x g at 4°C for 15 minutes. 
After centrifugation, the bacterial pellet was resuspended in 8ml resuspension buffer 
(Macherey-Nagel), and 8ml lysis buffer (Macherey-Nagel) added to the suspension before 
incubation at room temperature for 5 minutes. During this period, the column and filter were 
equilibrated using 12ml equilibration buffer (Macherey-Nagel). The buffer was slowly applied 
to the top rim of the column in an anti-clockwise motion. After the 5 minute incubation of the 
lysate was complete, the lysis reaction was stopped by the addition of 8ml neutralisation 
buffer (Macherey-Nagel), and the tube inverted three times to ensure even mixing. The lysate 
was then applied to the column filter. This was achieved by slowly pipetting the lysate onto the 
rim of the column in an anti-clockwise motion. After the lysate had flowed through the column 
by gravity flow, 5ml equilibration buffer was then applied to the column in the same anti-
clockwise motion as before, and the column filter discarded. 8ml of wash buffer (Macherey-
Nagel) was then applied to the silica membrane and allowed to clear the column by gravity 
flow. The column was then transferred to a sterile 50ml tube and the plasmid DNA eluted by 
the addition of 5ml elution buffer (Macherey-Nagel). 
Plasmid DNA was then precipitated with the addition of 3.5ml isopropanol, followed by 
centrifugation at 15,000 x g for 5 minutes. The isopropanol was removed by pipetting and the 
plasmid DNA pellet air dried for 10 minutes at room temperature. The DNA was then 
reconstituted in dH2O. 
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3.3.3.2 Fluorescent Labelling of FISH Probes 
The extracted DNA was labelled using the Nick Translation DNA labelling system (Enzo Life 
Sciences). Nick translation makes use of the actions of DNA Polymerase I and DNase I to 
replace unmodified nucleotides with fluorophore-labelled nucleotides. DNase I introduces 
multiple nicks in DNA, whilst DNA Polymerase I catalyses the incorporation of nucleotides to 
the 3’-OH terminus of the nick and simultaneously removes nucleotides from the 5’-PO4 
terminus. In a clean 1.5ml microcentrifuge tube, the following reagents were added (all Enzo 
Life Sciences); 1µg DNA template in 25µl of dH2O; 5µl reaction buffer; 5µl dNTP mix; 2.5µl 
dTTP mix; 2.5µl Fluorophore-dUTP; 5µl DNA Polymerase I; and 5µl DNase I. The reagents were 
mixed by flicking and incubated for 120 minutes at 15°C before chilling on ice. The reaction 
was then terminated by the addition of 5µl Stop Buffer and heating to 65°C for 5 minutes. 
The nick translated probes were then precipitated to allow the preparation of a hybridisation 
mix. 5.5µl of the nick translation reaction was added to a fresh 1.5ml microcentrifuge tube 
with 3µg Human Cot-1 DNA (Invitrogen) and the mixture made up to a total volume of 16µl 
with dH2O. 1.6µl of 3M sodium acetate (Sigma-Aldrich) was added, followed by 40µl of ice-
cold 100% ethanol before mixing by pulse vortexing and incubation on ice for 15 minutes. The 
DNA was pelleted by centrifugation at 13,000 x g for 30 minutes in a microcentrifuge chilled to 
4°C. The pellet was then resuspended in 6µl dH2O and 14µl hybridisation buffer (Cytocell, UK). 
Probes were then purified using illustra ProbeQuant G-50 Micro Columns (GE Healthcare), 
which utilise Sephadex G-50 to purify probes by gel filtration in order to remove 
unincorporated nucleotides left by the nick translation. The column was first prepared by pulse 
vortexing to resuspend the Sephadex resin. The cap was then removed from the base of the 
column, and the Sephadex column placed into a collection tube. The tube was centrifuged at 
735 x g for 1 minute to slightly dry the column. The probe suspension was then immediately 
applied to the centre of the Sephadex resin and the column placed in a fresh 1.5ml 
microcentrifuge tube. The column was then centrifuged for 2 minutes at 735 x g to elute the 
purified sample into the microcentrifuge tube and purified probes were stored at -20°C. 
3.3.3.3 General FISH Technique 
FISH was performed on 76mm x 26mm Superfrost glass microscope slides (Thermo Scientific) 
cleaned with fresh fixative. 2µl of fixed cell nuclei suspension was applied to the centre of the 
slide and allowed to air dry. Probe solution was mixed 1:1 with hybridisation buffer (Cytocell) 
in a 0.5ml microcentrifuge tube and 2µl of the mixture applied to a 13mm diameter No. 1.5 
glass coverslip (VWR International). The coverslip was applied to the dried fixed cells present 
on the microscope slide and sealed using Fixogum (Marabu), before transferring the slides to a 
HYBrite probe hybridisation platform (Abbott Molecular) for hybridisation. Hybridisation was 
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performed by heating the samples to 75°C for 5 minutes, followed by incubation at 37°C for 16 
hours. After this incubation step, the gel fixative was removed and the slide was soaked in 
2xSSC solution until the coverslip fell away. The slides were then transferred to WASH 1 
(Chapter 2.1.5) and incubated at 72°C for 2 minutes, followed by incubation at room 
temperature for 2 minutes in WASH 2 (Chapter 2.1.5). Slides were then removed from the 
wash and excess solution drained, before 7µl of 4',6-diamidino-2-phenylindole (DAPI) solution 
(Vector Laboratories) was applied and the microscope slide covered with a 24mm x 50mm No. 
1 glass cover slide (VWR International). 
FISH slides were viewed using a BX61 fluorescence microscope (Olympus) equipped with a 
100x magnification, 1.30 aperture oil-immersion objective lens. 
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3.4 Results 
3.4.1 Copy Number Array Analysis 
Publicly available copy number array data from AML patients were downloaded from the Gene 
Expression Omnibus and analysed as described in Section 3.3.1. This allowed analysis of 866 
patients across a total of 1442 data files including matched controls and relapse samples. 
3.4.1.1 Cohort Characteristics 
The cohorts used each had a different selection criterion as indicated in Table 11. The mean 
ages of the studies, where this information was available, were generally low when compared 
to the mean age of diagnosis in AML which is usually around 70 years (Kumar, 2011). The 
percentage of males included for study was also slightly lower than expected, with 55% of AML 
cases diagnosed in males (CRUK, 2014). 
Study GEO 
Accession 
Array 
Type(s) 
Number 
of 
Patients 
Number 
of 
Matched 
Controls 
Selection Mean Age 
(Years) 
% Male 
Radtke et 
al. 2009 
GSE15347 500K, 
100K 
111 65 Paediatric 
AML 
9.3 49 
Bullinger 
et al. 
2010 
GSE19101 500K, 
100K 
157 157 Normal 
Karyotype 
46.1 46 
Gupta et 
al. 2012 
GSE20672 SNP 6.0 56 56 Adult 
AML 
- - 
Barresi et 
al. 2010 
GSE21780 SNP 6.0 19 11 Normal 
Karyotype 
43.2 47 
Parkin et 
al. 2010 
GSE23452 SNP 6.0 114 112 Non AML-
M3 
61.3 58 
Haferlach 
et al. 
2011 
GSE27832 SNP 6.0 7 0 12p 
Deletion 
70.7 43 
Kühn et 
al. 2010 
GSE32462 SNP 6.0 300 175 AML-M3 - - 
Rücker et 
al. 2012 
GSE34542 SNP 6.0, 
500K 
102 0 Complex 
Karyotype 
- - 
Total   866 576    
Table 11. The AML patient cohorts utilised in this study. Where age and sex information was available, this is also 
displayed. 
3.4.1.2 Deletions of Chromosome 12p 
The overall incidence of 12p deletions across those data sets that had not been specifically 
selected for the detection of 12p deletions was 45 of 859 patients (5.2%), whilst deletions of 
12p were detected in 2 of 111 cases (3.6%) from the paediatric AML data set (Radtke et al., 
2009, GSE15347).  A total of 6 patients had deletions encompassing the entire 12p 
chromosome arm. An example of a patient with a deletion is shown in Figure 6, where it can 
be seen that the copy number is reduced to one. 
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 Figure 6. An example of a patient with a deletion of chromosome arm 12p.Sample GSM393735 from series 
GSE15347 (Radtke et al., 2009). The deleted region is highlighted in red. 
Detailed information on each patient found to have a deletion of 12p is displayed in 
Supplementary Table 34. In all cases except two, the ETV6 gene was within the minimally 
deleted region. One of these exceptions was previously reported by Haferlach et al. (2011), in 
which the region of deletion spanned 12,113,639 base pairs from the 12p telomere to 
13,763,702. The second patient to exclude ETV6, from the Rücker et al. (2012) study, had a 
deleted region from 12,120,652 to 13,495,401, after remapping of genomic coordinates from 
hg18 to hg19. 
Through the alignment of deletions (after conversion of genome coordinates to the same 
human genome build - hg19), a MDR was derived, which contained 10 genes: BCL2L14, LRP6, 
MANSC1, LOH12CR1, DUSP16, CREBL2, GPR19, CDKN1B, APOLD1 and DDX47. 
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 Figure 7. Minimally deleted region determined for chromosome 12p determined by SNP array analysis to derive a 
region of copy number alteration. The minimally deleted region contained 10 genes. 
3.4.1.3 Gains and Amplifications of Chromosome 11q 
The 866 patient cohort obtained from public databases was also analysed to identify gains and 
amplifications of the long arm of chromosome 11. Gains of regions of 11q with a copy number 
of 3 were found in 22 patients, the sizes of which varied greatly between patients. One patient 
was found to have gained an entire copy of chromosome 11, whilst two more had gains 
encompassing the entire 11q chromosome arm. Some small focal gains were observed, for 
example in sample GSM472689, a relatively small region of 0.2MB was gained, containing 9 
genes. Full details of samples with gains are outlined in Supplementary Table 35.  
Three patients had gains with a copy number of 4, details of which are shown in 
Supplementary Table 36. One of these patients, GSM850809 showed an additional gain of 
most of 11q on a background of what appeared to be trisomy 11.  
Five patients were identified with amplifications of 11q displaying a copy number greater than 
4. Four of these patients were from the complex karyotype study (Rücker et al., 2012, 
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GSE34542). Full details of these amplifications are outlined in Supplementary Table 37. The 
only sample with an amplification of 11q that was not from the Rücker et al. (2012) complex 
karyotype dataset was from the Parkin et al. (2010) non-M3 AML study. This sample, 
GSM631097 showed high levels of amplification between 126,953,865 and 130,834,263 
(Figure 8). This region contains a number of genes, including the potential proto-oncogenes 
ETS1 and FLI1. There was no indication of amplification involving MLL or surrounding genes in 
this sample. Additional information was available from the annotation file for this patient: 
They were a 76 year old female with no history of previous AML or MDS, classified into the del 
(9q) prognostic group based on their cytogenetic data (MRC Intermediate risk). The SNP array 
data showed that the patient had a deletion of 5q and CN-LOH of the 17p region containing 
TP53, in combination with a mutation of TP53. 
 
Figure 8. Sample GSM631097 showing amplification of 11q, analysed by SNP 6.0 microarray. This patient was found 
to have a copy number of 2 for most of chromosome 11 and a small focal region of high level amplification 
encompassing 11q23. 
Sample GSM850743 was of particular interest due to an unusual pattern of amplification. The 
sample had a baseline copy number of 3 for most of the 11q arm, with a large area amplified 
that included ETS1 and FLI1 but not the MLL locus (Figure 9). Unusually, this sample also 
showed high level focal amplification in a region between 132,168,501 and 132,570,489, 
containing the 3’ end of the NTM gene and the 5’ end of the OPCML gene. 
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 Figure 9. Sample GSM850743 displaying amplification of the long arm of chromosome 11 analysed by SNP 6.0 
microarray. This sample showed a copy number of 3 for the majority of the 11q arm, with increasing stepwise copy 
number towards the terminal region, with a focal amplification in a small region containing parts of the NTM and 
OPCML genes. 
The three remaining 11q amplified samples were from 500K array data in the Rücker complex 
karyotype dataset. GSM850721 was found to have an amplification spanning from 11q23.3 
containing the MLL gene to the end of chromosome 11 (Figure 10A). GSM850724 had a small 
focal amplification containing part of MLL, as well as the genes: TTC36, TMEM25, C11orf60, 
ARCN1, PHLDB1, TREH, DDX6, CXCR5 and BCL9L (Figure 10B). The final case, GSM850821, had 
two focal regions of amplification. The first contained the MLL gene, whilst the second region 
was distal of the first and contained the ETS1 and FLI1 genes, appearing to have a slightly 
higher copy number for this region compared to the MLL containing region (Figure 10C). 
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 Figure 10. Samples displaying amplification of 11q analysed with 500K SNP microarrays. A. Sample GSM850721, 
showing amplification of the terminal portion of 11q. B. Sample GSM850724 showing a small focal region of 
amplification of 11q23. C. Sample GSM850821 showing two focal regions of amplification of 11q23.3 and 11q24.3. 
Through the alignment of these amplifications with previously reported examples of 
amplification (Zatkova et al., 2009), three commonly amplified regions were identified. The 
genes from within these regions are summarised in Figure 11. 
65 
 
 Figure 11. Commonly amplified regions on chromosome 11q derived from analysis of 500K and SNP6.0 microarray 
data. Three commonly amplified regions were identified, highlighted in red, containing a total of 32 genes. 
3.4.2 Multiplex Ligation-dependent Probe Amplification 
The MLPA technique was utilised to screen a panel of patients with normal karyotypes to 
further refine the minimally deleted region defined by the copy number array analysis. Normal 
karyotype patients were selected based on the findings of the SNP array work described in this 
chapter in addition to a previous study (Andreasson et al., 1997), which have suggested that 
12p deletions were present in some of these patients below the resolution of cytogenetic 
analysis. These deletions are likely to be smaller, therefore potentially more informative for 
the identification of a MDR.  
Probe pairs were designed to specifically hybridise to genes of interest on 12p. Additionally, 
these probes were designed to avoid SNPs, which involved designing probes to bind to introns 
where SNP coverage is well known. Probe pairs were also designed to produce PCR products 
corresponding to a range of discrete sizes, allowing their individual resolution through capillary 
electrophoresis. The gene targets and probe sizes used are listed in Table 12. 
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Target Gene Product Size 
(base pairs) 
CREBL2 104 
APOLD1 108 
LRP6 112 
CDKN1B 118 
CDKN1B 126 
ETV6 130 
ETV6 136 
ANO2 142 
MANSC1 146 
Table 12. Custom designed MLPA Probe sizes used for the screening of 12p deletions in normal karyotype AML DNA 
samples. 
The probeset was mixed with the SALSA MLPA P200-A1 Human DNA Reference Probemix 
(MRC Holland) and reaction conditions optimised using control male and female DNA. Probe 
peaks were of a satisfactory height (between 2000 and 10000 units) and the reference 
probemix was able to correctly identify the presence of the Y chromosome in the male 
reference sample (Figure 12A and C), whilst also correctly identifying the presence of 2 X 
chromosomes in the female control sample (Figure 12B and D). 
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 Figure 12. Male and female controls analysed using MLPA in combination with a custom designed 12p probeset. A. 
Peak heights for male control. B. Peak heights for female control. C. Relative peak ratio for male control sample. The 
green squares represent the custom 12p probes, while the blue squares represent the control probes included in the 
P200 kit (MRC Holland). D. Relative peak ratio for female control sample. The increased peak ratio point represents 
the X chromosome, whilst the value of 0 corresponds to the Y chromosome probe pair. 
The 12p probeset was then tested with a selection of cell line DNA. The cell lines KG-1 and 
GDM-1 were selected as these cell lines have a monoallelic deletion of 12p. Additionally, a 
patient sample with a 12p deletion detected by karyotyping was included (8070).  
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The probes used were able to correctly identify deletions in the 12p deleted cell lines (Figure 
13A and B). The retained probe at 142 base pairs in both samples represents the ANO2 gene, 
selected for its proximity to the 12p telomere. As it was retained in these samples, it confirmed 
that the deletion of 12p in these cell lines was interstitial. Furthermore, the reference probes 
confirmed the gain of chromosome 13 in the GDM-1 cell line, known from karyotyping and 
SNP array data. Interstitial deletion of 12p was also identified in patient 8070 (Figure 13C). The 
quality control fragments (visible in the top left) were amplified in this patient sample 
suggesting that the DNA was poor quality, however the expected result was still visible. 
 
Figure 13. Control samples analysed using MLPA in combination with a custom designed 12p probeset. A. KG-1 cell 
line with 12p deletion. B. GDM-1 cell line with 12p deletion. C. Patient 8070 with 12p deletion detected by 
karyotyping. The red squares show probes from the 12p kit with a signal ratio below 0.75, and were therefore 
determined to be deleted. The retained probe in this area represents the 12p terminal probe for the ANO2 gene, 
suggesting an interstitial deletion of 12p in this cell line. 
After optimisation, the probeset was then used to screen normal karyotype AML patients for 
the presence of 12p deletions. Two examples of patients with identified deletions of 12p are 
shown in Figure 14. Among 75 patients, five were found to have deletions of 12p (6.7%). Two 
of these patients had deletions that included the ANO2 gene close to the 12p telomere, 
suggesting a large deletion of the p arm of at least 7MB in size. Fixed cell nuclei were available 
for four of these five patients, and FISH using a probe targeting ETV6 within the deleted region 
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confirmed 12p deletions. These deletions were shown to be at least the same size as the 
minimally deleted region established from the SNP array data, so it was not possible to further 
refine the 12p candidate gene list from these data. 
 
Figure 14. Normal karyotype patients analysed with the 12p MLPA kit, found to have deletions of 12p through MLPA 
screening. These are shown by the red squares on the left hand side of the peak ratio plots, which sit below the 0.75 
threshold. 
3.4.3 Cell Line Selection 
3.4.3.1 12p Deleted AML Cell Lines 
The Sanger COSMIC Cell Line database was screened for publicly available SNP 6.0 data to find 
deletions of chromosome arm 12p in AML cell lines. Three suitable cell lines were identified: 
GDM-1, KG-1 and NKM-1. These lines were selected as they had interstitial deletions of 12p 
including all genes established through SNP array analysis, in conjunction with relatively few 
other genetic aberrations. 
Cell Line AML Subtype FAB Subtype Gender Age (Years) Reference 
GDM-1 Myelomonoblastic M4 F 66 Ben-Bassat et 
al., 1982 
KG-1 Myeloblastic M1 M 59 Furley et al., 
1986 
NKM-1 Myeloblastic with 
granulocytic 
maturation 
M2 M 33 Kataoka et al., 
1990 
Table 13. AML Cell Lines with deletion of chromosome arm 12p, found using the Sanger COSMIC Cell Line database. 
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3.4.3.2 11q Amplified AML Cell Lines 
Three AML cell lines reported to have amplification of the MLL gene have been described in 
the literature. 
Cell Line AML Subtype FAB Subtype Gender Age (Years) Reference 
2L1 Myeloblastic M5 M 6 Felix et al. 
1998 
UoC-M1 Megakaryocytic M7 M 68 Allen et al. 
1998 
SAML-2 Myelomonocytic M4 M 42 Knutsen et al. 
2003 
Table 14. AML Cell Lines with amplification of chromosome 11q, found through literature review. 
The cell line 2L1 was established from the bone marrow of a child who developed t-AML after 
treatment for neuroma and rhabdomyosarcoma. In this cell line, multiple signals were 
detected with a probe targeted to the MLL gene on a der(5)t(5;11) chromosome, as well as on 
a der(11) chromosome (Felix et al., 1998). This cell line is no longer available, due to 
contamination of cell stocks (Correspondence with Dr. Peter Aplan, National Cancer Institute, 
USA). The cell line SAML-2 was also established from a t-AML, in this case from a patient 
receiving treatment for Hodgkin disease. This cell line has two der(8) chromosomes, formed 
from translocations between chromosomes 8 and 11, resulting in both MYC and MLL 
amplification (Allen et al., 1998). There has been some difficulty in culturing this cell line, 
possibly due to its slow growth and fragile nature. This has resulted in extremely low stocks of 
the line remaining worldwide and as such is not available (Correspondence with Dr. Turid 
Knutsen, National Cancer Institute, USA and Prof. Hans Drexler, DSMZ, Germany). The UoC-M1 
cell line was established at the University of Chicago in 1998 from a patient with AML-M1. The 
cell line carries a dicentric chromosome 11, containing alternating segments of chromosomes 
9 and 11, with a total of four copies of MLL present (Allen et al., 1998; Knutsen et al., 2003). 
Although the presence of four copies is not regarded by all as true amplification (Myllykangas 
et al., 2006) the expression of genes from the 11q region has been shown to be increased in 
this cell line relative to other AML cell lines (Allen et al., 1998), therefore it is a suitable model 
for amplifications of 11q. 
The UoC-M1 cell line was received as a kind gift from Michelle LeBeau, University of Chicago. 
As there were no publicly available SNP array data for the line, SNP 6.0 and FISH analyses were 
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performed to gain more information about the genetic aberrations present. FISH using a MLL 
probe confirmed the presence of 4 copies of this gene, as shown in Figure 15. The SNP 6.0 data 
also showed 4 copies of this region, stretching from 11q22.3 to the 11q terminus, as shown in 
Figure 16. Interestingly, the SNP analysis also showed a number of aberrations of chromosome 
21 that had not previously been reported in this cell line. These data showed amplification of 
multiple genes on chromosome 21, including the putative oncogenes ERG and ETS2. Another 
putative oncogene, RUNX1 was not amplified to a high level, although there were 4 copies. The 
pattern of amplification on chromosome 21 is shown in Figure 17. Multiple copies of ERG were 
confirmed by FISH (Figure 18). 
 
Figure 15. FISH performed on the UoC-M1 cell line using a MLL break-apart probe. As four fusion signals are 
observed, it is inferred that four copies of MLL are present in the cell line. 
 
Figure 16. SNP 6.0 Array data from UoC-M1 Chromosome 11. The terminal region containing the minimally amplified 
regions found earlier in the project has a copy number of 4. 
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 Figure 17. SNP 6.0 Array data from UoC-M1 Chromosome 21, showing variable copy number across the long arm of 
the chromosome, with some regions of amplification. 
 
Figure 18. FISH performed on the UoC-M1 cell line using probes for ERG (Red) and a Chromosome 21q22.13 probe 
(Green). The presence of multiple red signals signifies amplification of the chromosome region containing ERG. 
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3.5 Discussion 
As discussed in Chapter 1, deletions of 12p and amplifications of 11q are recurrent cytogenetic 
abnormalities in AML that correlate with a poor prognosis. The aim of this chapter was to 
establish minimal regions of deletion and amplification that could be used to produce a 
candidate gene list for further investigation in subsequent work. The availability of public 
databases were instrumental in completing this line of work, and such a study was only 
possible due to the large amount of studies that have submitted their data to GEO, as well as 
the Sanger database of copy number alterations and mutations in cancer cell lines. 
3.5.1 Deletions of Chromosome 12p 
Deletions of 12p were detected in 2 of the 111 cases (1.8%) in the Radtke et al. dataset, which 
contained only paediatric cases, in line with previously reported incidences of this abnormality 
in this age group (Harrison et al., 2010). In the absence of specific age information for the 
other studies, only the overall incidence across all samples can be studied. The 5.2% incidence 
(excluding the selected 12p deleted cases) is as expected taking into account the 1-5% 
previously reported (Grimwade et al., 2010; Harrison et al., 2010). The detection rate may 
have been slightly higher than traditional cytogenetic techniques due to the use of sensitive 
SNP array technology, as it has been previously shown that deletions of 12p may be below the 
resolution of cytogenetic techniques. Andreasson et al. (1997) reported that up to 10% of 12p 
deletions were missed by cytogenetics but were subsequently detected using specific FISH 
probes (Andreasson et al., 1997). In this study, 5.1% of patients across the two studies 
focussing specifically on normal karyotype patients had deletions of 12p, lending further 
support to this notion. 
The MLPA probeset developed for this section of work was shown to be an accurate method of 
screening patient DNA for copy number aberrations of the 12p region. Four of the five normal 
karyotype cases shown by MLPA to have deletions of 12p were successfully validated using 
FISH. Although the MLPA was unable to identify cases to further refine the minimally deleted 
region established by the SNP array study, it provided information about 12p deletions in 
normal karyotype patients: 6.7% of these patients were found to have a deletion of this region. 
This portion of the study may have benefitted from a larger cohort of patient material to 
screen, however this was not available at the time. Future studies utilising these techniques 
could easily be performed as the probeset has now been designed, optimised and validated.  
The minimally deleted 12p region contains 10 genes (BCL2L14, LRP6, MANSC1, LOH12CR1, 
DUSP16, CREBL2, GPR19, CDKN1B, APOLD1 and DDX47). ETV6 was excluded based upon copy 
number data obtained from two patients. One of these patients was from the previously 
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discussed Haferlach et al. (2011) study, and the other from the Rücker et al. (2012) study. 
Despite these findings, it was decided to include ETV6 in the candidate gene list for functional 
follow up. As only copy number SNP arrays were used to determine the MDR, it is unknown if 
other chromosomal rearrangements that do not affect copy number may alter the expression 
of ETV6. The 12p13 chromosomal region has been shown to have an increased degree of 
instability, with multiple break points possible that lead to complex rearrangements (Sato et 
al., 2001). It would be ideal to further assess the prevalence of rearrangements in this region 
using sequence data obtained from AML patients both with and without deletions of 12p, that 
have been analysed on high throughput sequencing platforms. Analysis in this way would have 
the added benefit of providing mutation data which may be more informative in implicating 
certain genes in a tumour suppressor role. 
In addition to this lack of genomic information, there is a body of evidence implicating ETV6 in 
having a functional tumour suppressor role. ETV6 can form fusion genes when translocated in 
AML, but these often do not result in a functional transcript. Instead it has been suggested that 
they lead to altered wild type ETV6 dosage through haploinsufficiency (Silva et al., 2008). 
Mutations in ETV6 have also been reported in AML, some of which are believed to have 
dominant negative effects disrupting ETV6 function in the absence of a second hit (van Doorn-
Khosrovani et al., 2005). Finally, research by Feurstein et al. (2014) has found that ETV6 
expression is effectively halved in patients with deletions of 12p13 compared to those without 
12p abnormalities, providing evidence that decreased dosage of this gene may be a driver of 
leukaemogenesis in these patients (Feurstein et al., 2014).  
Three AML cell lines have been identified with deletions of 12p that will be utilised in future 
work – GDM-1, KG-1 and NKM-1. These cell lines were selected as they carry interstitial 
deletions encompassing the MDR, and have relatively few other chromosomal aberrations 
(Ben-Bassat et al., 1982; Furley et al., 1986; Kataoka et al., 1990; Catalogue of Somatic 
Mutations in Cancer). 
3.5.2 Amplifications of Chromosome 11q 
Overall, 31 patients (3.6%) had gain of material on chromosome 11q. From the complex 
karyotype group, 12 of 102 patients (11.8%) were found to have gains. This is a little lower 
than the previously reported 15-40% of patients in the complex karyotype group (Schoch et al., 
2002; Rücker et al., 2006).  
Twenty four patients had gains that resulted in a copy number of three or four on 11q. Of 
these, 15 had large regions of gain that included MLL, ETS1 and FLI1. A further four patients 
had gains including MLL but not ETS1 and FLI1, whilst 3 patients had gains of ETS1 and FLI1 but 
75 
 
not MLL. Finally, two patients had focal gains located outside the established common regions 
of gain. As these two focal regions were not recurrent and have not previously been reported, 
it is likely that they are passenger mutations that do not result in a leukaemogenic effect. 
Of the five patients identified with amplifications of 11q, four of them also had a complex 
karyotype. As most amplifications of 11q are found in patients with complex karyotypes, this 
observation was expected.  The overall incidence of 11q amplifications across all patients 
sampled was low (0.6%), although the large numbers of normal karyotype and paediatric AML 
samples used in this study is likely to have contributed as 11q amplifications are rare in these 
groups. 
Through combining array data with previously published data, three common regions of 
amplification have been identified that will be investigated in the next stages of the project. 
These regions contain a total of 30 genes, including the putative proto-oncogenes MLL, ETS1 
and FLI1. For functional investigation, the cell line UoC-M1 will be used. Although not carrying 
true amplification of the region of interest, the cell line has four copies of the candidate genes, 
and it has been demonstrated to have significantly increased expression of genes from this 
region when compared to control samples (Allen et al., 1998). 
3.5.3 Amplifications of Chromosome 21q 
Although not the focus of this project, an interesting observation was the amplification of the 
long arm of chromosome 21 found in the UoC-M1 cell line. Amplifications of chromosome 21 
have previously been reported in AML, with one study finding amplifications of this region to 
be more common than amplifications of chromosome 8q, but less frequent than amplifications 
of chromosome 11q (Roller et al., 2013). Another study has linked amplification of APP, ETS2 
and ERG from within the chromosome 21q region with an increased level of expression (Baldus 
et al., 2004), suggesting a functional relevance for these genes. The amplified region identified 
in the UoC-M1 cell line overlaps with the amplified regions identified in these two studies, 
although a separate study has suggested that the putative oncogenes ERG and ETS2 are not 
the target of chromosome 21 amplification (Canzonetta et al., 2011). This conflicting evidence 
combined with the observation of recurrent amplifications of this region make future 
functional investigations of this region an interesting prospect that would be facilitated using 
the UoC-M1 cell line. 
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Chapter 4 Identification of Driver Genes by Negative Selection 
4.1 Introduction 
4.1.1 HIV Lentivectors 
As the cause of one of the most prevalent diseases affecting modern humans, human 
immunodeficiency virus (HIV) has been continuously investigated over the last three decades. 
This research has provided a great depth of knowledge about a number of aspects of HIV, 
including its genome, particle structure and viral life cycle. As a member of the retrovirus 
family, HIV has the ability to integrate its genome with that of its host cell, resulting in long 
term infection and continuous transcription of viral products. Furthermore, HIV is able to 
replicate in slowly dividing and non-dividing cells, hence its classification as a lentivirus. This 
unique set of attributes has resulted in significant interest in developing HIV based gene 
delivery vector systems for research purposes. 
4.1.1.1 The HIV Life Cycle 
The first step in the HIV life cycle involves the entry of the viral particle into the target host 
cell, which is mediated through the interaction of HIV envelope proteins (Env) with the surface 
membrane of the target cell (Gomez and Hope, 2005). This interaction leads to the formation 
of a six helix protein bundle that fuses the virion membrane with the target cell membrane, 
allowing delivery of the viral core to the target cell cytoplasm (Melikyan et al., 2000). 
The viral core is made up of proteins cleaved from the polyprotein transcribed from the viral 
gag (Group specific antigen) gene transcripts. When the viral core is exposed to the host cell’s 
cytoplasm, the viral RNA genome is released from its capsid (Arhel, 2010). Reverse 
transcription of the genome is mediated by reverse transcriptase encoded by the HIV pol gene, 
at first forming an RNA-DNA complex, from which the RNA strand is degraded and a double 
stranded DNA copy of the viral genome is formed (Moore et al., 2009; Simon-Loriere et al., 
2011). Integrase, another product of the pol gene, then integrates the double stranded DNA 
helix into the host cell genome. The integrase enzyme first acts by cleaving both 3’ ends of the 
DNA molecule, creating sticky ends amenable to integration (Fanales-Belasio et al., 2010). It 
then transfers the DNA into the host cell nucleus and facilitates its integration into the 
genome.  
After integration with the host genome, synthesis of HIV transcripts and their translation to 
proteins occurs, allowing new viral particles to be produced which push through the host cell 
membrane, budding into complete virions that can go on to infect other cells (Gomez and 
Hope, 2005). The entire HIV replication process is summarised in Figure 19, and a schematic of 
the complete virus particle is shown in Figure 20. 
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 Figure 19. The HIV Life Cycle. After binding the host cell membrane, the viral core is exposed and uncoated before 
reverse transcription into double stranded DNA takes place. Integrase mediates the integration of viral DNA into the 
host cell genome, where viral mRNA sequences are transcribed leading to the production of new viral proteins. These 
proteins are assembled and complete viral particles push through the host cell membrane and bud, forming 
complete virions capable of infecting additional host cells (Rambaut et al., 2004; Engelman and Cherepanov, 2012). 
 
Figure 20. The Fully Assembled HIV Particle. The main structures are listed in bold, along with the gene that encodes 
the related proteins, listed underneath. The viral genome is encased within a core made up of products of the gag 
(group specific antigen) gene. Products of the pol (polymerase) gene are also present, providing the enzymes 
required to integrate into new host cells. The products of the env (envelope) gene, provide the surface proteins 
responsible for binding target cells. The lipid membrane is provided by the host cell when the completed viral particle 
pushes through the host membrane in the budding process (Robinson, 2002; Fanales-Belasio et al., 2010). 
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4.1.1.2 Using HIV as a Gene Transfer Vector 
The primary concern when considering the use of HIV to deliver gene expression constructs is 
safety. This is achieved by ensuring that replication competent virus particles cannot be 
produced, but are still able to achieve the goal of integrating constructs capable of driving long 
term expression of target genes. With this goal in mind, Naldini et al. (1996) designed a HIV 
packaging system consisting of three plasmids. The genes required to produce functional 
lentiviral particles are transiently expressed by plasmids in order to produce viral particles that 
are not themselves capable of reproducing, but are able to integrate a viral sequence 
containing one or more genes to be expressed in the target cell (Naldini et al., 1996). 
The packaging construct contains the viral gag and pol genes, with the regulatory genes tat 
and rev, as well as the HIV accessory genes vif, vpr and nef. All of these genes are under the 
control of a cytomegalovirus (CMV) promoter to induce gene expression in a wide range of cell 
types. More significantly, the env gene is disrupted, with the RRE (rev response element) from 
within the gene remaining as the only functional env feature. Retention of the RRE ensures 
exportation of full length mRNAs coding for Gag and Pol proteins from the packaging cell 
nucleus (Naldini et al., 1996). 
As the env gene is disrupted on the packaging plasmid, without another source of envelope 
proteins provided, it would not be possible to produce mature lentiviral particles. The 
envelope plasmid instead contains the vsv-g gene, again under the control of a CMV promoter. 
This drives the production of the Vesicular Stomatitis Virus (VSV) Glycoprotein-G coat protein, 
which is used instead of the HIV Env proteins to produce a pseudotyped virus consisting of the 
HIV core surrounded by a VSV-G coat. Viral particles pseudotyped in this way are no longer 
specific to one cell type (for example CD4+ cells as with HIV viruses) and are instead able to 
transduce all cell types (Naldini et al., 1996). For other applications, such as gene therapy 
vectors, viral coat proteins from other viruses can be substituted to create pseudotyped 
viruses that are specific to certain cell types. 
The transfer vector provides the sequences to be integrated into the target cell genome. By 
including truncated forms of the gag and env genes, two copies of full length mRNAs 
transcribed from this plasmid are able to form complexes with replication enzymes and form 
the nucleocapsid structure of mature viral particles. The RRE from within env ensures nuclear 
exportation, and sequences within gag ensure correct localisation to the viral membrane 
(Gomez and Hope, 2005). The transfer vector can include full length cDNA sequences in 
combination with a promoter of choice, to drive gene expression in infected cells where the 
transfer cassette is successfully integrated. 
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This combination of packaging plasmids is transfected into the 293T cell line, or one of its 
derivatives. The 293T line was derived from 293 cells through the introduction of the SV40 
large T-antigen, and allows the episomal replication of transfected plasmids that contain the 
SV40 origin of replication which improves lentiviral particle production (Oka et al., 2010). The 
SV40 large T-antigen also inhibits phosphorylated Rb protein, leading to an increased growth 
rate in 293T cells compared to 293 which improves their ease of use in culturing and the 
production of lentiviral particles (Meng et al., 2010). 
 
Figure 21. Production of lentiviral particles in the 293T cell line. Plasmids are transfected through the endocytosis of 
cationic liposomes, cationic polymers or phagocytosis of calcium phosphate precipitates. Packaging plasmids encode 
for viral protein components, whilst the transfer vector provides the ssRNA to be contained within the lentiviral 
particle for delivery into target cells. 
This basic three plasmid system has subsequently been modified to further reduce the risk of 
producing replication competent retrovirus particles. In the second generation of these vectors 
described by Zufferey et al. (1997), the packaging construct was reduced by removing the 
accessory genes vif, vpr and nef, which were found to be surplus to requirements for viral 
production in vitro. In the third generation of vectors, tat is replaced by constitutively active 
promoter sequences in the packaging construct. In addition to this, the third generation of 
vectors have a self-inactivating (SIN) deletion of the 3’ Long Terminal Repeat (LTR). This 
deletion is transferred to the 5’ LTR of integrated proviral DNA, and abolishes viral promoter 
activity (Zufferey et al., 1998), preventing the synthesis of full length vector RNA in target cells. 
This further ensures the safety of produced lentiviral particles and has the added effect of 
ensuring that host genes near to the integration site are not aberrantly expressed as a result of 
viral promoter activity. 
A number of other features can be included to tailor the produced lentivirus particles for 
specific applications. For example in this project, transfer vectors based on the SIN-SIEW 
vector will be utilised. In this transfer vector, the internal spleen focus forming virus (SFFV) 
80 
 
promoter is selected to drive the expression of integrated cDNAs, for its high activity in 
haematopoietic cell types, including haematopoietic stem cells (Demaison et al., 2002). Other 
elements such as the Woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE) further enhance expression and increase the amount of produced lentivirus. The 
inclusion of an internal ribosome entry site (IRES) allows for translation initiation in the middle 
of transcribed mRNA sequences (Hellen and Sarnow, 2001), and can therefore drive the 
translation of a second coding sequence present on the construct. In regards to this project, 
this means that enhanced green fluorescent protein (eGFP) can be expressed alongside a cDNA 
of choice from a single integrated construct. 
4.1.2 Murine In Vivo Screening Techniques 
In vivo screening techniques have been incredibly useful in determining the functions of many 
genes. Multiple different approaches have been taken across a wide range of species to 
elucidate the underlying mutations causing varying phenotypes. The earliest studies focussed 
on lower organisms such as E. coli, C. elegans, and D. melanogaster, and used varied genetic 
techniques to determine whether underlying genetic mutations causing certain observed 
phenotypes were caused by either natural or induced mutagenesis (Justice, 2000). Whilst 
these proved to be successful in determining the function of some human genes and their 
roles in disease, the evolutionary span between humans and these species is often so large 
that useful information is lost when bridging the genetic distance between model organisms. 
Mice have been shown to have an extremely large number of genes (over 90% sequence 
homology) in common with humans (Mouse Genome Sequencing Consortium, 2002), as well 
as sharing similar physiology. Advances in genetic techniques and the completion of the mouse 
genome project (Waterston et al., 2002) now means that murine models are highly suitable for 
application in the study of human diseases.  
4.1.2.1 Early Insertional Mutagenesis Screening 
Early murine screen approaches were focussed on chemical mutagenesis, in particular N-ethyl-
N-nitrosourea (ENU), pioneered by Bill Russell of the Oak Ridge National Laboratories (Russell 
et al., 1979). These were coupled with positional cloning to identify the phenotype produced 
by exposure to the chemical mutagen (Justice, 2000).  
More recent advances have moved on from chemical mutagenesis, and approaches such as 
the Sleeping Beauty (SB) transposon system have been developed. The SB system is based on a 
synthetic transposon and transposase created from studying the phylogeny of inactive 
Tc1/mariner-type transposases isolated from a number of fish species. For its use in in vivo 
screening, the SB system is based upon the use of two transgenic mouse lines. One of these 
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lines contains the SB DNA transposase vector, while the other line carries the SB transposon 
transgene. When these two lines are crossed, the transposon is mobilised, allowing its 
integration elsewhere in the mouse genome. Should the transposon relocate within a gene, 
the production of functional protein from that gene locus is disrupted. O’Donnell et al. (2012) 
used this to identify potential tumour suppressor genes contributing to MYC-driven liver 
cancer. In this study, mice carrying the SB transposon vector and SB transposase inserts were 
crossed with an existing model of MYC-induced liver cancer, in which mice overexpress MYC in 
response to tetracycline within their liver cells. In this case, the SB transposon contained a 
gene trap element (T2/Onc), allowing identification of integration sites easily. They found that 
in those mice containing the SB transposase and transposon, liver tumour development was 
significantly accelerated and they identified 16 disease associated genes using this method 
(O’Donnell et al., 2012). 
4.1.2.2 Retroviral Based Insertional Mutagenesis 
Retroviral based insertional mutagenesis screens have primarily been used to identify 
oncogenic mutations in an in vivo setting. These systems typically make use of slowly 
transforming retroviruses, which induce tumours in mice with a latency of between 3 and 12 
months (Uren et al., 2005). The mutation of different genes is facilitated by the integration of 
proviral elements, which themselves drive and regulate the transcription of sequences 
required to produce further retroviral particles, infecting more cells. The integration of the 
proviral sequences can lead to the dysregulation of nearby genes with a number of differing 
effects. These include the activation of proto-oncogenes or the disruption of tumour 
suppressor genes, which then confer a selective growth advantage to that particular cell, 
encouraging clonal outgrowth (Uren et al., 2005).  
To identify genes driving the accelerated clonal expansion of cells, viral insertion sites are 
mapped to their location on the genome. Where insertion sites are found to occur in a 
particular region at a rate higher than expected by chance, the nearby genes are implicated in 
providing the growth advantage held by these cells. Within a single clonal tumour there are 
often three or four insertions near different oncogenes and tumour suppressor genes (Uren et 
al., 2005; Ranzani et al., 2013), although one recent screen identified an average of 20 
insertions per gene (Uren et al., 2008).   
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4.1.2.3 Gene Trapping 
Gene trapping is a technique that has been applied to generate many knockout stores of 
mouse embryonic stem cells, and has been the most widely used technique applied to produce 
a library of embryonic stem cell lines, each lacking a different gene of the mouse genome. The 
International Knockout Mouse Consortium (IKMC) is the umbrella organisation encompassing 
multiple smaller organisations with the collective aim of completing this mouse embryonic 
stem cell library. As of 2011, the consortium had achieved knockout of around 17,000 genes 
(Dolgin, 2011). As with ENU mutagenized ES cells, the stored cells can be thawed and injected 
into blastocysts to establish a mouse line carrying the particular conditional knockout of 
interest (Limaye et al., 2009). 
Gene-trap vectors are functionally similar to the other mutagenesis techniques discussed 
above, and are introduced on to a cell by either retroviral delivery or electroporation. Upon 
integration, they lead to the disruption of endogenous gene expression, as well as expression 
of a reporter gene. The advantage of gene trap vectors is that they contain a splice acceptor 
site at the 5’-end of the reporter gene, which allows a fusion transcript between the reporter 
and endogenous gene to be formed (Lee et al., 2007). By using a gene trap vector to disrupt 
the expression of a gene, the integration site can be quickly identified using 5’ or 3’ rapid 
amplification of cDNA ends (RACE). This allows gene-trap vectors to be used in high 
throughput approaches to generate knockout libraries. Although many different vectors have 
been used in combination with both delivery methods, a small subset of genes have been 
difficult to target with this method, because integration is biased, with some sites being 
favoured over others (Stanford et al., 2001). 
4.1.3 Functional Screening 
Functional screening using murine systems typically involves the introduction of genetic 
material through the use of retroviral systems to drive the production of various genetic 
molecules, including shRNAs, cDNAs and miRNAs. The wide variety of vectors and target cells 
available to researchers provide an extremely flexible set of systems, a subsection of which will 
be discussed here.  
Functional screens have been extremely useful in identifying genes important in a range of 
cancers. A number of considerations have to be made when designing a functional screen to 
identify putative oncogenes and tumour suppressors. The first concerns delivery of the vector. 
shRNAs are useful for a number of reasons. They are strong activators of the RNAi machinery 
within the host cell able to efficiently repress gene expression even when expressed from only 
a single genomic copy (Fellmann et al., 2013). The widespread availability of shRNAs already 
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integrated into lentiviral constructs and available in library formats further facilities their ease 
of use in large scale screening projects. cDNA screens can require more effort in terms of 
preparing lentiviral constructs containing the cDNA of choice, but can have the advantage of 
providing a more informative representation of the functions of a particular gene. miRNA 
screens have been useful in uncovering gene functions, as they have the potential to interact 
with a number of sites across the genome and have implicated previously unrelated genes in 
certain cellular functions (Hausser and Zavolan, 2014).  
The screening process can be applied to a range of cell types, often determined by the model 
being studied. A recent study combined RNAi screening techniques using shRNAs with a 
previously well-defined mouse model of liver cancer, in which hepatocellular carcinomas were 
induced by genetically manipulating cultured liver progenitor cells before transplanting them 
into the livers of recipient mice (Zender et al., 2008). To this already established model, a pool 
of 48 shRNAs, targeting various genes from within commonly deleted regions of liver 
carcinoma, were introduced. By quantifying the shRNAs in carcinoma samples a number of 
potential tumour suppressor genes were identified. 
In some screens, the target cell has been the limiting factor to the size of the pool being 
investigated. For example, a study by Adams et al. (2012) investigating haematopoietic injury 
response, used mouse haematopoietic stem progenitor cells (HSPCs). They calculated that 
their barcoded miRNA pool would be limited by the HSPCs to be used, in terms of total number 
of HSPCs available from one source, and in the limited number of engraftment events 
occurring per mouse. As they found this factor to be a bottleneck in their experiment, they 
limited the number of miRNAs to be studied to 135, creating a library which focussed 
specifically on haematopoietically-expressed miRNAs (Adams et al., 2012). More recent studies 
of shRNAs have successfully used much larger libraries in HSPCs, with a study by Wang et al. 
(2012) utilising a library containing shRNAs targeted to 947 cancer-related genes. In this study, 
they achieved much higher rates of viral infection compared to the Adams et al. (2012) study, 
as well as high levels of cell engraftment in the mouse models used (Wang et al., 2012). 
Quantification and validation of cancer related genes identified in functional screens can take a 
number of different forms. Some studies have isolated integrated events before cloning them 
into a recipient vector for quantification using sequencing (Zender et al., 2008). This approach 
has an added advantage in that the recipient vector can then itself be used for subsequent 
validation techniques. Another approach is to extract all the genomic DNA, and then perform 
deep sequencing (Wang et al., 2012). This method relies upon widespread integration of 
events of interest, as well as a large depth of sequencing to avoid missing potentially 
interesting results. Barcoding approaches have also been successful and allow for the 
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detection of specific barcodes using PCR in combination with a bead based detection system 
(Adams et al., 2012). qPCR approaches have also successfully been utilised, especially in 
smaller scale screens (Hope et al., 2010), where the labour intensity of the technique is less 
noticeable.  
Construct quantification is expected to identify a number of hits, which are typically validated 
using a range of approaches. In large scale screens, hits are usually confirmed in smaller 
experiments focussing only on the gene of interest. Different shRNA sequences can be used to 
ensure that the results seen are not due to off target effects. Where shRNAs or cDNAs have 
been used in the initial screen, the reciprocal experiment can be performed. In samples where 
shRNAs targeted to 3’ untranslated regions (UTRs) have been used, these can be rescued 
through expression of cDNAs that do not contain this region and therefore cannot be targeted 
by these shRNAs. Researchers may also wish to investigate the expression levels of the locus in 
question in a selection of human disease samples. Functional analysis can then be performed 
to analyse the role of the gene, although exactly what this entails varies greatly depending on 
the known functions of the candidate gene and disease being studied. 
4.1.4 Negative Selection Assay 
The selection assay used in this project is based on the concept of negative selection. cDNAs 
representing potential tumour suppressor genes from chromosome 12p or shRNAs targeted to 
potential oncogenes from chromosome 11q were delivered by lentiviral expression vectors 
into cells containing the aberration of interest. The cells were then expanded in vitro and in 
vivo in immunocompromised mice and any detrimental effects on growth by vector expression 
were measured by sequencing the relative proportions of integrated vectors before and after 
leukaemic cell expansion, as well as at a number of time points during in vitro culturing. An 
overview of the negative selection strategy is shown in Figure 22. 
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 Figure 22. The negative selection assay to be used in this project. Lentiviral particles, each containing an individual 
expression construct for a different shRNA or gene are pooled and used to transduce target cells containing the 
genetic aberration of interest. The cells are then cultured in vitro or engrafted into immunocompromised Nod-Scid 
Gamma mice. The relative abundance of each construct is then measured before and after engraftment into the 
mice, and at multiple time points during the in vitro expansion. In this example, gene 3 is negatively selected against 
and would therefore be considered a hit. 
4.1.5 Immune-Deficient Mouse Models 
The vast majority of in vivo experimentation using mouse models to study leukaemia is centred 
upon immune-deficient strains. These strains are unable to produce the full complement of 
haematopoietic lineages and accept transplants of human HSCs, which localise to the BM and 
populate the blood. The first major breakthrough in developing an immune-deficient mouse 
model was with the severe combined immune-deficient (Scid) strain of mouse, which lacked 
both B and T cells (Bosma et al., 1983). Experimentation with the Scid mouse successfully 
demonstrated that the strain could be populated with human haematopoietic cells. Moisier et 
al. (1988, 1991) infused leukocytes isolated from peripheral blood (PB), and demonstrated the 
mouse was able to produce human B and T cells that could mount an immune response when 
exposed to tetanus toxin (Moisier et al. 1988, 1991). McCune et al. (1988) also demonstrated 
the ability of cells to engraft and produce B and T cells, but did so by transplanting human 
foetal tissues and foetal liver cells. (McCune et al., 1988) The fact that human lymphocytes 
could survive in this mouse strain meant that they could be infected with HIV-1, subsequently 
establishing the first humanised models of AIDS. 
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Despite these successes, the Scid model was limited, as the strain still displayed high levels of 
innate immune function, as well as the spontaneous emergence of B and T cells with age. 
Shultz et al. (1995) backcrossed Scid mice with nonobese diabetic (NOD) mice, which 
harboured defects in their innate immune systems. The resulting NOD-scid mice supported 
high levels of human cell engraftment (Shultz et al., 1995). Further investigation into this strain 
using long positional cloning identified the Sirpa gene to be responsible for enabling NOD mice 
to support human haematopoietic stem cells (Takenaka et al., 2007). Human CD47, expressed 
on all haematopoietic cells, is tightly bound by NOD Sirpa protein, present on the surfaces of 
NOD mouse myeloid cells. It induces host macrophage tolerance after the transplant of human 
HSCs, allowing the human cells to grow without a macrophage response from the host animal. 
In other mouse strains, Sirpa does not bind CD47 and macrophages phagocytose the foreign 
cells (Jaiswal et al., 2009). 
Whilst the NOD-scid mouse model addressed human haematopoietic transplantation issues 
identified in the Scid strain, other drawbacks were identified. The NOD-scid model suffers from 
a high incidence of thymic lymphoma, preventing many long-term studies. Furthermore, they 
still have an active NK population that provide some resistance to engraftment. For this 
reason, two derivative strains of NOD-scid mice were developed. Both of these strains carry 
altered IL-2R common γ chains, a critical component in IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 
signalling. In NOG (NOD/Shi-scid/IL-2Rγnull) mice, the chain is truncated, whilst in NOD scid 
gamma (NSG) mice, the chain carries a mutation (Ito et al., 2002, Shultz et al., 2005). As a 
result of these changes, these mice have a complete loss of B, T and NK cells, and they 
subsequently demonstrate a 5-fold higher rate of engraftment of CD34+ human 
haematopoietic cells. The defects in cytokine signalling implemented by these changes also 
prevent lymphomagenesis (Ito et al., 2002; Shultz et al., 2005), allowing for long term studies 
to be successfully undertaken after engraftment of human HSCs. 
These strains are currently being further developed to produce more humanised mice that 
express human cytokines such as thromobopoietic, IL-3 and GM-CSF (Willinger et al., 2011). 
These models are designed to further boost the rate at which human HSCs are successfully 
engrafted. 
4.1.6 Next Generation Sequencing 
The Sanger sequencing method has been at the forefront of DNA sequencing technologies for 
much of the last 25 years, highlighted by its role in completing the only finished-grade human 
genome sequence (Human Genome Consortium, 2004). This method is based upon the use of 
dideoxynucleotide triphosphates (ddNTPs), which terminate chain elongation by DNA 
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polymerase, and are either radioactively or fluorescently labelled for detection by eye or in an 
automated machine. Although revolutionary when first introduced, the Sanger method is an 
ageing technology with a number of unresolved drawbacks, which have resulted in a reduction 
in its use over the last few years. Instead, preference for a number of new technologies, 
referred to as Next Generation Sequencing (NGS) methods, has emerged. Addressing issues 
such as high cost, low speed and developing the ability to sequence longer DNA fragments has 
been the focus of developments in NGS technologies. This project has made use of the Illumina 
MiSeq system for the quantification of lentiviral construct integration, in conjunction with a 
PCR-based method of target enrichment. 
4.1.6.1 Illumina Sequencing by Synthesis 
The Solexa sequencing platform, available since 2006, was acquired by Illumina in 2007. The 
Illumina platforms are based upon the principles of sequencing-by-synthesis in combination 
with reversible terminator nucleotides for each of the four bases (Mardis, 2008). A fragmented 
DNA library is prepared and special adaptors are ligated to both ends. One end of these 
adaptors is immobilised to a solid flow cell. The DNA then bends over and attaches to the flow 
cell at its other end, resulting in the formation of a bridge. This bridge is then amplified 
multiple times, using Bst polymerase for the synthesis of new strands and formamide to 
denature complete DNA strands. This amplficiation process results in the formation of clusters 
containing approximately 1000 single stranded amplicons formed from the same template 
(termed polonies), which are located in distinguishable locations within the flow cell (Mardis, 
2008). 
At this stage, a sequencing primer is added which hybridises to universal primer sites present 
on the adaptors flanking the DNA sequence. Specially modified reversible terminator 
nucleotides are also added, which carry a fluorophore specific to the base it is attached to (A, 
C, T or G). These nucleotides are blocked at the 3’ end, and require the cleavage of two 
chemical bonds to remove the fluorophores from the base. Once a nucleotide has been 
incorporated, the slide is scanned with two lasers to detect which nucleotide has been added 
to the sequence. Chemical cleavage removes the block from the 3’ end of the nucleotide, 
restoring the 3’ –OH group and allowing further extension of the sequence. The read length 
and data output of the MiSeq machine used in this project are flexible, depending on which 
reagent kit is used and the settings applied to the machine. Read lengths available range from 
25 nucleotides with a single direction of coverage, up to a maximum of 300 nucleotides with 
forward and reverse coverage. In a paired end run, the same molecule is read in one direction, 
and then in the reverse direction on the opposite strand. This provides information about both 
ends of the molecule, as well as the physical distance between them in the genome, helping in 
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both the resolution of structural rearrangements and the assembly of genomes across 
repetitive regions (Fullwood et al., 2009). Each run on the machine can produce up to 15 
gigabases of data, with run times of around 4 hours for a single-read run, and 1-2 days for a 
paired end run (Fullwood et al., 2009).  
For the quantification of integrated viral vectors in this project, two rounds of PCR are used to 
prepare libraries before sequencing. The first round of PCR is performed on DNA extracted 
from cell populations transduced with lentiviral pools, which amplifies either the whole shRNA 
or part of the cDNA, depending on which vectors are integrated. The primers in this first round 
of PCR add adaptor sequences that are complementary to the second round PCR primers. In 
this second round, viral vector sequences are further amplified and barcode sequences are 
added that label specific samples. At this stage, multiple samples can be pooled and primers or 
primer-dimers are removed by bead purification in preparation for the sequencing process.  
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4.2 Aims 
After the identification of a commonly deleted region on chromosome arm 12p and three 
commonly amplified regions on chromosome arm 11q described in the previous chapter, the 
objectives of the studies in this chapter were therefore: 
• To establish an optimised pipeline to perform functional screening using a negative 
selection assay. This will include: 
o Optimisation of lentiviral particle production. 
o Characterisation of AML cell line growth in an in vivo model. 
o Design of primers and optimisation of PCR conditions to produce amplicons 
suitable for the quantification of integrated lentiviral constructs by next 
generation sequencing. 
• To identify tumour suppressor genes from within the commonly deleted 12p region 
through the expression of cDNAs corresponding to the identified candidate genes in 
a negative selection assay. 
• To identify oncogenes from within the commonly amplified 11q regions through the 
expression of shRNAs targeted to the identified candidate genes in a negative 
selection assay.  
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4.3 Methods 
4.3.1 Cloning of cDNAs into SIN-SIEW 
4.3.1.1 Gateway Expression Clone Production 
Open reading frames (ORFs) were purchased from Source BioScience and Genecopoeia in the 
Gateway PLUS Shuttle Clone format. These are plasmids that consist of the desired ORF 
flanked by attL recombination sites. In the presence of Gateway Plus Recombination enzyme 
and a suitable destination vector containing the complementary attR recombination sites, the 
ORF can be recombined into the destination vector of choice. For this project, the ORFs were 
cloned into the SIN-SIEW lentiviral transfer vector (a kind gift from Prof. Olaf Heidenreich, 
Newcastle University) This process is summarised in Figure 23. 
 
Figure 23. The Gateway recombination process and associated sequences. 
Shuttle clones that were received as agar stabs were spread onto LB agar plates containing 
chloramphenicol using a sterile pipette tip. The plates were cultured at 37°C for 16 hours, and 
a single colony was taken to establish an overnight culture in 5ml of LB agar containing 
chloramphenicol. A QIAprep Spin Miniprep Kit (Qiagen) was then used to extract the plasmid 
DNA from these preparations as described previously. 
To perform the LR recombination, 100ng of entry clone (Genecopoiea) was mixed with 150ng 
of destination vector in a total reaction volume of 8µl, diluted in TE buffer (pH 8.0). 2µl LR 
clonase II enzyme (an Invitrogen proprietary mixture of Integrase, integration host factor and 
Excisionase) was then added to each sample and the solution mixed briefly by pulse vortexing. 
The mixture was then incubated at 25°C for 16 hours. The ligase was then cleaved by the 
addition of 1µl proteinase K (Sigma-Aldrich) solution to each reaction and incubation at 37°C 
for 30 minutes. 
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Competent One Shot Stbl3 E. coli cells (Life Technologies) were thawed on ice and split into 
aliquots of 250µl each. To each aliquot, 1µl of recombination reaction was added and the 
suspension mixed by flicking before incubation on ice for 30 minutes. After this period, 
samples were heat shocked by placing them into a 42°C heat block for 45 seconds before being 
returned to ice for a further 2 minutes. 125µl Super Optimal Broth with Catabolite repression 
(SOC) medium was added to each sample and samples were placed into a shaking incubator 
for 1 hour. The sample was then spread onto an LB-agar plate containing ampicillin using an 
angled glass pipette that had been flame sterilised. The plates were then cultured at 37°C for 
16 hours and inspected for colony formation. Growth indicated that the LR recombination was 
successful and single colonies were isolated for the preparation of glycerol stocks and 
subsequent plasmid extraction by either Qiagen Mini or Maxi prep as described in Chapter 
2.2.1. 
4.3.1.2 Sequencing of Lentiviral Inserts 
To sequence the ORFs inserted into SIN-SIEW, universal primers were used. A forward primer 
was used to prime a PCR reaction from the SFFV promoter present on SIN-SIEW (SFFV F), whilst 
a complementary reverse primer primed the PCR reaction from the IRES present after the 
inserted ORF. The reagents and conditions for these reactions are listed in Table 15 and Table 
16. A list of primers used is supplied in Supplementary Table 33. 
Reagent Volume Final Concentration 
5 x Hf Buffer 20µl 1x 
10mM dNTPs 5µl 200µM 
Phusion Hot Start II 
Polymerase 
1.25µl 1 unit 
H2O 63.75µl - 
SFFV F 10µM Primer 5µl 500pM 
IRES R 10µM Primer 5µl 500pM 
1ng SIN-SIEW Plasmid 1µl - 
Table 15. Reaction mixture for lentiviral insert sequencing 
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Step Temperature Time (mm:ss) Cycles 
Denaturation 98°C 00:30  
Denaturation 98°C 00:20  
35 Annealing 63°C 00:40 
Elongation 72°C 02:00 
Elongation 72°C 10:00  
 4°C Hold  
Table 16. Reaction conditions for lentiviral insert sequencing. 
4.3.1.3 PCR Purification 
To purify the products of the sequencing PCR, the QIAquick PCR Purification Kit (Qiagen) was 
used. This kit binds DNA to a silica membrane within a spin column in the presence of a high 
salt concentration, where it is washed before elution in a suitable volume of water. The 
binding buffer in the kit is designed to allow the efficient binding of single or double stranded 
PCR products larger than 100 base pairs, and to remove over 99% of contaminating primers 
and unused nucleotides. 
To the 100µl of PCR product, 500µl of binding buffer PB was added and the solution mixed by 
pipetting. The pH indicator present turned yellow if the pH of the solution was correct. If the 
solution was orange or violet, 10µl of 3M sodium acetate (pH 5.0) was added and the solution 
mixed, which resulted in the mixture turning yellow. The sample solution was applied to a 
QIAquick spin column and centrifuged at 17,900 x g for 60 seconds. The resulting flow through 
was discarded and 750µl of wash buffer PE applied to the column and centrifuged at 17,900 x 
g for 60 seconds. The flow through was discarded again and the centrifugation step repeated 
to ensure the removal of residual ethanol present in buffer PE. The QIAquick column was then 
transferred to a 1.5ml microcentrifuge tube and 50µl elution buffer EB applied to the silica 
membrane. The column was incubated at room temperature for 1 minute before 
centrifugation at 17,900 x g for 60 seconds. The eluted DNA was measured for concentration 
and purity using a NanoDrop 1000 Spectrophotometer (NanoDrop), and sent to DBS Genomics 
(Durham University) for sequence analysis using Sanger sequencing. 
4.3.2 Production of Lentiviral Particles 
In order to safely produce lentiviral particles capable of transducing human cells, the genes 
required to code for the various viral components have been split between multiple packaging 
plasmids. These packaging plasmids are transiently co-transfected with a transfer vector into a 
packaging cell line, where the viral genes are expressed and the components packaged into a 
complete virus particle. Schematics for plasmids used in this project are shown in Figure 24. 
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Lentiviral particles were produced in the transformed human embryonic kidney cell line 293T, 
or variants derived from this cell line. The 293FT cell line was produced by Life Technlogies and 
is a fast growing derivative of the 293T cell line, selected for its superior ability to produce 
lentiviral particles when compared to 293T. Lenti-X 293T is another variant of the 293T cell line 
which was developed by Clontech for use with the Clontech Lenti-X HTX Packaging System. 
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4.3.2.1 Plasmids used for Lentiviral Production 
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Figure 24. Maps of plasmids used for the production of lentiviral particles. RRE: Rev Response Element, cPPT: Central 
Polypurine Tract, eGFP: Enhanced Green Fluorescent Protein, IRES: Internal Ribosome Entry Site, Puror: Puromycin 
Resistance, shRNA: shRNA entry site, WPRE: Woodchuck hepatitis Posttranscriptional Regulatory Element, 3’∆LTR: 
Truncated HIV/FIV 3’ Long Terminal Repeat retroviral promoter, SV40 Poly A: Simian Virus 40 poly(A) site, SV40 ori: 
Simian Virus 40 origin of replication, pUC ori: Plasmid origin of replication, Ampr: Ampicillin Resistance, 5’ LTR: 
HIV/FIV 5’ Long Terminal Repeat retroviral promoter, Zeor: Zeocin Resistance, CMV: Cytomegalovirus Promoter, 
tGFP: Turbo Green Fluorescent Protein, 
Three different methods were used for the transfection of the lentiviral packaging plasmid 
mixture, and these are listed below. 
4.3.2.2 Calcium Phosphate Precipitation 
For the production of pGIPZ based lentiviral particles, the Trans-Lentiviral Packaging System 
was used (GE Dharmacon). This system utilises five separate packaging plasmids to package 
pGIPZ based transfer vectors with a high efficiency. Calcium phosphate forms complexes with 
DNA that co-precipitate and are absorbed by cells through phagocytosis. 24 hours before 
transfection, 1.2 x 106 packaging cells were plated into wells of a 6-well tissue culture plate in 
2ml DMEM. Before transfection, 6µg of transfer vector was mixed with 4.3µl Trans-Lentiviral 
Packaging mix and the mixture made up to 135µl using dH2O. 15µl of CaCl2 (concentration not 
defined by manufacturer) was added to the DNA mixture and the tube mixed by pulse 
vortexing. Whilst vortexing, 150µl 2x Hank’s Balanced Salt Solution (HBSS) was added dropwise 
to the mixture. The mixture was then incubated at room temperature for 3 minutes before 
addition to the packaging cells. The cells were then incubated at 37°C, 5% CO2 for 16 hours, 
when the media was exchanged for DMEM containing 5% FCS and incubated for a further 48 
hours before harvesting of viral supernatant. 
4.3.2.3 EndoFectin 
EndoFectin (GeneCopoeia) allows the transfection of plasmids as it forms cationic polymer 
complexes with plasmid DNA that are incorporated into cells through endocytosis. 3 x 106 
packaging cells were plated into 10cm tissue culture plates 24 hours before transfection in 
10ml DMEM. On the day of transfection, two solutions were prepared in 1.5ml microcentrifuge 
tubes. The first is the packaging mix, which consists of 200µl Opti-MEM I (Gibco), 10µg transfer 
construct, 2.5µg pCMV∆R8.91 and 7.5µg pMD2.G. An EndoFectin dilution was also prepared by 
mixing 200µl Opti-MEM I with 15µl EndoFectin. The EndoFectin dilution was then added to the 
packaging mix by dropwise pipetting, whilst the packaging mix was constantly agitated by 
flicking of the tube. The resulting mixture was then incubated at room temperature for 20 
minutes. This incubation allows the EndoFectin (a cationic polymer) to form a complex with 
the nucleic acids present in the packaging mixture, increasing transfection efficiency. The 
96 
 
entire mixture was added dropwise to the packaging cells and the plate gently shaken, not 
swirled to ensure even distribution of nucleic acid complexes. 
After incubation at 37°C, 5% CO2 for 16 hours, the media was exchanged for 10ml DMEM 
containing 5% FCS and cells were cultured for a further 48 hours before harvesting of viral 
supernatant. 
4.3.2.4 Lenti-X Polymer Packaging 
The Lenti-X HTX Packaging System is designed by Clontech and consists of a specially 
formulated packaging mix in conjunction with a transfection polymer to produce high titre 
lentivirus. 24 hours prior to transfection, 4 x 106 packaging cells were seeded onto 10cm tissue 
cultures plates in 10ml DMEM. Immediately before transfection, a packaging mix and a 
polymer mix were prepared in 1.5ml microcentrifuge tubes. The packaging mix was made up 
of 557µl Xfect reaction buffer, 36µl Lenti-X HTX packaging mix and 7µl of transfer vector 
diluted to 1µg/µl. The polymer mix consisted of 592.5µl Xfect Reaction Buffer and 7.5µl Xfect 
Polymer. It was critical at this point that the Xfect Polymer did not remain in aqueous solution 
for longer than 30 minutes so the subsequent steps were completed quickly. The polymer 
solution was added to the packaging solution and mixed by pulse vortexing for 10 seconds. The 
DNA-polymer mixture was then incubated at room temperature for 10 minutes to allow the 
polymer to form complexes with the DNA, before the entire mixture was added dropwise to 
the packaging cells. After incubation at 37°C, 5% CO2 for 16 hours, the media was exchanged 
for fresh DMEM containing 10% FCS and the cells incubated for a further 48 hours before viral 
supernatant was harvested. 
4.3.3 Lentiviral Particle Harvesting 
The viral particles produced are released into the cell culture supernatant. This was carefully 
removed by pipetting and centrifuged for 5 minutes at 400 x g to pellet cellular debris. The 
supernatant from this step was then syringe filtered through a low protein binding 0.45µm 
Millex Syringe Polyvinylidene Difluoride (PVDF) filter (Merck Millipore). If a second harvest was 
required, the media was replaced with fresh DMEM and the harvesting procedure repeated 24 
hours later. If no concentration step was to take place after harvesting, the supernatant was 
divided into aliquots and stored at -80°C. 
4.3.4 Lentiviral Particle Concentration 
4.3.4.1 Lenti-X Concentrator 
Lenti-X Concentrator (Clontech) is a reagent which allows for concentration of lentiviral 
particles without the high centrifugation speeds of ultracentrifugation.  The clarified viral 
supernatant, harvested as described above was mixed in a 3:1 ratio with Lenti-X Concentrator. 
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The mixture was then incubated at 4°C for between 30 minutes and 16 hours, and the sample 
subsequently centrifuged at 1500 x g for 45 minutes at 4°C. The supernatant was carefully 
removed and the viral pellet resuspended in a volume of DMEM equivalent to 1% of the initial 
volume of viral supernatant used. The sample was then split into aliquots and stored at -80°C. 
4.3.4.2 Ultracentrifugation 
For the concentration of lentiviral particles by ultracentrifugation, the ultracentrifuge buckets, 
lids adaptors and disposable conical centrifuge inserts were sterilised using 70% ethanol and 
air dried in a laminar flow hood. 30ml of clarified viral supernatant was transferred to the dry 
centrifuge inserts and paired centrifuge buckets were carefully balanced to within 0.2g of each 
other using extra medium. The ultracentrifugation was performed at 86,242 x g for 2 hours, in 
a Beckman Optima ultracentrifuge fitted with a SW 32Ti rotor cooled to 4°C. A constant 
vacuum was applied to the samples for the duration of the centrifugation step. After the 
centrifugation, the supernatant was carefully removed by decanting and pipetting, and the 
viral pellet resuspended in 1% of the starting volume of viral supernatant loaded into the 
centrifuge. Resuspended viral particles were aliquoted and stored at -80°C. 
4.3.5 Lentiviral Transduction 
Suspension cell lines were transduced by the addition of lentivirus containing media to the 
suspension culture in the presence of 8µg/ml polybrene. Polybrene increases transduction 
efficiency by neutralising the charge repulsion that occurs between virions and sialic acid 
present on cell surfaces (Davis et al., 2004). Spinfection was also used to increase transduction 
efficiency. Cells were plated into wells of either 6-well or 24-well plates at a concentration of 
0.5 x 106 cells/ml, with a total volume per well of 3ml for 6-well plates and 1ml for 24-well 
plates. Media containing viral particles was added to each well in addition to polybrene, and 
the plates were wrapped in Parafilm. The plates were then placed into a centrifuge warmed to 
32°C and spinfection performed at 1500 x g for 2 hours. Following spinfection, the parafilm 
was removed and the cells incubated for 16 hours at 37°C. 
After this incubation period, the media containing viral particles and polybrene was exchanged 
for fresh culture media to allow ongoing culturing of transduced cells. Larger volume cultures 
were transferred to a suitably sized flask. 
4.3.6 Lentiviral Titre Determination 
Lentiviral stocks were titrated in 293T or 293FT cells. 1 x 105 cells in 1ml media were plated in 
each well of a 24-well tissue culture plate. Between 1µl and 100µl of viral supernatant was 
added to each well and the spinfection protocol followed as detailed in 4.3.5. The percentage 
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of cells expressing GFP was measured as detailed in 4.3.10.1and the viral titre calculating using 
the following formula: 
𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑡𝑡𝑡𝑡𝑡𝑡𝑒𝑒𝑡𝑡,𝑇𝑇𝑇𝑇𝑚𝑚𝑚𝑚−1 = 𝑒𝑒 × 𝑁𝑁100 × 𝑉𝑉 × 𝐷𝐷𝑓𝑓 
Where F = % of eGFP-positive cells as determined by FACS, N = estimated number of target 
cells per well, V = volume (in ml) of the lentivirus-containing supernatant that was added per 
well and Df = the dilution factor for lentivirus-containing supernatant. 
4.3.7 In Vivo Experimentation 
4.3.7.1 Project Approval 
Animal experiments were conducted under the Home Office Project License (PPL 60/4552), by 
trained researchers who had completed Home Office training courses and held Personal 
Licenses under the Animals (Scientific Procedures) Act 1986 (Personal License I2B4BD9C7). 
4.3.7.2 General Handling and Monitoring of Mice 
Mice were kept with littermates in individually ventilated cages (IVCs) provided with a sterile 
filtered air supply. The mice were regularly checked for condition and the growth of tumours 
was carefully monitored. Mouse weights were recorded weekly and animals were immediately 
culled if their weight dropped below 90% of their previously recorded maximum weight, or 
tumours were measured to be larger than 1cm in diameter. Mice were also culled if their 
condition fell to unacceptable levels, or if disease burden was affecting their quality of life by 
restricting movement or causing the animals to experience excessive levels of pain. 
4.3.7.3 Murine Anaesthesia 
Mice were anaesthetised by placing them into an induction chamber filled with 95% oxygen 
and 5% isoflurane, set to a flow rate of 1L/min. Mice were monitored for signs of anaesthesia 
including loss of movement, loss of self-righting ability, reduction in breathing rate and failure 
to respond to physical stimuli (‘pinch test’).  
4.3.7.4 Intrafemoral Injection 
After the induction of anaesthesia, isoflurane concentration was reduced to 2.5% and the 
mouse transferred to a face mask equipped with an anaesthetic scavenger mechanism to 
prevent leakage of anaesthetic gas. The legs of the mouse were shaved using a small electric 
clipper and the skin sterilised with antiseptic solution. An insulin needle was used to draw up 
50µl cell suspension per mouse, containing the cells to be engrafted suspended in full media. 
The mouse leg was flexed to expose the head of the femur, and an empty insulin needle used 
to bore through the head of the femur and form a canal within the bone marrow for engrafted 
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material to be injected. The empty needle was removed and the needle containing the cell 
suspension inserted into the canal bored in the femur, where 50µl of cell suspension was then 
injected. The mouse was ear punched whilst under anaesthetic to provide identification (LN – 
left ear notch, RN – right ear notch, BN – both ear notch, NN – no ear notch, 2LN – two left ear 
notches, 2RN – two right ear notches) and subcutaneously injected with 10µl of carprofen 
(Rimadyl) diluted 1:10 as post-surgery analgesia. 
4.3.7.5 In Vivo Imaging System 
Before introducing immunocompromised mice to the in vivo imaging system (IVIS) Spectrum, 
the machine was thoroughly sterilised with 70% ethanol and allowed to air dry. 20 minutes 
prior to imaging taking place, mice were intraperitoneally injected with 100µl of luciferin 
reagent. The mice were then placed under anaesthesia as described in Section 4.3.7.3, and 
after the induction of anaesthesia the isoflurane concentration was reduced to 2.5% and the 
mice transferred to anaesthetic nose cones present within the IVIS, supplied with the same gas 
supply used for the induction of anaesthesia. Mice were orientated to the required position for 
imaging and bioluminescence was measured over a period of time automatically determined 
by the system. The luminescent signal was quantified in radiance photons/second. 
4.3.7.6 Harvesting of Organs 
A post mortem dissection was performed on dead mice and organs examined for signs of 
engraftment. The spleen was always removed from mice and the liver and kidneys were taken 
if they appeared to be enlarged or had other signs of engraftment such as white spots caused 
by excess blast accumulation. Organs were weighed and suspended in PBS. The mouse legs 
were dissected to excise the femurs and tibias, which were flushed using a 25 gauge needle 
attached to a 5ml syringe filled with PBS to release cells contained within the bone marrow. 
The organs were transferred to individual 10cm sterile petri dishes and minced by fine slicing 
with a scalpel, before passing them through a 25 gauge needle to break up remaining pieces. 
The cell suspension was then passed through a 40µm cell strainer to remove debris and 
centrifuged at 400 x g for 10 minutes. The cells were resuspended in RPMI and cell 
concentration estimated using a Neubauer improved haemocytometer.  
If required, human cells were isolated from the cell suspension using Ficoll-Paque PREMIUM 
1.077 reagent. Ficoll-Paque makes use of density gradient centrifugation to isolate human 
mononuclear cells from other blood cells, including those found in rodents which have a higher 
average density than human mononuclear cells. The required volume of Ficoll-Paque was 
drawn up into a syringe by inserting a 25 gauge needle through the septum of the Ficoll-Paque 
bottle. 3ml of Ficoll-Paque was then added to a 15ml centrifuge tube and 4ml of the cell 
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suspension from the processed organ was carefully layered on top using a glass Pasteur 
pipette equipped with a rubber bulb. The layered sample was then centrifuged at 400 x g for 
40 minutes at room temperature. After centrifugation, the mononuclear cells were removed 
using a glass Pasteur pipette and washed by the addition of 10ml fresh media and 
centrifugation at 400 x g for 10 minutes. The washed cell pellet was then resuspended in 10ml 
fresh media and cell concentration determined using a Neubaeuer improved haemocytometer. 
Cells were pelleted and either used immediately to extract genomic DNA or stored at -80°C. 
Additional viable cells were frozen and stored in liquid nitrogen as described previously. 
4.3.8 Preparation of Sequencing Libraries 
To produce a library for quantification of integrated lentiviral constructs, primers were 
designed to amplify a small section of integrated ORFs using a universal forward primer 
targeted to the SFFV promoter in conjunction with individual reverse primers targeting each 
integrated ORF. This allowed for a multiplex PCR approach to be taken to enrich the proportion 
of integrated construct sequences relative to background genomic DNA, whilst maintaining 
relative quantities of each construct in the pool. The 5’ ends of the primers consisted of 
universal CS1 sequences that were the targets for a second round PCR with primers including 
Illumina adaptors and barcode sequences. 2µl of each product was analysed by agarose gel 
electrophoresis to ensure there was no contamination of the sample by unwanted PCR 
products, and to estimate the quantity of DNA produced by comparison with DNA standards of 
known concentration. If bands were especially faint, the round 2 PCR was repeated with an 
increased number of cycles to provide sufficient material for the sequencing reaction. Full 
details of reagents and conditions used are listed in Table 17, Table 18, Table 19 and Table 20. 
Primers used are detailed in Supplementary Table 33. 
Reagent Volume Final Concentration 
10 x Reaction Buffer 2µl 1x 
25mM MgCl2 3.6µl 4.5mM 
DMSO 1µl  
10mM dNTPs 0.4µl 200µM 
Fast Start Enzyme 0.2µl 1 unit 
H2O 6.8µl - 
CS1-SFFV F Primer 10µM 1µl 500pM 
CS1 Pooled Reverse Primers 
10µM 
1µl 500pM 
Sample DNA (50ng/µl) 4µl 10ng/µl 
Table 17. Reaction mixture for round 1 PCR amplification 
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Step Temperature Time (Minutes) Cycles 
Denaturation 95°C 10:00  
Denaturation 95°C 00:15  
25 Annealing 60°C 00:30 
Elongation 72°C 01:00 
Elongation 72°C 03:00  
 4°C Hold  
Table 18. Reaction conditions for round 1 PCR amplification 
Reagent Volume Final Concentration 
10 x Reaction Buffer 2µl 1x 
25mM MgCl2 3.6µl 4.5mM 
DMSO 1µl  
10mM dNTPs 0.4µl 200µM 
Fast Start Enzyme 0.2µl 1 unit 
H2O 4.8µl - 
Barcode Primers 4µl - 
Round 1 DNA (1:100 Dilution) 1µl - 
Table 19. Reaction mixture for round 2 PCR amplification 
Step Temperature Time (Minutes) Cycles 
Denaturation 95°C 10:00  
Denaturation 95°C 00:15  
15-25 Annealing 60°C 00:30 
Elongation 72°C 01:00 
Elongation 72°C 03:00  
 4°C Hold  
Table 20. Reaction conditions for round 2 PCR amplification 
4.3.9 Illumina MiSeq Sequencing 
Sequencing libraries were created by pooling PCR products, using 1ng of product per target 
construct for each sample. Library purification was then performed to remove primers and 
excess dNTPs. To achieve this, AMPure XP beads (Agilent Technlogies) were used, which bind 
DNA of specific size ranges and can be isolated using a magnet, allowing small DNA fragments 
to be removed. The AMPure XP beads were incubated at room temperature for 30 minutes 
after removal from the fridge. The bottle was then shaken until homogenous in colour, and 
180µl of beads were added to each 100µl of library, and mixed by pipetting. The mixture was 
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then incubated for five minutes at room temperature and the tube placed into the magnetic 
separation device. When the solution became clear, it was removed by pipetting whilst still on 
the rack. The beads were then washed with 200µl of 70% ethanol, allowed to settle and the 
ethanol was removed. This wash step was repeated again and the beads allowed to air dry for 
5 minutes whilst heated to 37°C. To the tube, 22µl of nuclease free water was added and the 
tube mixed by briefly pulse vortexing, before incubation at room temperature for two 
minutes. The tube was then returned to the magnetic separation device and allowed to stand 
until the beads had collected. The supernatant was then removed by pipetting and stored for 
subsequent use. 
After purification, sample clean-up was confirmed using a 2100 Bioanalyser Instrument 
(Agilent Technologies) to ensure removal of primers and dNTPs, and retention of the correct 
library fragment size. Prepared libraries were then sent to Edinburgh Genomics (formerly The 
GenePool) for analysis on the Illumina MiSeq platform. Raw data files were quality controlled 
and number of reads associated with each construct calculated using the SeqNext software (JSI 
Medical Systems). 
4.3.10 Flow Cytometry 
4.3.10.1 Assessment of GFP Expression 
The transduction efficiency was measured by assessing the proportion of cells expressing 
enhanced green fluorescent protein (eGFP) from SIN-SIEW constructs or turbo green 
fluorescent protein (tGFP) from pGIPZ constructs. 
Approximately 5 x 105 cells were pelleted by centrifugation at 400 x g for 5 minutes, and 
resuspended in 1ml PBS. Samples were then analysed using a FACS Calibur (BD Biosciences) 
equipped with a 488nm laser and a 530/30nm filter. Using forward and side scatter profiles, 
live cells were selected for, and dead cells and cell debris were eliminated from the analysis. A 
minimum threshold for GFP expression was set using a non-transduced population in order to 
correct for auto-fluorescence. GFP positive cells were defined as those cells with a signal 
greater than the threshold. 
4.3.10.2 Cell Surface Phenotype Analysis 
Engrafted cell populations were assessed using a FACS Canto II (BD Biosciences). Frozen cell 
aliquots were diluted in PBS and cells pelleted by centrifugation at 400 x g for 5 minutes. Cell 
pellets were resuspended in 1ml PBS and counted. 5 x 105 cells were taken from each aliquot 
and PBS added to a volume of 100µl. To each sample, the following stained antibodies were 
added: 10µl anti-human CD13, 10µl anti-human CD33, 2.5µl anti-murine CD45 and 2.5µl anti-
murine Ter119. Tubes were then incubated in the dark at room temperature for 30 minutes. 
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The samples were subsequently washed twice by pelleting in a centrifuge at 400 x g for 5 
minutes and were finally resuspended in 500µl PBS ahead of analysis using a FACS Canto II flow 
cytometer. Murine cell populations were excluded by gating against cells positive on the 
Phycoerythrin-Cy7 (PE, anti-murine CD45 and anti-murine Ter119) channel, whilst engrafted 
human cells were identified as those positive on the PE (anti-human CD13) and Fluorescein 
Isothiocyanate 1  (FITC, anti-human CD33) fluorescence channels. 
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4.4 Results 
4.4.1 Lentiviral Transfer Vector Selection 
Initial work focussed on the GDM-1 and KG-1 cell lines, and two lentiviral delivery systems 
were tested. The HIV-based pSLIEW transfer vector packaged in combination with pMD2.G and 
pCMV packaging vectors was compared with the Feline Immunodeficiency Virus (FIV)-based 
commercially available pReceiver-Lv81 (pLv81) transfer vector and Lenti-Pac packaging system 
(GeneCopoeia). By comparison with 293T, neither cell line showed evidence of efficient 
transduction. However, slightly higher levels of GFP positive cells were achieved with KG-1 
than with GDM-1. Of the two constructs, pSLIEW performed better and was used in future 
experiments (Figure 25). 
At this time, the NKM-1 cell line was obtained and tested with the pSLIEW transfer construct. 
Using an equal number of infectious viral particles as with the GDM-1 and KG-1 cell lines, a 
much higher level of GFP positivity was obtained. For this reason, the NKM-1 cell line was 
selected for use in the negative selection assay in combination with the pSLIEW and SIN-SIEW-
Gateway transfer vectors. 
 
Figure 25. FACS analysis of 12p deleted cell lines transduced with equal units of pSLIEW and pLv81 lentiviral 
particles, as titred in 293T. Histograms for the negative control are shown as purple infill and for transduced cells as 
green traces. The x-axis represents FL1-Height, proportional to the amount of GFP present in each cell, whilst the y-
axis shows the number of cells detected at each FL1 intensity point. The right hand marker was set using control 
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non-transduced cells, and the percentage indicates the proportion of cells determined to be GFP positive that are 
present within this region. 
As only one cell line was available for the 11q project, the UoC-M1 cell line was transduced 
with a population of pGIPZ non silencing control lentiviral particles. Analysis of GFP positivity 
demonstrated that sufficient proportions (>10%) of positive cells were reached with ease 
(Figure 26). For this reason, the pGIPZ shRNA lentiviral vector system was selected for use in 
the 11q amplification project. 
 
Figure 26. FACS analysis of UoC-M1 cells transduced with lentiviral particles produced using the pGIPZ non silencing 
control transfer vector. Histograms for the negative control are shown as purple infill and for transduced cells as 
green traces. The x-axis represents FL1-Height, proportional to the amount of GFP present in each cell, whilst the y-
axis shows the number of cells detected at each FL1 intensity point. The right hand marker was set using control 
non-transduced cells, and the percentage indicates the proportion of cells determined to be GFP positive that are 
present within this region. 
4.4.2 Optimisation of Lentiviral Particle Production 
As the SIN-SIEW lentiviral vector system is not commercially packaged in an optimised kit, 
various lentiviral packaging conditions were tested. Three cell lines (293T, LX293T and 293FT) 
were assessed for their ability to produce lentiviral particles using the pSLIEW transfer vector 
with pCMV and pMD2.G packaging plasmids using the EndoFectin Lenti reagent. Highest titres 
of lentivirus were achieved with the 293FT cell line (Figure 27) which was selected for use in 
further optimisation. 
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 Figure 27. Comparison of packaging cell lines for lentiviral production in the 293T cell line with 2 of its derivatives. 
pSLIEW transfer vectors were packaged using the same amount of pCMV and pMD2.G packaging plasmids, 
transfected into the cells using EndoFectin Lenti packaging reagent. Lentiviral particles were harvested 72 hours 
after transfection and titred using the 293T cell line and subsequent flow cytometry, allowing the number of 
transducing units produced per millilitre of supernatant to be calculated. 
Three reagents that enable plasmid uptake into the packaging cell lines were tested, including 
two cationic lipid formulations (Lipofectamine LTX at a range of concentrations and 
EndoFectin-Lenti at a standard concentration) and one polymer based formulation (Lenti-X 
Xfect) (Figure 28). Whilst there was a small difference observed between the optimal 
concentration of Lipofectamine LTX and EndoFectin Lenti, the EndoFectin lenti was selected as 
the reagent of choice for future experiments based on its relatively lower cost. 
 
Figure 28. Comparison of transfection reagents for lentiviral production in 293FT. pSLIEW transfer vectors were 
packaged using the same amount of pCMV and pMD2.G packaging plasmids, transfected into the cells using a range 
of  packaging reagents, with Lipofectamine used at a range of concentrations, following the manufacturer’s 
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protocol. Lentiviral particles were harvested 72 hours after transfection and titred using the 293FT cell line with 
subsequent flow cytometry, allowing the number of transducing units produced per millilitre of supernatant to be 
calculated. 
A range of additives were tested that have been suggested to improve lentiviral yield when 
present in the post transfection media. These included caffeine (2mM, Ellis et al., 2011), 
chloroquine (25µM, Kutner et al., 2009), sodium butyrate (10mM, Cribbs et al., 2013) and Titer 
Boost (1µl/ml, GeneCopoeia) reagent, as well as exchanging regular FCS with heat inactivated 
FCS. Many of the additives had a detrimental effect, most significantly caffeine which saw a 
decrease in yield of approximately 60%. However, the presence of chloroquine was found to 
increase the lentiviral yield by over 30%, as shown in Figure 29, and was used in subsequent 
experiments. 
 
Figure 29. Comparison of post-transfection media additives for lentiviral production in 293FT. pSLIEW transfer 
vectors were packaged using the same amount of pCMV and pMD2.G packaging plasmids, transfected into the cells 
using EndoFectin Lenti. A range of post transfection additives were tested as follows – Foetal Calf Serum (FCS) 
exchanged for Heat Inactivated FCS (H.I. FCS), the addition of 2mM caffeine, 25µM chloroquine, 10mM Sodium 
Butyrate, or 1µl/ml Titer Boost reagent. Lentiviral particles were harvested 72 hours after transfection and titred 
using the 293FT cell line with subsequent flow cytometry, allowing the number of transducing units produced per 
millilitre of supernatant to be calculated. 
In addition, the effects of polybrene and spinfection on lentiviral transduction efficiency were 
assessed. The presence of polybrene (8µg/ml) increased transduction efficiency by 
approximately 20% in NKM-1 cells and almost 300% in UoC-M1 cells. In conjunction with 
spinfection (centrifugation at 400 x g for 2 hours 30 minutes), transduction efficiency was 
further increased by an additional 20% in NKM-1 cells and over 100% in UoC-M1 cells, as 
demonstrated in Figure 30. 
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 Figure 30. Comparison of transduction conditions for the lentiviral transduction of NKM-1 and UoC-M1 cell lines. 
Lentiviral particles containing the pSLIEW transfer vector produced in the 293FT cell line were used to transduce 5 x 
105 NKM-1 or UoC-M1 cells. Some cells were exposed to polybrene (1µg/ml), or a combination of polybrene and 
spinfection (centrifugation at 400 x g for 2 hours 30 minutes). After 72 hours of incubation, GFP expression was 
assessed using flow cytometry. 
4.4.3 In Vivo Models of AML Engraftment 
To investigate the engraftment of the selected cell lines in the NSG mouse model, a population 
of each cell line was transduced with pSLIEW lentiviral particles. The expression of luciferase 
from this lentiviral vector allowed the growth of leukaemia to be monitored in vivo. 1x105 cells 
were injected intrafemorally into female NSG mice (this procedure was performed by Dr. 
Helen Blair, Newcastle University, subsequent intrafemoral injections were performed by 
myself) and the mice were imaged at multiple time points (Figure 31). Injected cells formed 
solid tumours around the injection site. After sacrificing the mice, cells were recovered from 
the dissected tumours. In three mice, spleens were 0.1g or above in weight, suggesting that 
engraftment had occurred at this site (Table 21). 
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 Figure 31. Engraftment of AML cell lines in NSG mice. A. GFP positivity determined by flow cytometry, 3 days after 
transduction before intrafemoral injection into female NSG mice. These injections were performed by Dr. Helen Blair, 
Newcastle University, whereas all subsequent injections were performed by myself. The x-axis represents FL1-Height, 
proportional to the amount of GFP present in each cell, whilst the y-axis shows the number of cells detected at each 
FL1 intensity point. The right hand marker was set using control non-transduced cells, and the percentage indicates 
the proportion of cells determined to be GFP positive that are present within this region. B. Bioluminescence imaging 
75 days after injection, following intraperitoneal injection of luciferin reagent (100µl). Units shown are radiance x 
10-4 (p/sec/cm3/sr). 
Mouse LN RN BN NN 
Cell Line UoC-M1 UoC-M1 NKM-1 NKM-1 
Culled on day 100 76 104 95 
Tumour Weight 0.67g 4.17g 0.02g 0.96g 
Spleen Weight 0.07g 0.13g 0.6g 0.10g 
Table 21. Time between transplant and cull, tumour and spleen weight for NSG mice injected with AML cell lines to 
investigate engraftment. 
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4.4.4 Optimisation of PCR Conditions for Quantification of Integrated Constructs by 
Next Generation Sequencing 
Various combinations of first and second PCR cycle numbers were tested. Ultimately 25 first 
round cycles were selected to be combined with 15 second round cycles as this combination 
produced PCR products of sufficient yield that had not yet reached the plateau phase of PCR 
amplification. Detailed figures are shown in Supplementary Figure 55. 
4.4.5 12p Negative Selection Pilot Study 
ORF sequences corresponding to each of the 11 genes to be investigated from chromosome 
12p were inserted in the SIN-SIEW lentiviral vector using the Gateway recombination system 
as detailed in Section 4.3.1. Lentiviral particles were produced on an individual basis and titred 
in the NKM-1 cell line (as selected in Section 4.4.1). This allowed for the preparation of a 
mixture containing equal numbers of each lentiviral construct to be prepared, and this pool 
was used to transduce 12x106 NKM-1 cells. The majority of these cells were cultured in vitro, 
whilst some cells were injected intrafemorally into NSG mice (5x105 cells per mouse). DNA was 
extracted from cells cultured in vitro every 3-4 days, and from the organs of culled mice after 
separation over Ficoll-Paque by density centrifugation. 
4.4.5.1 In Vitro Results 
Copy number of individual integrated constructs relative to the entire pool at each time point 
was calculated from the number of sequence reads, as determined by Illumina sequencing. 
Relative copy numbers at each time point were then normalised to the starting time point 
level (Figure 32). Of the 11 constructs tested, the expression construct for CDKN1B was 
strongly and rapidly selected against in the first 21 days after transduction. The changes in 
CDKN1B construct proportion were highly significant when tested using Multivariate Analysis 
of Variance (MANOVA) (Table 22, p=<0.0001). The expression construct for CREBL2 was 
significantly reduced as a proportion of the pool between the first and second time points, but 
no more effects were seen after this time, suggesting that this may be an artefact (p=<0.001). 
The expression constructs for ETV6 were weakly selected against, with a p-value of 0.027 when 
analysed using MANOVA. Although APOLD1 showed some reduction in construct copy 
number, this was not found to be significant (p=0.344). 
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 Figure 32. Relative construct proportions during the in vitro portion of the 12p negative selection assay pilot study in 
the NKM-1 cell line. Error bars represent standard deviation between sequence reads obtained for library generation 
PCRs performed in triplicate. The expression construct for CDKN1B is strongly and rapidly selected against.  
Gene CDKN1B CREBL2 ETV6 
p-value < 0.001 0.001 0.027 
Table 22. Significant p-values calculated for changes in construct copy number during the in vitro portion of the 12p 
negative selection assay pilot study in the NKM-1 cell line. Significance and associated p-values were calculated 
using MANOVA.  
4.4.5.2 In Vivo Results 
Six mice were intrafemorally injected with NKM-1 cells transduced with the 12p lentiviral 
particle pool. Two of the injected mice showed no evidence of tumour formation around the 
bone of the injected femur. The first of these mice (RN) was sacrificed at 32 days after showing 
signs of difficulty in movement, whilst the second of these mice (2LN) unexpectedly died at 53 
days. The remaining 4 mice showed signs of tumour formation, and were culled between 54 
and 60 days after injection with cells.  After the mice were sacrificed, cells were extracted from 
the bone marrow, tumours, livers and spleens, and separated using density centrifugation over 
Ficoll-Paque, before DNA was extracted. 
In contrast to the in vitro data, relative copy number of expression clones determined by 
Illumina sequencing was highly variable between samples, as shown in Figure 33. For some 
samples, a single clone became highly overrepresented, for example in the tumour sample 
from the LN mouse DUSP16 appears to be highly overrepresented. In some mice, these results 
were consistent across all organs sampled, for example the expression clone for DDX47 was 
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overrepresented in all tissues of the 2LN mouse. Overall, there were no samples in which the 
expression clone for ETV6 was overrepresented when compared to the starting cell population 
in any of the 22 mouse samples tested. Similarly, the expression clone for LOH12CR1 was only 
overrepresented once, and the expression clone for CDKN1B was overrepresented twice. All 
other expression clones were overrepresented in at least 3 of the samples tested. 
 
Figure 33. Relative copy number of cDNA constructs integrated in NKM-1 cells before and after expansion in vivo. 
The number of days refers to the time point at which the mouse was culled. 
4.4.6 12p Negative Selection Repeat Studies 
The in vitro negative selection assay was repeated in triplicate with the NKM-1 cell line. Across 
all three experiments, the expression clone for CDKN1B was strongly and rapidly selected 
against (p=<0.001, Table 23). The selection seen in the pilot study against expression clones for 
APOLD1 and CREBL2 was not observed in the repeat studies, a weak selection remained 
against the expression of ETV6 observed across all three studies (p=0.010). 
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 Figure 34. Variation in construct copy number during repeat studies performed in the NKM-1 cell line for the 12p 
negative selection assay. Figure shown is representative of three experiments. Error bars represent standard 
deviation between experimental repeats. 
Gene CDKN1B ETV6 
p-value < 0.001 0.010 
Table 23. Significant changes in construct copy number observed across all experiments in the NKM-1 cell line for the 
12p negative selection assay. Significance and associated p-values were calculated using MANOVA.  
Triplicate studies were also performed in another AML cell line with a deletion encompassing 
the minimally deleted region on chromosome 12p, GDM-1. The effect of selection against 
CDKN1B appeared to be weaker in this cell line, although the result was still highly significant 
(Table 24, p=<0.0001) and there were no significant effects observed in selection against other 
expression clones (Figure 35). 
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 Figure 35. Variation in construct copy number during repeat studies performed in the GDM-1 cell line for the 12p 
negative selection assay. Figure shown is representative of three experiments. Error bars represent standard 
deviation between experimental repeats. 
Gene CDKN1B 
p-value < 0.001 
Table 24 Significant changes in construct copy number observed across all experiments in the GDM-1 cell line for the 
12p negative selection assay. Significance and associated p-values were calculated using MANOVA.  
4.4.7 11q Negative Selection Studies 
4.4.7.1 Assessment of CMV Promoter Silencing 
As silencing of the CMV promoter over time is a concern for long term studies using lentiviral 
transduced populations, a population of UoC-M1 cells was transduced with a non-silencing 
control shRNA and GFP positivity was measured over a period of 80 days. A high level of GFP 
positivity in the cell population was reached after 7 days (Figure 36), and this was maintained 
for over 60 days, suggesting that silencing of the CMV promoter would not be a problem for in 
vitro cultures using the negative selection assay with the GIPZ lentiviral shRNA system. 
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 Figure 36. Proportions of GFP positivity over time determined by FACS analysis in a population of UoC-M1 cells 
transduced with pGIPZ non silencing control lentiviral particles 
4.4.7.2 11q Negative Selection Assay 
Two methods of GIPZ lentiviral particle library preparation were used. In the first method, each 
shRNA-containing transfer plasmid was prepared on an individual basis, through culturing 
picks taken from glycerol stocks overnight on a small scale before extraction with the Plasmid 
Mini Kit (Qiagen). In the second method, bacterial stocks were cultured in pools containing 10 
shRNAs each, across a total of nine pools. Each bacterial pool was cultured on a large scale and 
extracted using the EndoFree Plasmid Maxi Kit (Qiagen). For both methods, lentiviral particles 
were produced in pools of 10 shRNAs each and used to transduce 5x106 UoC-M1 cells. All 
experiments were then repeated twice. Henceforward, the individually prepared clones will be 
referred to as MinP (Mini prepared), whilst the clones prepared on the large scale will be 
referred to as MaxP (Maxi prepared). 
At multiple time points during the in vitro culture, DNA samples were collected and the relative 
proportions of shRNAs was assessed using high throughput sequencing methods as described 
above (Section 4.3.8). A list of significantly affected shRNAs was compiled through the use of 
MANOVA, and two strong hits were identified with significance in both MinP and MaxP 
samples. In the MaxP samples, MPZL3 shRNA 1 (p=<0.001) and MPZL3 shRNA 3 (p=0.035) were 
selected against. In the MinP samples, shRNA 1 was again significantly selected against 
(p=<0.001), whilst shRNA 3 was selected against (p=0.050)(Figure 37 and Table 25). The second 
identified hit was UBE4A. In the MaxP samples, shRNA 1 was significantly selected against 
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(p=0.033), whilst in the MinP samples, shRNAs 1 (p=<0.001) and 3 (p=0.050) were significantly 
selected against (Figure 38 and Table 26). 
 
Figure 37. Mean individual results for negative selection using shRNAs targeted to MPZL3. sh1 and sh3 in both the 
MaxP and MinP samples were identified as hits. Error bars represent standard deviation between experimental 
repeats. 
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 shRNA MaxP MPZL3 sh1 MaxP MPZL3 sh3 MinP MPZL3 sh1 MinP MPZL3 sh3 
p-value < 0.001 0.035 < 0.001 0.050 
Table 25. Significant changes in MPZL3 shRNA construct copy number observed in the UoC-M1 cell line for the 11q 
negative selection assay. Significance and associated p-values were calculated using MANOVA.  
 
Figure 38. Mean individual results for negative selection using shRNAs targeted to UBE4A. sh1 in both MaxP and 
MinP samples was identified as a hit, as well as sh3 in the MinP sample.  
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shRNA MaxP UBE4A sh1 MinP UBE4A sh1 MinP UBE4A sh3 
p-value 0.033 <0.001 0.050 
Table 26. Significant changes in UBE4A shRNA construct copy number observed in the UoC-M1 cell line for the 11q 
negative selection assay. Significance and associated p-values were calculated using MANOVA.  
4.5 Discussion 
4.5.1 12p Negative Selection Assay 
In this section of work, two lentiviral systems for the expression of cDNAs were tested; the FIV-
based pReceiver-Lv81 and the HIV-based SIN-SIEW lentivector system. Superior transduction 
efficiency was demonstrated using a combination of the SIN-SIEW vector with the NKM-1 cell 
line, therefore these were chosen for use in the first round of negative selection assays to 
identify tumour suppressor genes from the commonly deleted 12p region. cDNA sequences 
corresponding to 11 genes from the minimally deleted region established for chromosome 12p 
were cloned into the SIN-SIEW lentivector using the Gateway cloning method, and inserts were 
sequenced to confirm their integration and correct alignment. 
An optimal method of producing lentiviral particles was formulated and transduction 
conditions optimised within this system. Through the methodical testing of various conditions, 
a combination of the 293FT cell line with the EndoFectin reagent was selected. Chloroquine 
was added post transfection to enhance lentiviral yield, and the transduction protocol was 
improved with the addition of polybrene and a spinfection step. Next, the PCR conditions for 
preparing sequencing libraries were carefully optimised to ensure that amplicons were 
obtained in the logarithmic expansion phase of PCR. Collection in this phase preserves 
variation in amplicon copy number, which would be diminished if PCR proceeds to the plateau 
phase of amplification.  
In the pilot in vitro study for the negative selection assay, expression vectors containing 
CDKN1B were strongly and rapidly selected against. A less obvious negative selection effect 
was also observed for expression of ETV6 and CREBL2 and at this stage, it was hoped that 
repeating the studies would either clearly eliminate or substantiate these uncertain findings, 
the results of which are discussed below. The in vivo data was largely unclear, with a highly 
variable pattern representing each clone.  
In this project, leukaemic cells were introduced into mice by injection of cell suspension 
through the head of the femur into the bone marrow cavity. This route of injection was 
selected as it had been proven to be highly successful for ALL cell lines and primary patient 
material used in a related project (Bomken et al., 2012). In NSG mice injected with ALL cells, 
cells engraft in the bone marrow early, before spreading to the spleen and liver as the disease 
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develops. The spleens and livers of these mice are generally much larger and visible signs of 
leukaemic engraftment can be observed on the surface of these organs in the form of white 
spots. In some of these mice, there is also evidence of kidney involvement or central nervous 
system engraftment (Bomken et al., 2012). 
In the model of AML engraftment used in this project, cells appeared to be largely localised to 
the site of injection. Instead of developing in the bone marrow and then spreading throughout 
the body, they formed solid tumours around the femur of the mice. Density centrifugation 
performed by layering organ suspension over Ficoll-Paque demonstrated that there were AML 
cells present in the liver and spleen of culled mice, and that these cells could be collected and 
cultured in vitro. Despite the relatively low numbers of engrafted cells obtained from these 
organs, quantification of integrated lentiviral expression clones was possible. However, the 
data obtained across all mouse samples demonstrated a highly variable pattern of clone 
representation. In some mice one clone became greatly overrepresented across all organs as 
well as the tumour sample, whereas in others there were large inter-sample differences. These 
may have arisen due to a low numbers of cells engrafted into the host mice at the injection 
site, as well as when spreading to secondary sites. As in vivo studies have not, knowingly to 
myself, been performed using these cell lines, it is unclear whether the time taken for tumours 
to develop was within a normal range. 
Some brain and CNS samples from the mice shown in Figure 31, used to investigate the 
pattern of engraftment using the IVIS, were sent to Dr. Christina Halsey (University of Glasgow) 
for investigation as part of a collaborative project. As shown in Figure 39, AML cells were found 
engrafted in the CNS meningeal tissue, as well as in the brain tissue from the dissected mouse 
heads. This would suggest that the level of engraftment at the time of sacrifice was greater 
than expected, and that there was CNS engraftment that was unable to be detected using the 
IVIS. 
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 Figure 39. Immunohistochemical analysis of brain and CNS mouse tissues. Sacrificed mouse heads were analysed by 
Dr. Christina Halsey (University of Glasgow). Pictures shown are from NKM-1 cell line engrafted mouse NN (Figure 
31). 
Another route of injection may be considered for future studies. Similar selection assays have 
been performed using intravenous infusion of leukaemic cells, and these have shown success 
with lentiviral shRNA libraries containing over 1500 shRNAs (Wang et al., 2012; Miller et al., 
2013). The study performed by Wang et al. (2012) used HSC populations isolated with a 
cocktail of cell surface antigen markers. A positive selection approach was taken in looking for 
the enrichment of shRNAs. The second study (Miller et al., 2013) transduced a population of 
leukaemic stem cells originally generated by the introduction of a lentiviral vector driving the 
expression of MLL-AF9 in granulocyte-macrophage progenitor cells isolated from mice, in 
conjunction with negative selection of shRNAs. Although the cell types used in these examples 
were different to those used in this project, similar success may be achieved by using 
intravenous delivery of leukaemic cell lines. A concern was raised that human AML cell lines 
injected intravenously would form systemic tumours throughout the mouse, which may be 
difficult to recover (Meyer and Debatin, 2011; Theocharides et al., 2012). 
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Due to the difficulties experienced with the in vivo portion of the pilot study, experimental 
results were consolidated by performing additional in vitro studies in the same and a second 
cell line. In the NKM-1 cell line, CDKN1B was again strongly selected against across all three 
repeats. The weak negative selection effects that were found in the pilot study against CREBL2 
were not observed, suggesting that these were false positive results eliminated by the 
introduction of experimental replication. However, the weak selection against ETV6 in this cell 
line was reproduced. It is possible that expression of ETV6 does have a negative selection 
effect, but that in this model of AML expansion only highly expressing clones are selected 
against, whilst low and medium expression of ETV6 is tolerated. The role of ETV6 in 
haematopoiesis may also be highly relevant for this investigation. In primary AML samples, the 
loss of ETV6 may block differentiation and contribute to leukaemogenesis through this 
mechanism. However this may not be as relevant in established cell lines that have been 
cultured for many years and may have acquired additional blocks to differentiation. For this 
reason, it would be of interest to assess the functional consequences of overexpression of 
ETV6 in a range of cell lines and primary patient samples.  
In the experiments performed using GDM-1, selection against CDKN1B was less pronounced 
but remained highly significant (p=<0.001), with the relative proportion of integrated CDKN1B 
construct dropping by around 50% compared to the starting time point. Perhaps due to the 
smaller effects observed in these samples, it was also not possible to observe any clear weak 
effects from other expression constructs. The reduced degree of negative selection observed 
in this cell line, by comparison with NKM-1 is likely due to a relatively lower overall expression 
from integrated SIN-SIEW constructs in GDM-1 cells, as determined by analysis of GFP levels in 
early optimisation experiments using the pSLIEW construct (Figure 25). Despite these lower 
expression levels, clear confirmation of the negative selection effect of CDKN1B expression in 
another cell line was important, supporting the hypothesis that CDKN1B is the main target of 
12p deletions in AML. 
Within the minimally deleted region identified on 12p, there are two miRNAs – miR-613 and 
miR-1244-1. As the function of these two miRNAs is unknown, it would be interesting to study 
their function and possible roles in leukaemogenesis. 
4.5.2 11q Negative Selection Assay 
In this section of work, two methods for producing large pools of lentiviral particles containing 
expression constructs for shRNAs were assessed. Both methods produced lentiviral particle 
pools containing 90 shRNAs, however individual constructs were either pooled at the lentiviral 
particle production stage (MinP) or at the bacterial culture stage (MaxP). For the assessment of 
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potential hits, results from both sets of triplicate experiments were analysed together. Two 
novel candidate oncogenes from this region were identified, MPZL3 and UBE4A. Two out of 
the three shRNAs targeted to MPZL3 were identified as significant hits in both the MinP and 
MaxP experiments, whilst one of the shRNAs targeted to UBE4A was identified as a significant 
hit in both experiments, and an additional shRNA was identified as a hit in the MinP shRNAs 
only. The potential roles of these genes in leukaemogenesis will be discussed further in 
Chapter 5. 
The changes in relative construct proportion compared to the start point of this experiment 
were smaller compared to those seen in the 12p negative selection assay performed in the 
NKM-1 cell line. The largest change observed was for a shRNA targeted to UBE4A in the MiniP 
samples, which was reduced to 51% of its starting copy number proportion. Expression levels 
of shRNAs may have contributed to this observation, as the mean levels of GFP positivity 
attained in the UoC-M1 cell line with GIPZ lentiviral vectors were relatively low compared to 
those obtained in the NKM-1 cell line for the 12p project. The negative effects on growth 
mostly took place in the first 21 days of in vitro culturing (Figure 37, Figure 38), supporting the 
idea that a proportion of integrated shRNA constructs, with expression below a certain 
threshold, were tolerated by the cells in culture and not subject to negative selection.  
Perhaps unexpectedly, neither FLI1 nor MLL were identified as hits in this screen. FLI1 was a 
strong candidate proto-oncogene contributing to AML, based on functional analysis of its role 
in erythroleukaemias, where inhibition lead to the suppression of growth and induction of cell 
death (Cui et al., 2009). In the negative selection assay, one of the shRNAs targeted to FLI1 was 
significantly selected against in both MaxP and MinP samples (Figure 56). Although this was 
not identified as a top hit in the assay, it may still be of interest for future studies as not all 
GIPZ shRNAs are validated as knock down reagents. MLL is a gene of interest due to its role in 
many leukaemias in which the MLL gene is involved in translocations leading to its constitutive 
activation through expression of fusion transcripts (Zeisig et al., 2003). As shRNAs targeted to 
MLL were not selected against in this assay, this would suggest that its overexpression in 11q 
amplified AMLs does not contribute to leukaemogenesis. 
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Chapter 5 Functional Assessment of Candidate Driver Genes 
5.1 Introduction 
Three candidate genes of interest have been identified through the determination of minimal 
regions of copy number alteration followed by the use of a functional negative selection assay. 
One of these genes is located on chromosome 12p (CDKN1B), whilst the remaining 2 genes are 
located on chromosome 11q (MPZL3 and UBE4A). The introduction to this chapter will focus 
on a review of the current literature surrounding these 3 genes. 
5.1.1 Cyclin-dependent Kinase Inhibitor 1B (CDKN1B) 
Cyclin family proteins control the progression of cells through the cell cycle via the activation 
of cyclin-dependent kinase enzymes. There are two main classes of cyclin; G1/S phase cyclins, 
that are required for the transition of cells between the G1 and S phases of the cell cycle and 
the G2/M phase cyclins, which are responsible for the transition of cells between G2 and M 
phases. The CDKN1B gene encodes a 27kDa protein that prevents the activation of two G1/S 
cyclins; cyclin E, which forms a complex with CDK2; and cyclin D, which forms a complex with 
CDK4 or CDK6. Through the direct binding and inhibition of these complexes or their individual 
components, CDKN1B prevents phosphorylation of the Rb protein, which in turn prevents Rb 
from interacting with E2F-DP transcription factor complexes, halting the cell cycle (Calzone et 
al., 2008). A schematic of this is shown in Figure 40. 
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 Figure 40. The primary and most well studied role of CDKN1B in G1/S progression. Arrows represent an interaction, 
whilst flat headed lines represent an inhibition. CDKN1B is able to bind Cyclin-E/CDK2 complexes, Cyclin-D/CDK4/6 
complexes, or their individual components to inhibit the ability of these complexes to phosphorylate Rb, halting the 
cell cycle at G1/S phase. 
There are multiple regulatory systems affecting the activity of CDKN1B and its associated gene 
products. The transcription of CDKN1B is regulated by Forkhead box class O (FOXO) 
transcription factors, which activate CDKN1B transcription in response to Akt signalling, 
cytokines or PML protein (Dijkers et al., 2000; Medema et al., 2000).  The MYC transcription 
factor represses the CDKN1B promoter (Yang et al., 2001), and induces the expression of 
proteins that inhibit CDKN1B such as cyclin D1, as well as the CUL1 and CKS1B proteins that 
proteolyse CDKN1B (O’Hagan et al., 2000; Keller et al., 2007). 
CDKN1B translation is regulated by a number of proteins. PTBP1 binds CDKN1B transcripts and 
increases their translation (Cho et al., 2005), whilst ELAVL1 and ELAVL4 bind transcripts and 
inhibit their translation (Kullman et al., 2002). ELAV1 overexpression in ovarian and colon 
cancer cells has been reported, which may drive the reduction of CDKN1B levels observed in 
these cancer types (Lopez de Silanes et al., 2003; Denkert et al., 2004). Two miRNAs, miR-221 
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and miR-222, have been shown to bind to CDKN1B transcripts and subsequently inhibit their 
translation. High levels of these two miRNAs have been found in cancer cells, and their 
downregulation has been linked to an increase in CDKN1B and subsequent inhibition of 
tumour growth (le Sage et al., 2007). 
FOXO4 protein inhibits AKT to promote the nuclear localisation of CDKN1B, encouraging its cell 
cycle inhibitory function. Furthermore, FOXO4 acts to decrease the expression of COP9S5, 
which is translated into a protein mediator of CDKN1B degradation (Yang et al., 2005). Another 
FOXO class member, FOXM1 also increases the stability of CDKN1B (Wang et al., 2002). The 
proteolysis of CDKN1B is also controlled by the ubiquitination activity of the SCF complex 
(Bloom and Pagano, 2003), as well as a complex made up of SKP2, CUL4A and DDB1, which 
also marks CDKN1B for degradation by ubiquitination (Bondar et al., 2006). 
In cancer cells, SRC family members often show signs of upregulation, and this has been linked 
to EGFR and ERBB2 activity, both of which bind SRC to catalyse its kinase activity. The 
activation of SRC has been linked to a loss of CDKN1B during G1 phase progression and this is 
reflected in the significant correlation of ERBB2 amplification, SRC activation, and reduced 
CDKN1B protein levels in breast cancers (Spataro et al., 2003; Chu et al., 2007). The 
overexpression of EGFR and ERBB2 is not restricted to breast cancers only, suggesting that 
other epithelial cancers may downregulate CDKN1B levels in this manner to contribute to 
tumourigenesis (Arteaga et al., 2003). 
In leukaemias and lymphomas, activation of ABL, LYN, LCK and FYN have been linked with the 
increased proteolysis of CDKN1B (Moller et al., 1999; Tsihlias et al., 1999). CML cells expressing 
the BCR-ABL1 fusion gene have been shown to have reduced levels of CDKN1B, which is 
reversed by BCR-ABL1 inhibition using imatinib (Andreu et al., 2005). This mechanism has been 
shown to be due to a number of interactions between BCR-ABL1 and CDKN1B. BCR-ABL1 
downregulates CDKN1B through FOXO inhibition, as well as through SKP2 upregegulation 
leading to increased CDKN1B proteolysis (Andreu et al., 2005). BCR-ABL1 also directly 
phosphorylates CDKN1B on tyrosine-88, preventing it from functioning in CDK2 inhibition 
(Grimmler et al., 2007). 
5.1.1.1 Prognostic Indication 
Decreased expression levels of CDKN1B have been associated with poor prognosis and disease 
progression in lung cancer (Esposito et al., 1997; Catzavelos et al., 1999; Hayashi et al., 2001), 
head and neck cancer (Korkmaz et al., 2005; Langer et al., 2006) and colorectal cancer (Loda et 
al., 1997; Manne et al., 2004; Rosati et al., 2004). The most extensive investigations have taken 
place in breast cancers, with multiple studies reporting that reduced CDKN1B levels are of 
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prognostic significance, with low CDKN1B levels correlating strongly with poor survival (Gillett 
et al., 1999; Barnes et al., 2003; Pohl et al., 2003; Porter et al., 2006). 
In AML, a study of CDKN1B expression analysis of 286 patients found that those patients with 
low CDKN1B expression were more likely to carry certain abnormalities, including RUNX1-
RUNX1T1, PML-RARA rearrangements, MLL rearrangements and FLT3-TKD mutations. The 
study also found that patients with low CDKN1B expression generally had a longer overall 
survival when compared to patients with intermediate or high expression levels (Haferlach et 
al., 2012). 
5.1.1.2 Cytoplasmic CDKN1B 
A possible alternative role for CDKN1B has recently been well documented by the study of 
CDKN1B localised to the cytoplasm. Cytoplasmic CDKN1B has been shown to co-localise with 
actin fibres and stimulate cellular migration. This was demonstrated in Cdkn1b null mouse 
embryonic fibroblasts, which showed decreased cell motility compared to wild type fibroblasts 
(Besson et al., 2004). A similar loss of motility was seen in cancer cell lines with low versus high 
cytoplasmic CDKN1B. Through the expression of CDKN1B protein with a defective localisation 
signal, excess CDKN1B accumulated in the cytoplasm. In MCF-7 breast cancer cells, this led to 
an increase in cell motility (Wu et al., 2006). Similarly, expressing these defective proteins in 
melanoma increased cell motility and led to an increased incidence of metastasis in vivo 
(Denicourt et al., 2007). A mouse model carrying mutant Cdkn1b that lacks nuclear cyclin 
inhibitory functions has a higher rate of spontaneous tumour development than Cdkn1b null 
mice (Serres et al., 2011). 
In addition to the role of BCR-ABL1 in regulating CDKN1B activity as described above, it has 
been discovered that BCR-ABL1 can enhance CDKN1B cytoplasmic localisation in CML cells 
(Chu et al., 2010). A study by Agarwal et al. (2014) focussed on the role of cytoplasmic CDKN1B 
in CML cells, as CDKN1B is primarily cytoplasmic in the majority of CML cases studied. By 
knocking down CDKN1B in CML cells that had primarily cytoplasmic CDKN1B, induction of 
apoptosis was observed that did not occur in those cells with largely nuclear CDKN1B. In 
similar work to that conducted by Serres et al. (2011), they also demonstrated that a murine 
CML model with Cdkn1b that lacked nuclear cyclin inhibitory functions enhanced 
leukaemogenesis above the levels observed in a murine CML model that was null for Cdkn1b. 
Finally, expression of two types of mutant Cdkn1b in a murine CML model, one with enhanced 
stability and another with increased nuclear retention, both showed attenuation of 
leukaemogenesis when compared to wild type Cdkn1b models (Agarwal et al., 2014). 
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5.1.2 Myelin Protein Zero-like 3 (MPZL3) 
The MPZL3 gene was first identified as the mutated gene leading to the rough coat (rc) 
mutation in C57BL/6J mice. This mutation arose spontaneously in 1966 and affected mice had 
unkempt hair coats at weaning age, later developing into progressive hair loss (Dickie, 1966). 
Through the use of linkage analysis, the rc mutation was mapped to mouse chromosome 9, 
near to the Mpi1 gene (Eicher et al., 1977). Following these findings, the mutant strain was not 
further studied until the early 2000s. Ruvinsky et al. (2002) described a novel mutation in the 
mouse Brachyury gene that led to a similar phenotype to that of rc, however the authors 
found that the two mutations occurred in different alleles (Ruvinsky et al., 2002).  
Soon after this publication, the rc mutation was studied in detail by Hayashi et al. (2004), 
where they examined the effects of rc across a wide range of tissues. They demonstrated that 
rc mice showed a significant reduction in growth when compared to normal C57BL/6J 
littermates, with this difference progressing further with age. The hearts of rc mice were found 
to have multiple myocardial degeneration foci, with disoriented cardiac muscle fibres. They 
also contained reduced amounts of collagen and elastin, which was linked to the presence of 
distorted blood vessels with thinner walls. The bone marrow of rc mice showed diffused 
hyperplasia, and a lack of calcium deposits normally seen in the femurs of wild type mice. In 
the liver, rc mice had increased numbers of erythrocytes, lymphocytes, polymorphonuclear 
leukocytes and enlarged Kupffer cells in the hepatic sinusoids compared to normal mice. 
Finally the spleens of rc mice were shown to contain an increased number of macrophages 
containing hemosiderin granules (Hayashi et al., 2004). 
The rc mutation was successfully mapped to a gene locus through positional cloning, allowing 
researchers to identify a 246kb minimal region to sequence. A point mutation in a theoretical 
coding gene was identified and the gene was named Mpzl3 due to its homology to the MPZL2 
gene. The mutation was found to occur in the highly conserved Immunoglobulin-like V-type 
domain within the coding sequence and was predicted to alter the function of MPZL3 protein 
through the substitution of an arginine to glutamine at position 100 of the 237 amino-acid 
polypeptide sequence (Cao et al., 2007).  
To determine the cause of reduced body weight in rc mice, Czyzyk et al. (2013) set out to 
investigate a possible link between metabolism and Mpzl3. They generated a Mpzl3 knockout 
mouse model and found that these mice were hyperphagic yet had reduced body weight and 
fat mass, caused by a whole body increase in energy expenditure. The muscles of knockout 
mice were found to have increased oxidative capacity and contractile force, whilst their livers 
had reduced levels of triglycerides and increased Akt signalling stimulated by insulin. Overall, 
128 
 
this strongly suggested that in mice at least, Mpzl3 is important in regulating metabolism and 
energy expenditure (Czyzyk et al., 2013). Further studies of Mpzl3 knockout mice by Leiva et 
al., (2014) have focussed on the skin abnormalities seen in these mice. Through the transplant 
of Mpzl3 -/- HSCs into immune deficient C57BL/6 Rag -/- mice, they demonstrated that Mpzl3 -
/- HSCs remained able to fully repopulate the bone marrow of the deficient mice, which did 
not result in replication of the abnormal skin phenotypes seen in the Mpzl3 knockout mice. 
The group were able to replicate the reduced body weight seen in the Czyzyk et al. (2013) 
study and suggested that this was due to the lack of MPZL3 function leading to the suppression 
of hepatic lipid accumulation or increased levels of fat burning (Leiva et al., 2014). 
5.1.3 Ubiquitination Factor E4A (UBE4A) 
UBE4A was first identified as the human homologue of the yeast UFD2 gene (Koegl et al., 
1999). Ubiquitination is the process that results in the labelling of proteins for breakdown by 
the proteasome system. Substrates of the ubiquitin/proteasome system are earmarked for 
degradation by the conjugation of ubiquitin. Conjugation of multiple ubiquitin molecules is 
common (multiubiquitination) and substrates with many ubiquitin molecules are preferred by 
the proteasome, whilst proteins with only a single or a few ubiquitin molecules tend to be long 
lived or are degraded by alternative degradation pathways (Komander and Rape, 2012). 
The ubiquitination system relies on multiple classes of enzymes. The ubiquitin-activating 
enzyme E1 activates ubiquitin molecules through the use of ATP hydrolysis. The activated 
ubiquitin molecules are then processed by ubiquitin-conjugating E2 enzymes, which further 
activate ubiquitin and either attach activated molecules to substrate proteins, or pass them on 
to E3 ubiquitin-protein ligases for attachment to target proteins (Komander, 2009). The E4 
class of ubiquitination factors elongate ubiquitination chains in conjunction with E1, E2 and E3 
enzymes to produce long ubiquitin chains and promote degradation of target proteins 
(Metzger and Weissman, 2010). UFD2 and its human homologues UBE4A and UBE4B fit within 
this E4 class of ubiquitination enzymes (Hänzelmann et al., 2010). 
Both UBE4A and UBE4B lie within a commonly deleted regions in neuroblastoma, on 
chromosomes 11q and 1p respectively. Mutations in both of these genes identified in 
neuroblastoma samples are believed to be inactivating (Carén et al., 2006), suggesting that in 
this context, both UBE4A and UBE4B function as tumour suppressor genes. A case of a MLL-
UBE4A fusion has also been identified in an ALL. In this case, the fusion resulted in a head to 
head translocation of the MLL and UBE4A genes and was presumed to result in the effective 
loss of heterozygosity for the UBE4A gene (Meyer et al., 2009). 
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The expression of UBE4A, as well as other ubiquitination factors (USP2 and USP14) has been 
shown to be elevated in ovarian serous cystadenocarcinoma compared to adjacent normal 
tissues, suggesting that ubiquitinative activity is increased in ovarian cancer cells (Yang et al., 
2007). The expression of the E4 ubiquitin enzyme UFD2 in yeast has been shown to be 
beneficial in high stress situations suggesting that it is involved in the degradation of stress-
induced aberrant proteins (Koegl et al., 1999). If the same were true of the human 
homologues of UFD2, this could explain the increased levels of expression seen in ovarian 
cancer cells, which are likely to experience adverse extracellular conditions.  
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5.2 Methods 
5.2.1 Flow Cytometry 
5.2.1.1 Cell Cycle Analysis 
For the analysis of cell cycle distribution, the FxCycle PI/RNase staining solution (Life 
Technologies) was used. The Propidium Iodide (PI) in this solution is a fluorescent DNA stain 
which when excited, emits an emission spectrum proportional to DNA mass. The presence of 
RNase degrades RNA to prevent PI staining of RNAs present in the cell. A frequency histogram 
is plotted for signal intensity, providing information on the number of cells in G0/G1 phase (a 
single pair of chromosomes per cell), S phase (DNA synthesis stage with variable DNA content) 
and G2/M phase (two sets of paired chromosomes per cell). 
Cells were harvested by pelleting of cell suspensions using centrifugation at 400 x g, and 
washed in PBS. After pelleting a second time, cells were resuspended in PBS at a concentration 
of 1 x 106 cells/ml. An aliquot of 1ml was prepared and 3ml of cold ethanol chilled to -20°C was 
added dropwise whilst the cell suspension was mixed by pulse vortexing. The cells were then 
incubated for at least 1 hour at 4°C to complete the fixation process. 
Fixative was removed through pelleting of the cell suspension by centrifugation at 1200 x g. 
This wash step was repeated to ensure that no fixative remained, and the cell pellet was 
resuspended in 500µl of FxCycle PI/RNase staining solution. The samples were then incubated 
in the dark for 30 minutes at room temperature before cytometric analysis using the FACS 
Calibur (BD Biosciences). Samples were excited at 488nm and emission was detected at 585nm 
on the FL2 channel. 
5.2.2 Reverse Transcription Polymerase Chain Reaction 
5.2.2.1 cDNA Generation 
cDNA was reverse transcribed from RNA using the High Capacity RNA-to-cDNA kit (Life 
Technologies). 1µg of total RNA was used per reaction and reactions were prepared as 
described in Table 27. 
Reagent Volume 
Reverse Transcription Buffer 5µl 
Reverse Transcription Enzyme Mix 0.5µl 
RNA 1µg in up to 4.5µl 
H2O Quantity sufficient to 10µl total volume 
Table 27. RNA to cDNA reverse transcription reaction mixture. 
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Samples were loaded into a thermal cycler (Applied Biosystems) and the program was run as 
described in Table 28. 
Step Temperature Time (Minutes) 
Reverse Transcription 37°C 60:00 
Denaturation 95°C 05:00 
 4°C Hold 
Table 28. RNA to cDNA reverse transcription thermocycler settings. 
5.2.2.2 Quantitative Polymerase Chain Reaction 
Quantitative Polymerase Chain Reaction (qPCR) was used to assess relative levels of RNA 
transcripts present in samples. SYBR Green PCR Master Mix (Life Technologies) was used for 
qPCR reactions. The SYBR Green dye preferentially binds double stranded DNA, producing a 
fluorescent DNA-dye complex which, when excited, emits an emission spectrum with a peak of 
520nm. This allows SYBR Green to be used to quantify the amount of double stranded DNA 
when performing qPCR, and this signal can be continuously monitored in real time, as thermal 
cycling and the DNA amplification process proceeds. 
A master mix was prepared using the reagents and volumes per reaction listed in Table 29. The 
master mix was added to 4ng RNA equivalent of sample cDNA in a 384 well plate. A standard 
curve was prepared for each primer pair present on the plate using qPCR Human Reference 
cDNA, Random-primed (Clontech), containing the following range of cDNA amounts; 10ng, 
5ng, 2.5ng, 1ng, 0.5ng and 0.25ng. qPCR was performed using a ViiA 7 Real-Time PCR System 
(Life Technologies) on the standard Real Time PCR setting. All experiments were performed in 
triplicate, and obtained mean values were plotted onto a standard curve obtained for each 
primer pair using the reference samples. This allowed relative expression between 
experimental and reference samples to be calculated. 
Reagent Volume 
SYBR Green PCR Master Mix 5.1µl 
Forward Primer (10µM) 0.2µl 
Reverse Primer (10µM) 0.2µl 
H2O 0.5µl 
Table 29. qPCR master mix for determining relative transcript abundance. 
5.2.2.3 Primer Optimisation 
Before performing qPCR on samples, primer pairs were used to amplify cDNA from control 
Human Reference cDNA (Clontech), alongside a panel of primers targeted to housekeeping 
genes (GAPDH, ALAS, GUSB and TBP). A housekeeping gene was then selected that closely 
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matched the amplification efficiency of the target gene and was used in subsequent 
experiments to normalise target cDNA quantity between samples. 
5.2.3 Protein Extraction 
Protein was extracted from cultured cells using urea buffer (90% 8.8M Urea, 2% 5M NaH2PO4, 
8% 1M Tris pH 8.0). Urea acts as a protein denaturant, breaking disulphide bonds and 
increasing protein solubility, allowing protein concentration to be quantified and subsequently 
used for downstream applications requiring accurate amounts of protein. 
Up to 1 x 107 cells were pelleted by centrifugation at 400 x g for 5 minutes, and resuspended in 
50µl ice-cold urea buffer. The sample was then pulse vortexed for 15 seconds, and incubated 
at 4°C for 30 minutes before centrifugation at 15000 x g in a microcentrifuge chilled to 4°C for 
a further 30 minutes. The supernatant contained solubilised proteins and was stored long term 
in a freezer at -80°C. 
5.2.4 Pierce BCA Assay 
To quantify the amounts of solubilised proteins, the bicinchoninic acid (BCA) Protein Assay kit 
was used (Thermo Scientific). This kit is a colourimetric assay used to estimate protein 
concentration through comparison to a diluted bovine serum albumin (BSA) standard. The 
formation of Cu2+-protein complexes under alkaline conditions leads to the production of Cu1+ 
ions, through the reduction of Cu2+. BCA forms a purple coloured complex with Cu1+ under the 
alkaline conditions present, and this colorimetric change can be detected through the 
measurement of absorbance at 562nm. 
A series of standards were prepared for protein quantification. A stock solution of BSA 
provided with the kit (2000µg/ml) was serially diluted in PBS as detailed in Table 30. 
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 Dilution Volume of PBS 
(µl) 
Volume of BSA 
(µl) 
Source of BSA Final 
Concentration 
(µg/ml) 
1 0 30 Stock 2000 
2 12.5 37.5 Stock 1500 
3 32.5 32.5 Stock 100 
4 17.5 17.5 Dilution 2 750 
5 32.5 32.5 Dilution 3 500 
6 32.5 32.5 Dilution 5 250 
7 32.5 32.5 Dilution 6 125 
8 40 10 Dilution 7 25 
9 40 0 N/A 0 
Table 30. Standards produced for protein quantification using the Pierce BCA assay. 
A working reagent was prepared by mixing 200µl BCA Reagent A with 4µl BCA Reagent B for 
each sample to be measured. 25µl of each standard and 25µl of protein sample (diluted 1:5 
with PBS) was loaded into individual wells of a clear 96 well plate. 200µl of working reagent 
was added to each well and the plate was shaken for 30 seconds using a plate shaker. The 
plate was sealed with Parafilm and incubated at 37°C for 30 minutes. After incubation, the 
absorbance of each well was measured at 562nm using a Fluostar Omega plate reader (BMG 
Labtech). 
5.2.5 Western Immunoblotting 
In Western immunoblotting, proteins are first separated by molecular weight and 3-D 
structure by polyacrylamide gel electrophoresis. The proteins are then transferred to a 
membrane where they can be probed using antibodies specific to the protein of interest. The 
antibodies used are conjugated to enzymes or fluorophores that can be detected to show the 
physical location and intensity of a protein band present on the membrane. 
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Buffer Components 
10x Running Buffer 30.3g Tris(hydroxymethyl)aminomethane (Tris)  
144g Glycine 
10g Sodium Dodecyl Sulphate (SDS) 
10x Transfer Buffer 144g Glycine 
30.3g Tris 
10x Tris Buffered Saline-Tween-20 (TBS-T) 12.11g Tris 
29.22g Sodium Chloride 
10ml Tween-20 
All buffers were made up to 1L with distilled water for storage and diluted 1:10 with distilled 
water when required for use. 
Table 31. List of buffers used in Western immunoblotting. 
5.2.5.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
In order to separate whole protein lysates by size, sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was used. 25µg of protein was made up to 30µl with fresh urea 
buffer. 5µl of 6x loading buffer (Cell Signalling Technologies) was added to each sample and 
briefly mixed by pulse vortexing. Samples were then heated to 96°C for 5 minutes in a 
thermocycler and subsequently kept on ice until ready to load. An Amersham ECL Gel (GE Life 
Sciences) was rinsed in dH2O and placed into an Amersham ECL Gel Box (GE Life Sciences), 
filled with 180ml 1x running buffer. The gel was pre-run for 12 minutes at 160V and the well 
comb removed. The wells were then filled with 6ml of 1x running buffer and 35µg of protein 
samples loaded into each well. Into one empty well of each gel, 10µl of Spectra Multicolor 
Broad Range Protein Ladder (Thermo Scientific) was loaded. Remaining empty wells were filled 
with 30µl of urea buffer mixed with 5µl of loading buffer and when loading was complete, the 
gel was run at 160V for 60 minutes. 
5.2.5.2 Protein Transfer 
A square of PVDF membrane (Merck Millipore) approximately equal to the gel size was cut and 
activated by placing into 20ml of 100% methanol. The membrane was then transferred to 10ml 
of 1x transfer buffer to equilibrate for at least five minutes. 
After the gel had completed running, it was removed from the cassette and the stacking gel 
was cut away. The gel was placed onto a nitrocellulose blotting paper that had been pre-
soaked in 1x transfer buffer. The activated PVDF membrane was placed on top of the gel, and 
to this another pre-soaked piece of nitrocellulose blotting paper was added. This assembly was 
placed into a transfer cassette and inserted into a protein transfer tank filled with 1L of 1x 
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transfer buffer. An ice pack was added to the tank to maintain a low temperature during the 
transfer process, and proteins were transferred by running the equipment at 100V for 60 
minutes. 
5.2.5.3 Immunoblotting 
Successful protein transfer was confirmed by the transfer of coloured bands present in the 
protein ladder onto the PVDF membrane. The membrane was transferred to a solution of 5% 
skimmed milk powder in 50ml TBS-T and incubated at room temperature on a rocker (Bibby 
Scientific) for at least four hours to block the membrane. Antibodies were prepared in dilutions 
according to the manufacturer’s guidelines. The blocked membrane was placed into a 50ml 
Falcon tube with 5ml of antibody solution and incubated at room temperature on a roller for 1 
hour. Excess antibody was washed off by pouring off excess solution followed by the addition 
of 10ml TBS-T. The membrane was rocked at room temperature for 5 minutes, and the washes 
repeated a further two times. The corresponding secondary antibody was then incubated with 
the membrane following the same procedure, and the same wash process repeated. 
Antibodies and dilutions used are listed in Table 32. 
Primary 
Antibody 
Manufacturer Dilution Secondary 
Antibody 
Conjugate Manufacturer Dilution 
Rabbit 
Anti-
CDKN1B 
Santa Cruz 
Biotechnology 
1:100 Goat Anti-
Rabbit 
Horseradish 
Peroxidase 
(HRP) 
Cell Signalling 
Technology 
1:2000 
Mouse 
Anti-α-
tubulin 
Cell Signalling 
Technology 
1:1000 Rabbit 
Anti-
Mouse 
HRP Cell Signalling 
Technology 
1:1000 
Table 32. Antibodies used in Western Immunoblotting. 
After washing, a signal was generated using Amersham Enhanced Chemiluminescence (ECL) 
Prime Western Blotting Detection Reagent (GE Healthcare). 500µl each of reagents A and B 
were mixed and subsequently added to the PVDF membrane. After incubation at room 
temperature for one minute, excess reagent was removed by touching the edge of the 
membrane to tissue paper. The membrane was placed into a G:Box (SynGene) for the 
detection of chemiluminescent signals produced by the reaction of HRP with ECL reagent. 
5.2.5.4 Image Densitometry Analysis 
Images produced by the G:Box were analysed using the ImageJ software (Version 
1.48, http://rsb.info.nih.gov/ij/, National Institutes of Health). The software was used to relate 
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target band density to those produced by control antibodies, allowing for the normalisation of 
relative protein abundance between experiments and across gels. 
5.2.6 Cell Proliferation Assay (MTS) 
CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) was used for measuring 
cell proliferation rates in a 96 well format. This colourimetric assay relies on the cleavage of 
tetrazolium dye by nicotinamide adenine dinucleotide phosphate (NADPH)-dependent cellular 
oxireductase enzymes, reflecting the number of viable cells present. Cells were seeded into 
each well of a 96-well plate, at a concentration of 5 x 105 cells/ml in a volume of 90µl. The top 
and bottom rows of each test plate contained 90µl of media only to allow for blanking and 
control wells to be established. For drug dosing experiments, 10µl of media containing serially-
diluted drug or vehicle only control was added to this suspension. After 72 hours of incubation, 
10µl of AQueous One reagent was added to each well and the plate incubated at 37°C, 5% CO2 
for two hours. Absorbance was then measured at 490nm using a Fluostar Omega plate reader, 
allowing relative proliferation rates to be calculated after subtracting blanking values for 
media only wells. 
For the statistical analysis of correlation between transcript or protein and 50% growth 
inhibition (GI50) values, a Shapiro-Wilk test of normality was applied. As all tests performed 
found data that were not normally distributed, a non-parametric test of correlation was 
applied. The Spearman’s Rank Correlation Coefficient was used to calculate rho and an 
associated p-value. Shapiro-Wilk test of normality and Spearman’s Rank Correlation Coefficient 
tests were performed in STATA 11 (StataCorp).  
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5.3 Results 
5.3.1 Confirmation of CDKN1B Overexpression in NKM-1 Cell Lines 
A population of NKM-1 cells were transduced with SIN-SIEW-CDKN1B lentiviral particles and 
the expression levels of CDKN1B were measured using quantitative PCR. The qPCR showed an 
almost 30-fold increase in the expression levels of CDKN1B in the transduced population when 
compared to a non-transduced control population, as demonstrated in Figure 41. 
 
Figure 41. Mean transcript levels of CDKN1B measured by quantitative PCR in a control population of NKM-1 cells 
compared to NKM-1 cells transduced with SIN-SIEW-CDKN1B, 72 hours after transduction. Error bars show standard 
deviation of triplicate qPCR results. 
To confirm that CDKN1B transcripts produced from integrated lentiviral vectors were 
translated to protein, Western immunoblotting was performed to assess the levels of CDKN1B 
protein present.  In the transduced population a clear increase in CDKN1B levels was observed, 
as shown in Figure 42. Image densitometry analysis of the blotting image estimated a 20 fold 
increase in the amount of CDKN1B protein present. 
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 Figure 42. Western immunoblot of CDKN1B in a control population of NKM-1 cells compared to NKM-1 cells 
transduced with SIN-SIEW-CDKN1B, 72 hours after transduction. 
To validate the negative relationship between overexpression of CDKN1B and cell proliferation, 
an MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)) assay was used to assess the rate of proliferation in cell populations transduced 
with SIN-SIEW-CDKN1B as compared to control cells. As shown in Figure 43, transduction with 
SIN-SIEW-CDKN1B reduced the number of viable cells present 72 hours after transduction to 
less than half of those present in the non-transduced population. A t-test confirmed a 
significant difference between the two groups (p=0.012). 
 
Figure 43. NKM-1 cell proliferation in non-transduced cells compared to cells transduced with SIN-SIEW-CDKN1B. 
Proliferation assay was performed using AQueousOne reagent in a colourimetric MTS assay, 72 hours after 
transduction and seeding in equal numbers into a 96 well microplate. Error bars represent standard deviation of 
triplicate repeats. 
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Cell cycle analyses using PI were performed on the same populations, the results of which are 
shown in Figure 44. The data showed a small increase in the number of cells in G2/M phase in 
the NKM-1-CDKN1B population, with slight reductions in the proportion of cells in G0/G1 and S 
phase. However, as shown in Figure 44A, there was an accumulation of cells at the end of S 
phase that appeared to be unable to transition into the G2/M phase.  
 
Figure 44. Cell cycle analyses performed on NKM-1 control and SIN-SIEW-CDKN1B transduced populations using PI 
staining to determine cellular DNA content 72 hours after transduction.  Samples were gated after flow cytometry 
analysis to assess the numbers of cells in each cell cycle phase, though the use of three markers (M1-3) (A). Obtained 
values were subsequently plotted onto stacked column graphs (B). 
5.3.2 CDKN1B Expression in AML Cell Lines 
Expression levels of CDKN1B were measured in a panel of 13 AML cell lines using qPCR, as 
shown in Figure 45. Expression levels were calculated by relating observed CDKN1B levels to 
the expression levels of the housekeeping gene GAPDH (as selected by qPCR optimisation 
described in 5.2.2.3). A wide range of CDKN1B expression levels were observed across cell 
lines, with a particularly low level of expression in the GDM-1 cell line.  
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 Figure 45. Expression of CDKN1B measured in a panel of AML cell lines using quantitative Real Time PCR. Data 
shown are representative of CDKN1B expression normalised to a housekeeping gene (GAPDH). Error bars represent 
standard deviation calculated from triplicate qPCR repeats. 
For statistical analysis, cell lines were grouped into 12p deleted (NKM-1, KG-1 and GDM-1) and 
non 12p deleted lines (all other lines in the panel) as shown in Figure 46. An unpaired t-test 
showed no significant difference between the two groups (p=0.219). 
 
Figure 46. Expression of CDKN1B measured in a panel of AML cell lines split into two groups depending on 12p 
deletion status. CDKN1B expression levels were measured using quantitative Real Time PCR and normalised using 
the GAPDH housekeeping gene. The central bar shows the median, whilst the upper and lower bars of the inner box 
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represent the interquartile range (Non 12p Deleted only). The furthest bars from the central point of each box show 
the range. 
Protein was extracted from the same panel of AML cell lines and assessed using Western 
blotting. Band density was analysed and CDKN1B protein levels were normalised to α-tubulin 
controls. The 12p deleted samples (NKM-1, KG-1 and GDM-1) were run on all gels and used to 
normalise band density between experiments, as shown in Figure 47 (original gel pictures are 
displayed in Supplementary Figure 57).   
 
Figure 47. CDKN1B protein expression levels measured in a panel of AML cell lines. Bands imaged from Western 
blotting were quantified using band densitometry and normalised to α-tubulin controls. NKM-1, KG-1 and GDM-1 
samples were run on all gels and used to normalise samples run on different gels. 
For statistical analysis, cell lines were grouped into 12p deleted (NKM-1, KG-1 and GDM-1) and 
non 12p deleted lines (all other lines in the panel) as shown in Figure 48. An unpaired t-test 
between the two groups found no significant difference in the levels of CDKN1B protein 
detected (p=0.649). 
142 
 
 Figure 48. Expression of CDKN1B protein measured in a panel of AML cell lines split into two groups depending on 
12p deletion status. The central bar shows the median, whilst the upper and lower bars of the inner box represent 
the interquartile range (Non 12p Deleted only). The furthest bars from the central point of each box show the range. 
5.3.3 CDKN1B Expression in Patient Samples 
The expression levels of CDKN1B were assessed in 76 AML patient cDNA samples (kindly 
donated by Prof. Claudia Haferlach, Munich Leukemia Laboratory). Of these, 45 had deletions 
of 12p, whilst 31 samples were provided for use as controls. As shown in Figure 49, the levels 
of CDKN1B expression between the two groups were very similar in both median and range, 
although the median was slightly lower for the 12p deleted group. An unpaired t-test 
confirmed that there was no significant difference between the two groups (p=0.606). 
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 Figure 49. CDKN1B expression levels measured by quantitative Real Time PCR in a panel of 76 AML patients. In the 
12p deleted group were 45 patients, whilst there were 31 patient samples analysed in the control non 12p deleted 
group. CDKN1B expression levels were calculated relative to the GAPDH housekeeping gene. The central bar 
represents the median of the group, whilst the bars above and below the mean represent the interquartile range. 
5.3.4 CDKN1B Expression in Normal Myeloid Cells 
To gain a greater understanding of the role of CDKN1B in the samples analysed, expression 
microarray data was analysed to ascertain the CDKN1B expression levels relative to GAPDH in 
normal haematopoietic cells. Using the R2: Genomics Analysis and Visualization Platform 
(Academic Medical Center, the Netherlands), an expression microarray performed on flow 
sorted haematopoietic cell populations was analysed (Dataset GSE19599, Fioretos et al., 2012, 
Affymetrix Human Genome U133 Plus 2.0 Array). As shown in Figure 50, CDKN1B expression 
relative to GAPDH ranged from 0.05 to 0.10 across a range of myeloid and myeloid progenitor 
cells. Although analysed on a different platform, these are within a similar range to the 
majority of cells lines and patient samples using qPCR in this study. 
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 Figure 50. CDKN1B expression relative to GAPDH in normal haematopoietic cells, as measured by expression 
microarray on the Affymetrix Human Genome U133 Plus 2.0 Array platform. Array analysis was performed on flow 
sorted haematopoietic cells by Fioretos et al. and publicly released to the Gene Expression Omnibus (Accession 
number GSE19599). Expression data was then accessed using the R2: Genomics Analysis and Visualization Platform 
(Academic Medical Center, the Netherlands). 
5.3.5 Targeting CDKN1B with shRNAs in U937 Cells 
To analyse the role of CDKN1B in cell cycle regulation, the cell line with the highest level of 
CDKN1B expression (Figure 45 and Figure 47) was selected (U937). Cells were transduced with 
a pool of GIPZ lentiviral vectors driving the expression of shRNAs targeted to CDKN1B to 
reduce its expression. Puromycin selection was used to isolate a population of transduced cells 
and successful selection confirmed through the analysis of GFP expression in these cells (Figure 
51A). Cell cycle analysis using PI was performed on these populations, showing a reduction in 
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the number of cells in G0/G1 and S phases in the U937 cells transduced with the CDKN1B 
shRNAs. 
 
Figure 51. U937 cells transduced with a pool of GIPZ lentiviral vectors to drive the expression of shRNAs targeted to 
CDKN1B. Puromycin selection was used to isolate a population of successfully transduced cells which was confirmed 
by flow cytometry measuring GFP expression levels as shown in A. Cell cycle analysis using PI staining was performed 
using flow cytometry. The x-axis represents GFP expression levels whilst the y-axis shows the number of counts for 
each section of the histogram. B. The proportions of cells in different cell cycle phases were then calculated using 
propidium iodide staining of fixed cells. 
A cell viability assay was performed on equal numbers of U937 control and transduced cells 
seeded into individual wells of a 96 well microplate, after 72 hours of incubation. Whilst there 
was a slight increase in the number of viable transduced cells as shown in Figure 52 (1.08 vs. 
1), this was not significant (t-test p=0.101). 
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 Figure 52. Cell viability assay (MTS) performed on U937 control and CDKN1B GIPZ shRNA transduced cells cultured 
for 72 hours after seeding in equal numbers in triplicate wells of a 96 well microplate. 
5.3.6 Exposure of AML Cell Lines to Flavopiridol 
As discussed in 5.1.1, CDKN1B has been demonstrated to inhibit cell cycle progression through 
the binding of CDK2 and CDK4 complexes and their subsequent inhibition. If CDK2 and CDK4 
complexes were more readily activated in the absence of CDKN1B inhibition, in those AML cell 
lines with a reduced level of CDKN1B expression, it could be hypothesised that treatment with 
a CDK2/CDK4 inhibitor may be an effective replacement for CDKN1B function. The panel of 
AML cell lines described in previous experiments was treated with a range of flavopiridol 
concentrations for 72 hours to assess whether this link could be established through the 
calculation of 50% Growth Inhibition (GI50) values. An MTS assay was performed to assess cell 
viability and GI50 values were calculated and compared to CDKN1B transcript and CDKN1B 
protein levels, as shown in Figure 53. 
GI50 values were tested for normality using the Shapiro-Wilk test. The data were not found to 
be normally distributed, so a non-parametric test (Spearman’s rank correlation coefficient) was 
used to calculate correlation between GI50 and CDKN1B transcript or CDKN1B protein values. 
There was a moderate correlation between flavopiridol GI50 and CDKN1B transcript levels 
(rho=0.405), however this was not significant (p=0.320). There was a weak correlation 
between flavopiridol GI50 and CDKN1B protein levels (rho=0.262), but this was also not 
significant (p=0.531). 
147 
 
 Figure 53. A panel of AML cell lines were seeded into individual wells of a 96 well microplate and treated with 
flavopiridol for 72 hours to calculate GI50 values using an MTS assay. GI50 values were then correlated with CDKN1B 
transcript (A) and CDKN1B protein (B) levels, as calculated in Figure 45 and Figure 47. 
5.3.7 Validation of MPZL3 and UBE4A Knockdown in UoC-M1 Cells 
To confirm successful knockdown of the 11q screen hits MPZL3 and UBE4A, UoC-M1 cells were 
transduced on an individual basis with each lentiviral vector and puromycin used to select 
positive cell populations. Transcript levels of MPZL3 and UBE4A were then assessed using qPCR 
as shown in Figure 54. For all shRNAs targeted to both MPZL3 and UBE4A, transcript 
knockdown was found to be greater than 50% knockdown compared to NSC (Non Silencing 
Control) samples. 
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 Figure 54. MPZL3 and UBE4A expression in UoC-M1 cells transduced with pGIPZ non silencing control (NSC), or one 
of three shRNAs targeted to either MPZL3 or UBE4A. Puromycin selection was then applied to obtain a population of 
GFP positive cells indicating positive shRNA selection. mRNA was extracted and qPCR performed using primers 
specific to MPZL3 or UBE4A to calculate transcript abundance relative to GAPDH. Data shown is adjusted to relative 
transcript abundance compared to NSC samples. 
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5.4 Discussion 
5.4.1 Candidate Tumour Suppressor Gene CDKN1B 
To validate the effects of CDKN1B overexpression observed in Chapter 4, NKM-1 cells were 
transduced with the SIN-SIEW-CDKN1B lentiviral construct alone. Analysis of CDKN1B mRNA 
and protein levels were assessed in the transduced population and found to be greatly 
elevated compared to the non-transduced NKM-1 cells. A second assay measuring the number 
of viable cells 72 hours after seeding further confirmed the reduced rate of proliferation of 
these cells. 
As CDKN1B has a primary role in cell cycle checkpoint regulation, the cell cycle distribution of 
transduced cells was assessed and compared to control cells. The cell cycle distribution was 
similar between the two populations, but with an increased proportion of transduced cells in 
the G2/M phase. This was somewhat unexpected, as the primary and most well studied role of 
CDKN1B is in the inhibition of CDK2 and CDK4/6 complexes, which are regulators of the G1/S 
phase. Therefore, one would expect that overexpression of CDKN1B would lead to a block at 
this stage, increasing the proportion of cells in G1. 
The transcript and protein levels of CDKN1B were then measured in a panel of AML cell lines. 
The three cell lines carrying deletions of 12p (NKM-1, GDM-1 and KG-1) and UoC-M1 (used in 
the 11q project) have been used in previous experiments. An additional nine AML cell lines 
were acquired and CDKN1B expression assessed. A wide range of expression levels were 
observed across the cell lines, with no significant difference between cell lines carrying 
deletions of 12p and those without deletions of 12p. This could suggest that if CDKN1B is an 
important haploinsufficient tumour suppressor gene in AML, it is dysregulated through other 
mechanisms in different cell lines. Supporting this hypothesis is the research surrounding other 
mechanisms that exist to regulate CDKN1B, through its transcription, translation and 
proteolysis, as described in 5.1.1. Additionally, this would explain the lack of correlation 
between transcript and protein levels observed in some cell line samples. Targeting these 
mechanisms for treatment may be beneficial in returning CDKN1B expression levels to normal. 
The cell line with the lowest expression levels of CDKN1B transcript was the GDM-1 cell line 
used in the repeat negative selection assay performed in Chapter 4. This very low level of 
CDKN1B transcription, in conjunction with the lower level of expression from integrated 
lentiviral vectors in this cell line, could explain the smaller changes in relative construct copy 
number observed during leukaemic expansion as its expression from the integrated SIN-SIEW 
lentiviral vector may have been better tolerated. 
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The expression levels of CDKN1B were also measured in AML patient samples, both with and 
without deletion of 12p. Again, a range of CDKN1B expression levels were observed, and there 
was no significant difference between patients carrying a deletion of 12p and those without 
deletions of 12p (p=0.606). This further supports the hypothesis that CDKN1B may be down 
regulated by different mechanisms in samples that do not have a deletion of 12p. Additionally, 
the presence of cell lines and patients with higher levels of CDKN1B expression raises the 
possibility that CDKN1B may have an oncogenic role in some AML cases, which in turn could be 
explained by the alternative role of cytoplasmic CDKN1B that was described above. For this 
reason, it would be highly informative to quantify RNA and protein levels in nuclear and 
cytoplasmic fractions separated from AML cells. 
To assess whether the expression levels of CDKN1B found in the cell line and patient samples 
used in this study was similar to those found in normal haematopoietic cells, the R2: Genomics 
Analysis and Visualization Platform was utilised to extract data from a study performed by 
Fioretos et al. (2012) on flow sorted normal haematopoietic cells. CDKN1B expression was 
analysed relative to GAPDH expression, as had been performed in this study using qPCR. In the 
Fioretos et al. (2012) study, CDKN1B expression levels appeared to be between 5% and 10% of 
GAPDH expression. This is in line with the qPCR data obtained for both cell lines and patient 
samples, although there were exceptions from both datasets. Three cell lines (U937, Kasumi-1 
and MV4-11) demonstrated expression of CDKN1B at above 0.2 relative to GAPDH, whilst two 
12p deleted and three non-12p deleted patient samples had CDKN1B expression levels greater 
than 0.6 relative to GAPDH. This would suggest that there are some cases in which CDKN1B 
expression is elevated above normal myeloid cell expression levels, although due to the use of 
two different platforms (microarray and qPCR) it is not possible to draw any solid conclusions, 
but further investigation of this in the future may be warranted. 
To investigate the role of CDKN1B when highly expressed in AML, U937 cells were selected to 
be targeted with a pool of GIPZ shRNAs to knockdown CDKN1B. Puromycin was used to select 
for a population made up of transduced cells expressing these shRNAs. Cell cycle analysis 
showed a decreased proportion of cells in G0/G1 phase, suggesting that a greater proportion 
of cells were actively dividing. However, the difference was not significant when assessed using 
a cell proliferation and viability assay (p=0.101). Due to the lower level of expression found 
with GIPZ lentiviral constructs throughout this project, it would be beneficial to repeat this 
experiment with longer culture times to ascertain the true nature of CDKN1B in U937 cells. 
Finally, the effects of flavopiridol on AML cell line growth were assessed to investigate a 
possible link between the loss of CDK inhibition through low CDKN1B expression and the ability 
to re-establish it through treatment using a CDK inhibitor. Flavopiridol was selected as it has 
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been demonstrated to inhibit CDK2 and CDK4, both targets of CDKN1B, as well as having been 
used in clinical trials for a number of cancer types (primarily CLL) (Senderowicz, 1999; Stephens 
et al., 2013; Pierceall et al., 2014) and it is currently in phase II trials for the treatment of 
intermediate and high-risk AML (Zeidner et al., 2014). This study found a moderate correlation 
between CDKN1B transcript levels and GI50 values calculated for sensitivity to flavopiridol, 
although in a test of dependency these values were found to be independent (p=0.320). It 
would be desirable to perform further investigation of this link in additional cell lines, as well 
as combining the data with information on cytoplasmic and nuclear CDKN1B transcript and 
protein abundance in the cell lines tested. 
Although the data presented here are not entirely clear in implicating CDKN1B directly in cell 
cycle regulation in 12p deleted AML cases, it appears that CDKN1B does have a role in 
leukaemogenesis. These data suggest that CDKN1B can be dysregulated by alternative routes 
in non 12p deleted AML, although the existence of highly expressing cell lines and patient 
samples suggest that CDKN1B may also have an oncogenic role. The dual roles of CDKN1B 
could explain why neither homozygous deletions of 12p or mutations affecting the remaining 
allele in cases of heterozygous deletion have been reported. It is clear that more detailed 
investigations into the role of CDKN1B in AML are required to elucidate the contribution of 
CDKN1B in leukaemogenesis. 
5.4.2 Candidate Oncogenes MPZL3 and UBE4A 
To confirm transcript knockdown using the GIPZ lentiviral shRNA-containing vectors, UoC-M1 
cells were transduced with individual GIPZ vectors targeted to either MPZL3 or UBE4A. 
Puromycin was then used to select for a pure population of transduced cells and transcript 
levels were measured relative to GAPDH. A knockdown of over 50% was achieved with all 
shRNAs.  
For shRNAs targeted to MPZL3, the largest knockdown was achieved with shRNA 3, which 
showed the second greatest effect in the negative selection assay. Somewhat unexpectedly, 
shRNA 1, which showed the greatest effect in the negative selection assay, demonstrated the 
lowest level knockdown of the three shRNAs targeted to MPZL3. Of the shRNAs targeted to 
UBE4A, the greatest knockdown was achieved with shRNA 1. This is concordant with the data 
obtained in the negative selection assay, where shRNA 1 was selected against most strongly in 
both the MinP and MaxP samples. Similar levels of knockdown were achieved with shRNAs 2 
and 3. Whilst expression of shRNA 3 was selected against in the screening assay, expression of 
shRNA 2 was not. 
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It is somewhat conflicting that whilst knockdown of the target genes was achieved with all 
shRNAs, this was not always associated with negative selection in the assays performed in 
Chapter 4. Without further functional investigation, it is unclear for the reasons behind this, 
but possible reasons could be speculated. Due to the large number of lentiviral vectors present 
in the pools, it may be that relatively few starting cells were transduced with each GIPZ vector. 
This could lead to a situation where the majority of cells containing a particular vector express 
the contained shRNA at a low level, due to integration into a genomic site of low expression. 
Without the pressures of puromycin selection, these cells are not selected against and may 
therefore remain in the cell pool without any adverse effects due to shRNA expression. 
Alternatively, it may be the case that particular shRNAs are only capable of reducing the level 
of specific transcript splice variants, the loss of which may not lead to a reduction in functional 
protein levels. To assess this, it would be ideal to quantify the amounts of MPZL3 and UBE4A 
protein present in cells selected using puromycin. 
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Chapter 6 General Discussion 
6.1 Summary of Aims 
6.1.1 Defining the Extent of Chromosome 12p Deletions and Chromosome 11q 
Amplifications  
As there was no clear consensus on the extent of 12p and 11q copy number alterations in 
AML, the main objective of this body of work was to establish minimal regions of copy number 
alteration for both of these chromosomal regions. 
6.1.1.1 Deletions of Chromosome 12p 
Deletions and translocations of the short arm of chromosome 12 have previously been 
reported in a range of haematological malignancies, including AML, ALL, MDS and non-Hodgkin 
lymphoma. In AML, deletions have been reported in between 1% and 5% of AML patients 
(Grimwade et al., 2010; Harrison et al., 2010), and have been frequently associated with other 
abnormalities within a complex karyotype, including the unfavourable -7/-7q and -5/-5q (Wall 
et al., 2012). Further studies have suggested that up to 10% of normal karyotype AML patients 
may have deletions of 12p that are not detectable by cytogenetic analysis (Andreasson et al., 
1997).  
Although there are few studies that have investigated the prognostic impact of 12p deletions, 
two studies have demonstrated that in paediatric AML patients, deletions of 12p have a poor 
prognosis, with an event free survival of 35% compared to 59% in patients without deletions of 
12p (Harrison et al., 2010, von Neuhoff et al., 2010). There are no studies that have looked 
specifically at the prognostic relevance of these deletions in adult AML as they occur most 
frequently within a complex karyotype, however analysis of annotated microarray data (Parkin 
et al., 2010) revealed a poor prognosis in one study, albeit with relatively few patients (Section 
0, Figure 4).  
To define a miminally deleted region for chromosome 12p, eight studies that had made use of 
copy number microarrays, including one focussing 12p, were selected for reanalysis. A total of 
866 AML patient samples were assessed, and 5.2% of samples from studies that had not 
specifically been selected for deletions of 12p were identified as having a deletion 
encompassing this region. By overlaying the deletions in this region, a minimally deleted region 
was defined containing 10 genes: BCL2L14, LRP6, MANSC1, LOH12CR1, DUSP16, CREBL2, 
GPR19, CDKN1B, APOLD1 and DDX47. 
To determine the incidence of submicroscopic 12p deletions in normal karyotype AML 
patients, a MLPA probeset was custom designed to interrogate the copy number status of a 
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selection of genes from within and around the MDR. Nine probes were designed and 
optimised before testing on cell line and patient material with known deletions of 12p. The 
probeset was then used to screen 75 normal karyotype AML patients, five of which were found 
to have deletions of 12p (6.7%). The deletions in four of these five patients were confirmed 
using FISH. The remaining patient did not have the required material available for this 
verification. All five patients identified using MLPA were found to have deletions larger than 
the established MDR, and were therefore not informative in reducing the number of genes. 
At this stage, three AML cell lines with deletions of 12p encompassing the MDR, as well as 
relatively few other genetic aberrations that may have affected results obtained in functional 
anaylsis, were identified using the Sanger COSMIC Cell Line database – GDM-1, KG-1 and NKM-
1.  
The putative tumour suppressor gene ETV6 was absent from the 12p MDR from the cell lines 
chosen. However, ETV6 was included in the functional analysis for a number of reasons. The 
MDR was determined using copy number SNP arrays, thus it was unknown whether other 
chromosomal rearrangements may have been present that could alter the expression of ETV6 
without affecting copy number. This scenario is not unlikely as the 12p13 chromosomal region 
is known to be unstable, with multiple complex rearrangements previously reported (Sato et 
al., 2001). Translocations of ETV6 in AML have been shown to form fusion genes that do not 
result in a functional transcript, and these have been suggested to contribute to AML through 
lower expression of ETV6 resulting from haploinsufficiency (Silva et al., 2008). Although 
relatively rare in AML, some mutations of ETV6 have been reported to act in a dominant 
negative manner, disrupting ETV6 function in the absence of a second hit (van Doorn-
Khosrovani et al., 2005).  
6.1.1.2 Amplifications of Chromosome 11q 
Amplifications of chromosome 11q are relatively rare, occurring in 1 to 2% of AML patients. 
Gain of material from this region is among the most common aberrations observed in 15-40% 
of complex karyotype AML (Schoch et al., 2002; Rücker et al., 2006). It is likely that if there is a 
gene or genes with an oncogenic dosage effect present in this region, it would be present 
within common regions of gain and amplification observed across multiple patients. Due to the 
strong association with complex karyotype AML as well as an average older age of disease 
manifestation, amplifications of 11q carry a very poor prognosis. 
There have been two recent studies that have focussed on establishing a minimally amplified 
region of chromosome 11q in AML. In 2006, Rücker et al. identified three separate common 
regions of gain on chromosome 11q through the analysis of complex karyotype AML patients 
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using microarray technology. A more recent study by Zatkova et al. (2009) found nine 
recurrent regions of amplification on 11q, three of which were observed in all cases studied. 
These regions had considerable overlap with those found in the 2006 study and contained the 
suspected proto-oncogenes MLL, ETS1 and FLI1. 
To gain a greater understanding of 11q abnormalities in AML patients, gains and amplifications 
were mapped in the datasets also used in the 12p study. Across the entire cohort (n=866), 25 
patients were identified with gains of 11q, and five patients with amplifications of 11q. 
Through alignment of these data with the previously mentioned studies, three commonly 
amplified regions containing a total of 32 genes were identified and selected for functional 
analysis. 
The UoC-M1 cell line was selected for use in functional analysis work. Although this cell line 
has only four copies of the genes of interest, it had previously been demonstrated that 
expression of genes from the 11q arm were significantly elevated when compared to control 
samples (Allen et al., 1998).  
6.1.2 Identification of Genes Contributing to Disease Development Through the use of 
a Functional Negative Selection Assay 
The candidate gene lists established through analysis of array and MLPA data were taken 
forward for functional assessment using a negative screening assay. In this assay, cDNA or 
shRNA constructs targeting candidate tumour suppressor or oncogenes respectively were 
introduced into AML cell lines containing the genetic aberrations of interest using lentiviral 
transduction. Transduced cells were then expanded in vitro and in vivo through intrafemoral 
injection of cells into immunocompromised mice (12p project only). Detrimental effects on 
growth due to expression of cDNAs or shRNAs from integrated lentiviral vectors were 
measured through the comparison of relative construct proportion before and after leukaemic 
cell expansion using high throughput NGS. Optimised methodology for production of lentiviral 
particles as well as transfection and transduction conditions, were developed as part of this 
study. 
The engraftment of cell lines when intrafemorally injected into immunocompromised mice 
was assessed. Whole body bioluminescent imaging of mice injected intrafemorally with cell 
lines transduced with lentivirus expressing luciferase resulted in signals consistent with the 
development of solid tumours around the site of injection. However upon sacrifice of the mice, 
50% showed an increased spleen weight consistent with leukaemic infiltration. Subsequent 
analysis of preserved skulls (performed by Dr. Christina Halsey, University of Glasgow) showed 
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further leukaemic infiltration of the calvaria and leptomeningies in some samples, suggesting 
more extensive engraftment than first thought. 
6.1.2.1 Chromosome 12p Candidate Gene List 
An initial pilot study was performed using the NKM-1 cell line to assess the candidate genes 
from the 12p MDR. The pilot in vitro study showed strong and rapid selection against the 
CDKN1B expression construct, as well as weaker selection against constructs driving the 
expression of CREBL2 and ETV6. The pilot study in vivo results were less clear, with highly 
variable construct representation between samples, both between mice as well as between 
organs within an individual mouse. In some samples, a single expression construct was highly 
overrepresented. Whilst no solid conclusions could be drawn from these data, the expression 
clone for ETV6 was never overrepresented, the expression clone for LOH12CR1 was only 
overrepresented once, and the expression clone for CDKN1B was overrepresented twice. The 
remaining expression clones were overrepresented in 3 or more of the mouse samples 
analysed, suggesting that expression of these genes did not apply significant negative selection 
pressures. 
Following on from the pilot study, repeat studies were performed in triplicate using the NKM-1 
cell line. Expression of CDKN1B was strongly and rapidly selected against, and the selection 
against APOLD1 and CREBL2 was not recurrent, suggesting that they were spurious results 
from the pilot study that were eliminated through repetition. A weak selection effect against 
ETV6 remained and was observed across all three repeats. The negative selection assay was 
then performed in an additional cell line carrying deletion of 12p, GDM-1. Whilst the observed 
effects of negative selection were lesser in this cell line, there was still a highly significant 
selection against CDKN1B. However, the weak selection effect against ETV6 was not seen in 
this line and is likely due to a lower level of construct expression, previously demonstrated in 
FACS experiments assessing GFP levels in transduced cells. 
6.1.2.2 Chromosome 11q Candidate Gene List 
The negative selection assay performed on the genes present in the amplified 11q region 
targeted each gene with three shRNAs. Two methods of pooled lentiviral particle preparation 
were undertaken for this section of work. In the first, each shRNA-containing transfer plasmid 
was prepared on an individual basis in Plasmid Miniprep size cultures (MinP). In the second 
method, bacterial stocks were pooled in groups of 10 shRNAs each and extracted in nine 
separate Maxiprep size cultures (MaxP). Lentiviral particles were then produced in pools of 10 
shRNAs each for both methods, and used to transduce UoC-M1 cells. These two methods were 
carried out to assess whether pooling of lentiviral vectors at the bacterial stage (as in MaxP) 
might have led to highly uneven representation or even loss of some shRNAs, although this 
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needed to be balanced with the greatly improved vector yield obtained from MaxiPrep 
cultures when compared to MiniPrep cultures. 
Although there were no cases where all shRNAs targeted to one gene were found to be hits, 
shRNAs targeted to two genes were repeatedly selected against. The knockdown of MPZL3 
was significantly selected against by two shRNAs in both the MaxP and MinP samples, and the 
knockdown of UBE4A was also selected against by one MaxP and two MinP shRNAs. The 
relative changes in construct proportion observed across all experiments using GIPZ shRNAs 
was far lower than the changes observed using the SIN-SIEW lentiviral vectors for the 12p 
project, suggesting either a lower level of expression or silencing of lentiviral vectors over time. 
6.1.3 Investigating the Relevance of Targets Identified by the Screening Assay 
The functional follow up assessment of the targets identified by the negative screening assay 
mainly focussed on the strongest hit identified, which was CDKN1B. CDKN1B overexpression 
was confirmed in NKM-1 cells transduced with SIN-SIEW-CDKN1B through the use of qPCR, and 
subsequent translation of CDKN1B mRNA into protein was confirmed using Western 
immunoblotting. Culturing control and transduced cells for 72 hours resulted in a significantly 
reduced number of viable cells present in populations transduced with SIN-SIEW-CDKN1B, 
when assessed using an MTS assay. Cell cycle analysis of the same cells demonstrated a slight 
reduction in the proportion of cells in G0/G1 and S phase, and an increased number of cells in 
G2/M phase. The most well studied role of CDKN1B is in the inhibition of CDK complexes that 
regulate the G1/S phase, so this result was a little unexpected as it could be hypothesised that 
overexpression of CDKN1B would block this stage of the cell cycle and increase the proportion 
of cells in the G1 phase. 
The expression levels of CDKN1B were then measured in a panel of AML cell lines. The cell lines 
demonstrated a range of expression levels, with a particularly low level of CDKN1B expression 
found in the GDM-1 cell line. Grouping cell lines into 12p deleted and non-12p deleted 
categories did not reveal a significant difference between the two groups. The levels of 
CDKN1B protein in the same panel of cell lines was also assessed, again with a wide range of 
expression levels observed. Grouping the cell lines into the two categories mentioned above 
did not show a significant difference in the protein levels observed. These data therefore 
demonstrated that deletion of the 12p region does not correlate with a reduction in CDKN1B 
transcript or protein levels relative to other AML cell lines. 
Continuing on this theme, the expression levels of CDKN1B were measured in a panel of 76 
AML patient samples (kindly donated by Prof. Claudia Haferlach, Munich Leukemia 
Laboratory). Of these, 45 had deletions of 12p, whilst 31 samples were included as controls. 
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There was no significant difference in expression levels between the two groups when 
assessed using an unpaired t-test (p=0.606), although the median was slightly lower in the 12p 
deleted group when compared to the non-12p deleted group. This indicated that in AML 
patient samples, deletion of 12p did not lead to a significant relative reduction in CDKN1B 
transcript levels compared to non 12p deleted samples. It is possible that CDKN1B expression 
is reduced in most AML cell lines and patient samples that do not have a deletion of 12p 
through an alternative mechanism, which would result in no observed relative difference 
between the two groups. 
CDKN1B expression was then analysed in a panel of normal myeloid and myeloid progenitor 
cells, using the R2: Genomics Analysis and Visualization Platform and the GSE19599 dataset 
provided by Fioretos et al. (2012). Although this involved comparing data from two different 
platforms (expression microarray and qPCR), it was found that the levels of CDKN1B expression 
measured in this project were comparable to the CDKN1B expression levels found in the 
Fioretos et al. (2012) dataset, with a few exceptions in both cell lines and patient samples, 
which demonstrated elevated levels of CDKN1B expression relative to GAPDH. Although 
further investigation is required, if this was true, it would suggest that deletion of 12p does not 
result in a significantly altered expression of CDKN1B. 
Following this, the cell line with the highest level of CDKN1B expression, U937, was selected 
for further functional analysis. U937 cells transduced with GIPZ lentiviral targeted to CDKN1B 
showed a reduction in the number of cells in G0/G1 and S phases, but demonstrated no 
significant reduction in growth 72 hours after transduction. 
Finally, a panel of AML cell lines were exposed to the CDK2 and CDK4 inhibitor flavopiridol, 
with the hypothesis that inhibition of CDKN1B through reduced expression would lead to an 
increased susceptibility to treatment with a CDK2/CDK4 inhibitor. GI50 values were calculated 
and analysis with Spearman’s rank correlation coefficient testing showed a moderate 
correlation between flavopiridol GI50 and CDKN1B transcript levels (rho=0.405), although this 
was not significant (p=0.320). There was a moderate correlation between flavopiridol GI50 and 
CDKN1B protein levels (rho=0.262), but again this was not significant (p=0.531). The presence 
of a trend suggests that further work is required to confirm or refute this hypothesis, and this 
is discussed further in Section 6.3.3. 
The follow up work performed on the candidate genes identified by the 11q negative selection 
assay focussed on knockdown validation of shRNAs targeted to MPZL3 and UBE4A. UoC-M1 
cells were transduced with individual shRNAs targeted to each candidate gene and positively 
transduced cells were selected using puromycin. Transcript knockdown of over 50% was 
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confirmed for each lentiviral vector, however the levels of knockdown did not fully correlate 
with the level of negative selection observed in Chapter 4. The greatest levels of MPZL3 
knockdown was achieved with shRNA 3, followed by shRNA 2. However, in the negative 
selection assay, the greatest selection effect was seen with shRNA 1, followed by shRNA 3, 
whilst shRNA 2 showed no significant negative selection effect. For UBE4A knockdown, the 
greatest knockdown was achieved with shRNA 1, which also showed the largest effect in the 
negative selection assay. Similar levels of knockdown were seen with both shRNA 2 and shRNA 
3, but in the negative selection assay shRNA 3 was selected against, whilst shRNA 2 was not. 
The discordance between levels of knockdown and the results of the negative selection assay 
suggest that further validation of the negative selection assay results would be required to 
ensure that the results obtained were not due to random fluctuation of relative construct 
proportion. 
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6.2 Study Strengths and Limitations 
6.2.1 Chapter 3 
One of the major strengths of this chapter stemmed from the large number of researchers 
who have published their microarray data on databases such as Gene Expression Omnibus and 
ArrayExpress, without which this body of work would not have been possible. It allowed 866 
AML patient data files to be reanalysed with a focus on 12p deletions and 11q amplifications, 
many of which had matched remission or relapse data, allowing germline and relapse specific 
copy number alterations to be assessed. The high numbers involved made this study larger 
than any other published studies that have focussed specifically on deletions of 12p (Sato et 
al., 1995; Wlodarska et al., 1996; Andreasson et al., 1997; Andreasson et al., 1998; Baens et al., 
1999; Silva et al., 2008; Haferlach et al., 2009) providing greater power to identify a minimally 
deleted region and candidate gene list for deletions of 12p. Due to the low frequency of 11q 
amplifications in the data sets, this project found fewer patients with amplifications of 11q 
than other published studies (Rücker et al., 2006; Zatkova et al., 2009); although it was still 
possible to combine data from all three sources define a minimal region of gain and 
amplification on 11q. One limitation of this section of work is that only Affymetrix microarray 
data was used, although many other platforms could have been utilised, as well as other 
techniques, which will be discussed in 6.3.1 below. However, it could be argued as a strength, 
as the use of the same analysis protocol ensures that all samples are analysed in a 
standardised fashion, avoiding the introduction of technical bias. 
Another strength of the study was the custom designed MLPA probeset to target genes on 
12p. It provided rapid screening of large numbers of patients for deletions of 12p which was 
not previously available. Unfortunately, due to the small number of patient samples available, 
it was not possible to screen sufficient samples to build on conclusions drawn from the analysis 
of the microarray data. 
The Sanger database of cancer cell lines was invaluable to identify suitable AML cell lines for 
the negative selection assay. Three cell lines with deletions of 12p and relatively few other 
genetic aberrations were found (GDM-1, Ben-Bassat et al., 1982; KG-1, Furley et al., 1986; 
NKM-1, Kataoka et al., 1990). Due to the rarity of 11q amplifications in AML, cell lines were 
scarce. A literature review identified three candidate cell lines, however it was only possible to 
obtain one with four copies of the 11q region of interest. Although the cell line demonstrated 
elevated expression of genes present on 11q, a model with a higher level of amplification 
would have been more representative. 
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6.2.2 Chapter 4 
The main strength of the negative selection described in Chapter 4 was the novel nature of the 
assay. The use of an assay of this type for the functional interrogation of candidate genes from 
within regions of deletion or amplification in cancer has not previously been reported. It 
enabled a functional approach to identify those copy number aberrations driving leukaemic 
progression in AML with deletions of 12p and amplifications of 11q. 
One of the main drawbacks to this body of work was that only AML cell lines were assessed, 
while the use of primary patient material would have been preferred. As reviewed by Gillet et 
al. (2013), whilst some cancer cell lines have been valuable as models in a preclinical setting, 
others have failed. They suggested a number of limitations of using cell lines, such as a low 
relevance to actual disease states. This could produce misleading results if a gene assessed 
using the negative selection assay was important in leukaemic development, but its 
knockdown or overexpression was tolerated in a cell line setting. 
Another limitation concerns the negative selection assay performed for the 11q candidate 
genes. The two main hits identified were only identified as hits for three or four of the six 
shRNAs targeted to the genes of interest (three separate shRNAs total, with two methods of 
lentiviral vector replication). As demonstrated in the 12p part of the project, data replication is 
important to exclude spurious results and the data would have been stronger with more 
consistent findings. The source of this weakness is unclear, but it could be speculated that low 
levels of shRNA expression from integrated GIPZ vectors, possibly in combination with 
silencing of the CMV promoter, may have led to weak selection pressures when the shRNAs 
were expressed. The use of the UoC-M1 cell line, which only contains four copies of the region 
of interest, may demonstrate a lower expression of candidate genes when compared to AML 
samples with higher levels of 11q expression. This may mean that the cell line is less 
susceptible to shRNA targeting of these genes. Careful validation using alternative models such 
as patient material or mouse models would be required to confirm these findings. 
The in vivo body of this project was useful in furthering understanding of AML development in 
vivo, but failed to fully replicate the in vitro negative selection assay results, likely due to the 
pattern of leukaemic engraftment in the mice, as it appeared that a small population of cells 
had engrafted and expanded at each site, leading to overrepresentation of a small number of 
lentiviral vectors. There was little consistency in which lentiviral vectors were over or 
underrepresented, with major variation between both mice and between sites of engraftment 
isolated from within mice. Subsequent discussion and research has implied that tail vein 
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injection may be a more suitable route of leukaemic cell delivery, as demonstrated by Wang et 
al. (2012) and Miller et al. (2013). 
6.2.3 Chapter 5 
A strength of the 12p portion of this chapter was the successful confirmation of CDKN1B 
overexpression and investigation into its effects. However, this functional assessment ran into 
problems, where not all experiments corroborated the evidence presented in Chapter 4, 
suggesting that CDKN1B acts as a tumour suppressor through its mechanisms of action upon 
the cell cycle. This could be a highly significant finding if it was found that CDKN1B may have 
some oncogenic role as it does in CML (discussed in Section 5.1), which may explain why 
biallelic CDKN1B deletions are not reported in AML, if one copy is required to fulfil these 
oncogenic functions. It appeared that CDKN1B expression in both AML cell lines and patient 
samples was not always linked to 12p copy number status, an unexpected finding, but one that 
may be of interest in understanding the role of CDKN1B in AML. This chapter demonstrated 
that much work remains to be done before clear conclusions can be drawn (discussed further 
below in Section 6.3.3), but it has provided a solid foundation for future studies.  
Due to time constraints, it was not possible to perform more detailed investigations into the 
11q candidate oncogenes identified in the negative selection assay, which is a limitation of this 
portion of the project. However, successful knockdown of target genes was established, 
providing a useful starting point for future functional investigations. 
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6.3 Future Work 
6.3.1 Further Investigation of Copy Number Alterations in AML 
The work performed in Chapter 3 that investigated the extent of chromosome 12p deletions 
and chromosome 11q amplifications in AML could be further expanded. Since the investigation 
was performed, there are new platforms available for investigating copy number alterations 
(for example the Affymetrix CytoScan HD) and more data sets are now available on the GEO 
database. Expanding the database with additional data could identify more AML patients with 
the chromosomal aberrations of interest, providing further information about the extent of 
minimally altered regions. This would be particularly beneficial to the 11q section of this 
project as fewer individuals were found with this chromosomal aberration. As this project only 
made use of Affymetrix SNP arrays, further expansion could include a wider range of SNP array 
manufacturers, for example the Illumina range of Human Genotyping Arrays, to provide 
additional data. The inclusion of NGS data would also provide further information about the 
copy number status of genes within the regions of interest.  
As considerable effort was put into the development of a custom 12p MLPA probeset, it would 
be ideal to screen additional patient samples. Through screening additional karyotypically 
normal samples, more patients could be identified with small deletions of 12p, potentially 
refining the minimally deleted region and providing additional information on the occurrence 
of 12p deletions in these patients. Performing FISH on these samples may also identify 
additional mechanisms of dysregulation of the genes within the MDR, such as translocations of 
12p as previously shown (Harrison et al., 2010). Should appropriate material be available, it 
would be of interest to study the clonality of these deletions in leukaemic populations and 
assess the proportion of cells in each leukaemia that carry the deletion of 12p. This may inform 
the relative importance of the aberration in leukaemic development. 
Although publicly available sequencing data were screened in an attempt to identify 
inactivating mutations in CDKN1B, no such mutations had been reported in AML. A targeted 
sequencing approach, using PCR enrichment, could be undertaken to screen for CDKN1B 
mutations in a large cohort of AML patients, both with and without deletions of 12p. Screening 
for mutations affecting the other genes in the MDR, with a particular interest in ETV6, which 
showed a weak effect in the negative selection assay, would provide significant support to 
their role as tumour suppressor genes in AML. 
6.3.2 Expansion of Negative Selection Assay 
In vivo work undertaken in this project did not successfully replicate the in vitro negative 
selection assay within the mouse model. As discussed in Section 4.5.1, other researchers have 
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successfully used intravenous tail vein injection of mice following whole body irradiation to 
engraft a wide range of AML material, including difficult to engraft patient samples (Wang et 
al., 2012; Miller et al., 2013). These systems have shown considerable engraftment in both the 
bone marrow and organs of injected mice, and successful shRNA screens have been performed 
which have identified hits using similar methods.  Repeating the in vivo negative selection 
assay with tail vein injection may yield more informative data. 
This work could then be further expanded by performing the negative selection assay in AML 
material derived from patients with deletions of 12p. As cell lines have often been cultured for 
many years, during which time they have often gained additional chromosomal aberrations, 
they are not viewed as the gold standard for performing this type of study (Gillet et al., 2013). 
Patient’s leukaemic cells would then be engrafted and subsequently expanded in mice. This 
xenograft material could then be transduced and the negative selection assay performed as 
before. This model of AML would be more representative of human, providing a more accurate 
representation of the role of each gene studied in the selection assay. For the 11q project, an 
additional benefit would be the use of a model system from a patient with true amplification 
of 11q, rather than the UoC-M1 cell line which only has four copies of the 11q region of 
interest. 
Part of the original plan of the project was to perform a positive selection assay in cells derived 
from INK4a/ARF mutant mice, however due to time constraints this work could not be 
completed. Foetal liver cells were collected from these mice, which provide a source of HSCs 
that can be lentivirally transduced and engrafted into NSG mice. In the positive selection assay, 
putative tumour suppressor genes would be knocked down, and putative proto-oncogenes 
would be overexpressed. INK4a/ARF null foetal liver cells lead to the development of 
leukaemias when transplanted into NSG mice, thus the positive selection assay would identify 
which genes were able to potentiate this process as their corresponding shRNAs or cDNAs 
would have an elevated relative copy number after expansion compared to their starting copy 
number.  
6.3.3 Further Functional Analysis of Candidate Genes 
As discussed in Section 5.4.1, it would be important to gain a greater understanding of the 
expression levels of CDKN1B in normal haematopoietic cells compared to the AML cell lines 
and patient samples analysed in this project. Although it was possible to use an online 
resource to extract data from an expression microarray, it is not ideal to compare expression 
data between two different platforms. For this reason, future work might encompass 
extracting haematopoietic cells from normal blood and bone marrow samples and flow sorting 
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them into a range of haematopoietic cell compartments. The expression levels of CDKN1B 
could be directly compared to the expression levels of CDKN1B found in the AML samples. This 
comparison would shed further light on how expression levels of CDKN1B change in 
leukaemogenesis, in both 12p deleted and 12p non-deleted cases as well as in AML cell lines. 
As gene editing techniques such as the CRISPR/Cas system have become more popular, the 
techniques have been further refined and are now useful tools for a wider range of 
researchers. These techniques could be used to delete specific genes from target cells, which 
could be useful to specifically delete CDKN1B to assess the effects of its loss in haematopoietic 
stem cells and its role in leukaemogenesis. Additionally, knockout mouse models of CDKN1B 
could be beneficial to assess the role of CDKN1B in haematopoiesis and leukaemogenesis. A 
conditional knockout of CDKN1B in the haematopoietic compartment would be ideal, and the 
range of haematopoietic cells produced by the model could be studied to identify any bias 
towards the production of a specific cell type. The model could also be exposed to mutagens 
and the incidence of leukaemic development could be studied in relation to mouse models 
that are not missing a copy of CDKN1B.  
It would be of interest to co-express both CDKN1B and ETV6 in the same cell to assess whether 
the negative selection effect seen in the assay was increased by the expression of both genes 
together. If so, it would suggest cooperation between these genes in deleted 12p cases is able 
to drive leukaemogenesis more than the loss of a single one of them. It would also explain why 
the majority of patients with deletions of 12p have loss of both genes. 
The work performed exposing AML cell lines to flavopiridol and relating this to CDKN1B 
expression levels showed a trend towards a correlation between the IC50 values and CDKN1B 
expression. It would be of interest to assess more cell lines to confirm or refute the link 
between these two factors. Although flavopiridol affects CDKs 2, 4 and 6, it also inhibits other 
CDK family members, which may lead to its effects becoming less pronounced. For this reason, 
the test could be improved by utilising a more specific CDK inhibitor to investigate this link. 
As there was little time to perform any follow up work on the hits identified in the 11q 
negative selection assay, it would be of interest to assess the potential of the candidate genes 
as drivers of leukaemogenesis. Further insight is required into why specific shRNAs were not 
selected against in the functional assay, despite demonstrating knockdown in a puromycin 
selected population transduced with individual shRNA containing lentiviral vectors. The first 
step would be to validate the 11q negative selection assay using further repeats in a smaller 
pool of shRNAs. Next, the level of protein knockdown achieved using the GIPZ shRNAs should 
be assessed, as transcript knockdown may not lead to reduction in the levels of protein 
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present. As there is little known about the function and role of the identified candidate genes 
in driving oncogenesis, further work should focus on establishing how these genes may 
contribute to cancer development, before subsequently assessing how these mechanisms 
might be harnessed for targeted treatments in the future.  
6.3.4 Additional Project Applications 
Finally, the negative selection assay developed here could easily be applied to other 
chromosomal copy number aberrations as well as other candidate gene lists. For example, 
large scale expression studies could be performed to identify a list of genes most commonly 
dysregulated in AML leukaemogenesis, and this could be used as the basis for a larger scale 
study to determine which genes are functionally relevant and amenable to targeted treatment. 
The assay could also be applied to a range of cancer types, either with similar regions of copy 
number aberrations found across cancer types or by studying individual cancer subtypes with 
their own specific copy number aberrations. 
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6.4 Final Conclusions 
Utilising a number of methods and novel approaches, a greater understanding of the effects of 
deletions of the short arm of chromosome 12 and amplification of the long arm of 
chromosome 11 have in driving leukaemic development has been gained. This body of work 
has identified candidate genes that will contribute to the understanding of AML and may 
represent the first steps into the development of novel therapies. 
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Chapter 7 Supplementary Data 
7.1 Supplementary Tables 
7.1.1 Table of Primers 
Primer Primer Sequence 
CS1-SFFV F ACACTGACGACATGGTTCTACAAGCTGACCTGCAAGAAGAGG 
ETV6 R TACGGTAGCAGAGACTTGGTCTTGGGCTCTCTGGAGGTGTAT 
BCL2L14 R TACGGTAGCAGAGACTTGGTCTGGCCGAGGATTTTGAATTCTATGG 
DUSP16 R TACGGTAGCAGAGACTTGGTCTGTTCCACTTTCCAGCAGAGC 
CREBL2 R TACGGTAGCAGAGACTTGGTCTCACGTTTACCGGGCTTCTTT 
GPR19 R TACGGTAGCAGAGACTTGGTCTGGGCACCAGAAGTGTAGGAA 
CDKN1B R TACGGTAGCAGAGACTTGGTCTCATCCGCTCCAGGCTAGG 
APOLD1 R TACGGTAGCAGAGACTTGGTCTCTTCCGAGTACCCCTGGC 
DDX47 R TACGGTAGCAGAGACTTGGTCTTCCTCCTCTTCCACAATCGG 
LOH12CR1 R TACGGTAGCAGAGACTTGGTCTTGGCTCTATGCTTGGCTG 
MANSC1 R TACGGTAGCAGAGACTTGGTCTAGCAGACAGCCTTAGTGTCA 
LRP6 R TACGGTAGCAGAGACTTGGTCTATAAAGCAACAAAGGGGCCG 
pGIPZ Hairpin F ACACTGACGACATGGTTCTACACAACAGAAGGCTCGAGAAGG 
pGIPZ Hairpin R TACGGTAGCAGAGACTTGGTCTCCTTGAATTCCGAGGCAGTA 
GAPDH F (qPCR) CGACCACTTTGTCAAGCTCA 
GAPDH R (qPCR) GACTGAGTGTGGCAGGGACT 
CDKN1B F (qPCR) TAATTGGGGCTCCGGCTAAC 
CDKN1B R (qPCR) GAAGAATCGTCGGTTGCAGGT 
Table 33. Table of primers and associated sequences. 
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7.1.2 Table of 12p Deletions Detected by SNP Microarray 
Series 
Author 
Platform Sample  Chromosomal Location Start End 
Radtke 500K 393774 12pter - p12.1 0 22493864 
Radtke 500K 393776 12p 0 34855126 
            
Bullinger 500K 472597 12p13.2 - p13.1 11653772 13068046 
Bullinger 500K 472618 12p13.2 - p12.3 11388025 19047806 
Bullinger 500K 472670 12p13.2 - p13.1 11720446 13014076 
Bullinger 500K 472691 12p13.2 - p12.3 11276681 19039754 
            
Bullinger 100K 473086 12p13.2 11354241 12606882 
Bullinger 100K 473161 12p13.2 - p12.3 10869580 19279573 
            
Parkin SNP6.0 631015 12p13.2 - p12.2 10894814 20417967 
Parkin SNP6.0 631021 12p13.31 - p11.21 9178874 31119940 
Parkin SNP6.0 631027 12p13.31 - p11.22 9390271 28481984 
Parkin SNP6.0 631041 12p13.31 - p12.3 6822135 17766576 
Parkin SNP6.0 631075 12p13.31 - p13.2 9997003 14229914 
Parkin SNP6.0 631087 12p13.2 - p11.22 11526805 29335762 
Parkin SNP6.0 631099 12p13.2 - p13.1 11419362 14253967 
Parkin SNP6.0 631115 12p 0 34855126 
Parkin SNP6.0 631145 12p13.31 - p12.1 6543326 22039542 
Parkin SNP6.0 631167 12p13.31 - p12.1 9794659 22372509 
Parkin SNP6.0 631171 12pter - p12.2 0 21195776 
            
Haferlach SNP6.0 687172 12p13.2 - p13.1 11723293 12934854 
Haferlach SNP6.0 687173 12p13.2 - p12.1 11943146 22510427 
Haferlach SNP6.0 687174 12p13.2 - p13.1 12113639 13763702 
Haferlach SNP6.0 687175 12p13.2 - p13.1 11694841 12990759 
Haferlach SNP6.0 687176 12p13.31 - p11.21 9524658 32829294 
Haferlach SNP6.0 687177 12p13.2 - p13.1 11593665 13008381 
Haferlach SNP6.0 687178 12p13.2 - p12.2 11848875 20626553 
            
Kühn SNP6.0 802992 12pter - p12.1 0 22450199 
Kühn SNP6.0 802993 12p 0 34855126 
Kühn SNP6.0 808025 12p 0 34855126 
            
Rücker SNP6.0 850733 12pter - p13.12 0 49225974 
Rücker SNP6.0 850736 12p13.2 - p11.22 11712106 28075420 
Rücker SNP6.0 850746 12p13.31 - p13.1 9402956 14396622 
Rücker SNP6.0 850753 12p13.31 - p12 9956648 44516094 
Rücker SNP6.0 850790 12p13.31 - p11.21 9121580 31094615 
Rücker SNP6.0 850814 12p13.31 - p12.2 8812160 20662827 
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Rücker SNP6.0 850817 12p13.31 6930639 34792469 
Rücker SNP6.0 850818 12pter - p12.1 0 26132366 
Rücker SNP6.0 850820 12p13.1 9750671 12990836 
Rücker SNP6.0 850822 12pter - p12.2 0 20662827 
            
Rücker 500K 850723 12p - p12.2 6246808 21079711 
Rücker 500K 850724 12pter - p12.1 0 22283997 
Rücker 500K 850749 12p13.31 - p11.23 9118434 26827280 
Rücker 500K 850759 12p13.31 - p13.1 9394380 13653732 
Rücker 500K 850761 12p13.2 11660780 32156516 
Rücker 500K 850764 12p13.2 12120652 13495401 
Rücker 500K 850785 12p13.31 - p12.1 7241153 21816913 
Rücker 500K 850793 12pter - p11.23 0 26982620 
Rücker 500K 850804 12pter - p12.1 0 23565147 
Rücker 500K 850805 12p13.31 9895254 14822242 
Rücker 500K 850815 12pter - p13.11 0 48315759 
Rücker 500K 850821 12p13.2 - p11.23 10019903 26431458 
Table 34. Details of 12p deletion in all patients studied. Coordinates displayed for 100K and 500K platforms have 
been converted from hg18 to hg19. 
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7.1.3 Table of 11q Gains Detected by SNP Microarray – Copy Number 3 
Series 
Author 
Platform Sample 
GSM 
Chromosomal 
Location 
Copy 
Number 
Start End 
Radtke 500K 393614 11q22.3 - qter 3 105826003 134789366 
Radtke 500K 393697 11q24.2 - q24.3 3 127575608 129041737 
              
Bullinger 500K 472593 11q23.3 3 116894496 117088420 
Bullinger 500K 472616 11q23.3 3 118023622 118462667 
Bullinger 500K 472684 11q24.3 3 130695261 130817259 
Bullinger 500K 472689 11q23.3 3 118065299 118307939 
              
Bullinger 100K 473055 11q23.3 3 118354166 118805656 
Bullinger 100K 473063 11q23.3 3 118384917 119162891 
              
Gupta SNP6.0 518882 11q23.3 3 115405407 134853273 
       
Parkin SNP6.0 631107 11p11.12 - qter 3 48201061 134853273 
              
Kühn SNP6.0 803061 11q22.3 - qter 3 109254589 134853273 
Kühn SNP6.0 803325 11q22.3 - qter 3 105415417 134853273 
Kühn SNP6.0 805581 11q22.1 - qter 3 98168969 134853273 
Kühn SNP6.0 806093 11q21 - qter 3 94257452 134853273 
              
Rücker SNP6.0 850719 11q13.3 - qter 3 69132499 134853273 
Rücker SNP6.0 850726 11p12 - qter 3 43222827 134853273 
Rücker SNP6.0 850739 Entire 11 3 0 134853273 
Rücker SNP6.0 850748 11q22.1 - qter 3 98688110 134853273 
Rücker SNP6.0 850769 11q24.2 – q25 3 127691866 132547504 
Rücker SNP6.0 850808 Entire 11q 3 50952568 134853273 
              
Rücker 500K 850761 Entire 11q 3 48244485 134789366 
Rücker 500K 850718 11q24.1 - qter 3 122375795 134789366 
Table 35. Details of 11q gains in all patients studied. Coordinates displayed for 100K and 500K platforms have been 
converted from hg18 to hg19. 
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7.1.4 Table of 11q Gains Detected by SNP Microarray – Copy Number 4 
Series 
Author 
Platform Sample 
GSM 
Chromosomal 
Location 
Copy 
Number 
Start End 
Parkin SNP6.0 630959 11p11.12 - qter 4 51176560 134944800 
Parkin SNP6.0 631113 11p11.12 - qter 4 50090974 134944800 
              
Rücker SNP6.0 850809 Entire 11 3 0 134449982 
        4 66070303 134449982 
Table 36. Details of 11q gains with a copy number of 4 in all patients studied. 
7.1.5 Table of 11q Amplifications Detected by SNP Microarray 
Series 
Author 
Platform Sample 
GSM 
Chromosomal 
Location 
Copy 
Number 
Start End 
Parkin SNP6.0 631097 11q24.2 - q25 >4 126953865 130834263 
              
Rücker SNP6.0 850743 11q12.1 3 57175157 59616210 
      11q12.2 - q23.1 3 60763739 110965409 
      11q23.1 - q23.3 4 110965443 121521200 
      11q23.3 - q25 >4 121521200 132159600 
      11q25 >4* 132168501 132570489 
      11q25 >4 132570489 134161639 
              
Rücker 500K 850721 11q23.3 - qter >4 117536581 134944770 
Rücker 500K 850724 11q13.4 - q14.1 3 74649956 79536128 
      11q23.3 3 117844008 119955430 
      11q23.3 >4 118373919 118800198 
Rücker 500K 850821 11q13.4 - q14.1 3 74320458 77499823 
      11q14.1 4 77499823 78685950 
      11q23.3 >4 118121958 119161489 
      11q24.2 >4 126846631 131148234 
Table 37. Details of 11q amplifications in all patients studied. Coordinates displayed for 100K and 500K platforms 
have been converted from hg18 to hg19. * = very high signal strength. 
 
173 
 
7.2 Supplementary Figures 
7.2.1 PCR Optimisation of NGS Library Preparation 
 
Figure 55. The PCR optimisation process to select numbers of first and second round amplification for sequencing 
library preparation. Various combinations of round 1 and round 2 cycle numbers were tested to find the optimal 
combination producing PCR products that are not in the plateau phase of amplification. Round 1 only samples were 
included in undiluted form for size references as successful round 2 PCR increases product size through the addition 
of barcode and adapter sequences. In the left and right most lanes, 100bp ladder was loaded for analysis of PCR 
product sizes. 
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7.2.2 FLI1 Negative Selection 
 
Figure 56. Mean individual results for negative selection using shRNAs targeted to FLI1. sh1 in the MaxP experiment 
was identified as a hit (p=<0.001). 
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7.2.3 CDKN1B Expression in AML Cell Lines 
 
Figure 57. Western Immunoblotting performed using a range of AML cell line protein extracts. Primary antibodies 
raised to CDKN1B and α-tubulin were used to bind target proteins, and secondary antibodies conjugated with HRP 
were used to detect bound protein bands. Samples KG-1, GDM-1 and NKM-1 were used to normalise between blots 
and band densitometry using ImageJ allowed quantification of protein bands as shown in Figure 47. 
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